INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38501, 16062, 'Ceftazidime', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38502, 16080, 'Ceftazidime', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38503, 16194, 'Ceftazidime', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38504, 19339, 'Ceftazidime', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38505, 19340, 'Ceftazidime', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38506, 19341, 'Ceftazidime', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38507, 19355, 'Ceftazidime', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38508, 19356, 'Ceftazidime', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38509, 20922, 'Ceftazidime', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38510, 21317, 'Ceftazidime', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38511, 22394, 'Ceftazidime', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38512, 22395, 'Ceftazidime', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38513, 23346, 'Ceftazidime', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38514, 23347, 'Ceftazidime', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38515, 28976, 'Ceftazidime', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38516, 28977, 'Ceftazidime', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38517, 29784, 'Ceftazidime', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38518, 29785, 'Ceftazidime', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38519, 29786, 'Ceftazidime', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38520, 2233, 'Ceftazidime', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38521, 2281, 'Ceftazidime', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38522, 2284, 'Ceftazidime', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38523, 2301, 'Ceftazidime', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38524, 2302, 'Ceftazidime', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38525, 2303, 'Ceftazidime', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38526, 2444, 'Ceftazidime', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38527, 2445, 'Ceftazidime', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38528, 5113, 'Ceftazidime', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38529, 6801, 'Ceftazidime', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38530, 6802, 'Ceftazidime', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38531, 10438, 'Ceftazidime', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38532, 10439, 'Ceftazidime', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38533, 16013, 'Ceftazidime', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38534, 16014, 'Ceftazidime', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38535, 16015, 'Ceftazidime', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38536, 16062, 'Ceftazidime', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38537, 16080, 'Ceftazidime', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38538, 16194, 'Ceftazidime', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38539, 19339, 'Ceftazidime', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38540, 19340, 'Ceftazidime', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38541, 19341, 'Ceftazidime', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38542, 19355, 'Ceftazidime', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38543, 19356, 'Ceftazidime', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38544, 20922, 'Ceftazidime', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38545, 21317, 'Ceftazidime', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38546, 22394, 'Ceftazidime', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38547, 22395, 'Ceftazidime', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38548, 23346, 'Ceftazidime', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38549, 23347, 'Ceftazidime', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38550, 28976, 'Ceftazidime', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38551, 28977, 'Ceftazidime', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38552, 29784, 'Ceftazidime', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38553, 29785, 'Ceftazidime', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38554, 29786, 'Ceftazidime', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38555, 16336, 'Certolizumab pegol', 'Infections', 'There have been reports of serious infections, including sepsis and opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic pathogens including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis and tuberculosis with TNF blockers.  Treatment with these agents should not be initiated in patients with an active infection, including clinically important localized infections.  Caution and close monitoring is recommended when considering their use in patients with a history of recurrent infections, underlying conditions which may predispose them to infections, or chronic, latent, or localized infections.  Administration of these agents should be discontinued if a patient develops a serious infection or sepsis.', '3', '"Product Information. Remicade (infliximab)." Centocor Inc  (2001):|"Product Information. Humira (adalimumab)." Abbott Pharmaceutical  (2003):|"Product Information. Cimzia (certolizumab)." UCB Pharma Inc  (2008):|"Product Information. Simponi (golimumab)." Centocor Inc  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38556, 16336, 'Certolizumab pegol', 'Neoplasms', 'In clinical trials malignancies have been observed in patients receiving TNF-blockers agents.  Patients with psoriasis should be monitored for non-melanoma skin cancers (NMSCs), particularly those patients who have had prior prolonged phototherapy treatment.  Melanoma and Merkel cell carcinoma have been reported in patients treated with TNF blocker therapy.  Periodic skin examination is recommended for all patients, particularly those with risk factors for skin cancer.  Postmarketing cases of fatal hepatosplenic T-cell lymphoma (HSTCL) have been reported in patients treated with TNF blockers.  Caution should be exercised when considering these agents in the treatment of patients with a history of malignancies or in continuing treatment in patients who develop malignancies while receiving these agents.', '3', '"Product Information. Remicade (infliximab)." Centocor Inc  (2001):|"Product Information. Humira (adalimumab)." Abbott Pharmaceutical  (2003):|"Product Information. Cimzia (certolizumab)." UCB Pharma Inc  (2008):|"Product Information. Simponi (golimumab)." Centocor Inc  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38557, 16336, 'Certolizumab pegol', 'Neurotoxicity Syndromes', 'The use of TNF blocking agents has been associated with rare cases of CNS manifestations of systemic vasculitis, seizure and new onset or exacerbation of clinical symptoms and/or radiographic evidence of central nervous system demyelinating disorders, including multiple sclerosis and optic neuritis, and peripheral demyelinating disorders, including Guillain-Barr syndrome.  Care should be exercised when considering the use of these agents in patients with neurologic disorders and discontinuing the agent is recommended if these disorders develop during therapy.', '3', '"Product Information. Remicade (infliximab)." Centocor Inc  (2001):|"Product Information. Humira (adalimumab)." Abbott Pharmaceutical  (2003):|"Product Information. Cimzia (certolizumab)." UCB Pharma Inc  (2008):|"Product Information. Simponi (golimumab)." Centocor Inc  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38558, 16336, 'Certolizumab pegol', 'Tuberculosis', 'Cases of reactivation of tuberculosis or new tuberculosis infections have been observed in patients receiving TNF blocking agents, including patients who have previously received treatment for latent or active tuberculosis.  Cases of active tuberculosis have also occurred in patients being treated with these agents during treatment for latent tuberculosis.  Prior to initiating TNF blocking agents, patients should be screened for latent tuberculosis infection with a tuberculin skin test and periodically during therapy.  Patients testing positive in tuberculosis screening should be treated by standard medical practice prior to therapy with TNF blocking agents.  Anti-tuberculosis therapy should also be considered prior to initiation of therapy in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent tuberculosis but having risk factors for tuberculosis infection.  Tuberculosis should be strongly considered in patients who develop a new infection during treatment, especially in patients who have previously or recently traveled to countries with a high prevalence of tuberculosis, or who have had close contact with a person with active tuberculosis.', '3', '"Product Information. Remicade (infliximab)." Centocor Inc  (2001):|"Product Information. Humira (adalimumab)." Abbott Pharmaceutical  (2003):|"Product Information. Cimzia (certolizumab)." UCB Pharma Inc  (2008):|"Product Information. Simponi (golimumab)." Centocor Inc  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38559, 16336, 'Certolizumab pegol', 'Heart Failure', 'Cases of worsening congestive heart failure (CHF) and new onset CHF have been reported with the use of certolizumab.  Caution should be exercised if a decision is made to administer certolizumab to patients with CHF and these patients should be closely monitored during therapy.', '2', '"Product Information. Cimzia (certolizumab)." UCB Pharma Inc  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38560, 16336, 'Certolizumab pegol', 'Hematologic Diseases', 'Cases of leukopenia, neutropenia, thrombocytopenia, and pancytopenia, some with a fatal outcome, have been reported in patients treated with TNF blocking agents.  Caution should be exercised when treating patients who have ongoing or a history of significant hematologic abnormalities.  Discontinuation of therapy should be considered in patients with confirmed significant hematologic abnormalities.', '2', '"Product Information. Remicade (infliximab)." Centocor Inc  (2001):|"Product Information. Humira (adalimumab)." Abbott Pharmaceutical  (2003):|"Product Information. Cimzia (certolizumab)." UCB Pharma Inc  (2008):|"Product Information. Simponi (golimumab)." Centocor Inc  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38561, 16336, 'Certolizumab pegol', 'Hepatitis B', 'The use of TNF blockers has been associated with reactivation of hepatitis B, in some cases fatal, in patients who were previously infected with the hepatitis B virus (HBV).  Therefore, screening for viral hepatitis should be performed in accordance with published guidelines before starting therapy with these agents.  Monitor patients at risk or with evidence of current or prior HBV infection for clinical and laboratory signs of hepatitis or HBV reactivation.  Prescribers should exercise caution in prescribing TNF blockers in patients previously infected with HBV.  It is recommended to monitor patients with evidence of current or prior HBV infection for clinical and laboratory signs of hepatitis or HBV reactivation during and for several months following therapy.  In patients who develop HBV reactivation, therapy should be stopped and antiviral therapy with appropriate supportive treatment should be initiated.  The safety of resuming these agents after HBV reactivation is controlled is not known.  Therefore, prescribers should weigh the risks and benefits when considering resumption of therapy.', '2', '"Product Information. Remicade (infliximab)." Centocor Inc  (2001):|"Product Information. Humira (adalimumab)." Abbott Pharmaceutical  (2003):|"Product Information. Cimzia (certolizumab)." UCB Pharma Inc  (2008):|"Product Information. Simponi (golimumab)." Centocor Inc  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38562, 0, 'Ceritinib', 'Long QT Syndrome', 'Ceritinib can cause dose dependent QT prolongation which may lead to an increased risk for ventricular arrhythmias, including Torsade de Pointes.  When possible, avoid use of ceritinib in patients with congenital long QT syndrome.  It is recommended to conduct periodic monitoring with electrocardiograms (ECGs) in patients with congestive heart failure, bradyarrhythmias, electrolyte abnormalities, or those who are taking medications that are known to prolong the QTc interval.  Withhold ceritinib in patients who develop a QTc interval greater than 500 msec on at least 2 separate ECGs until the QTc interval is less than 481 msec or recovery to baseline if the QTc interval is greater than or equal to 481 msec, then resume therapy at a reduced dose as clinically indicated.  Permanently discontinue ceritinib in patients who develop QTc interval prolongation in combination with Torsade de pointes or polymorphic ventricular tachycardia or signs/symptoms of serious arrhythmia.  This drug should be used with caution in patients with a known history of QT prolongation or patients who are taking medications known to prolong the QT interval.', '3', '"Product Information. Zykadia (ceritinib)." Novartis Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38563, 0, 'Ceritinib', 'Bradycardia', 'The use of ceritinib may cause bradycardia.  It is recommended to monitor heart rate and blood pressure regularly and in cases of symptomatic bradycardia that is not life-threatening, withhold therapy until recovery and adjust the dose of ceritinib.  It might be necessary to permanently discontinue ceritinib for life-threatening bradycardia if no contributing concomitant medication is identified; however, if associated with a concomitant medication known to cause bradycardia or hypotension, withhold therapy until recovery and resume therapy at a reduced dose with frequent monitoring.  Care and close monitoring is recommended.', '2', '"Product Information. Zykadia (ceritinib)." Novartis Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38564, 0, 'Ceritinib', 'Gastrointestinal Diseases', 'Severe gastrointestinal toxicity has been reported in patients treated with ceritinib.  It is recommended to monitor and manage patients using standards of care, or withhold ceritinib with resumption at a reduced dose as per clinical guidelines.  Care and close monitoring is recommended in patients reporting diarrhea, vomiting, or abdominal pain.', '2', '"Product Information. Zykadia (ceritinib)." Novartis Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38565, 0, 'Ceritinib', 'Hepatic Insufficiency', 'Ceritinib is eliminated primarily via the liver.  Patients with hepatic impairment may have increased exposure and drug-induced hepatotoxicity.  Based on results of population pharmacokinetic analysis no dose adjustment is needed for patients with mild hepatic impairment.  The pharmacokinetics of ceritinib has not been studied in patients with moderate to severe hepatic impairment; therefore, a recommended dose has not been determined for these patients.  It is recommended to monitor liver function tests including ALT, AST, and total bilirubin once a month and as clinically indicated, with more frequent testing in patients who develop transaminase elevations.  In some cases, it might be necessary to withhold ceritinib and resume therapy at a reduced dose, or permanently discontinue treatment.', '2', '"Product Information. Zykadia (ceritinib)." Novartis Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38566, 0, 'Ceritinib', 'Hyperglycemia', 'The use of ceritinib causes hyperglycemia.  It is recommended to monitor fasting serum glucose prior to the start of therapy and periodically thereafter as clinically indicated.  Initiate or optimize antihyperglycemic medications as clinically appropriate, and withhold therapy until hyperglycemia is adequately controlled, then resume at a reduced dose as clinically appropriate.  If adequate hyperglycemic control cannot be achieved with optimal medical management, permanently discontinue treatment with ceritinib.  Care should be exercised when using this agent in diabetic patients.', '2', '"Product Information. Zykadia (ceritinib)." Novartis Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38567, 0, 'Ceritinib', 'Pancreatitis', 'Pancreatitis, including a fatal case has occurred in patients receiving ceritinib.  It is recommended to monitor lipase and amylase prior to the start of therapy with ceritinib and periodically thereafter as clinically indicated.  It might be necessary to withhold the dose of ceritinib based on the severity of the laboratory abnormalities and resume therapy at a reduced dose per clinical guidelines.  Care is recommended when using this agent in patients at risk.', '2', '"Product Information. Zykadia (ceritinib)." Novartis Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38568, 0, 'Ceritinib', 'Kidney Diseases', 'Based on results of population pharmacokinetic analyses ceritinib exposures are similar between patients with mild to moderate renal impairment and patients with normal renal function.  No dose adjustment is needed for these patients.  Caution and monitoring is needed when using this agent in patients with severe renal impairment as no information is available.', '2', '"Product Information. Zykadia (ceritinib)." Novartis Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38569, 0, 'Ceritinib', 'Lung Diseases', 'The use of certain multikinase inhibitors has been associated with pulmonary toxicity.  Serious cases of interstitial lung disease (ILD), including fatal cases and interstitial pneumonitis or pulmonary fibrosis have been reported.  Caution is recommended when using these agents in patients with a history of interstitial pneumonitis or pulmonary fibrosis or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, and fever pending diagnostic evaluation.  If ILD is confirmed, permanently discontinue these agents and institute appropriate measures.  Immediately withhold treatment in patients diagnosed with ILD/pneumonitis and permanently discontinue therapy if no other potential causes of ILD/pneumonitis have been identified.', '2', '"Product Information. Vandetanib (vandetanib)." Astra-Zeneca Pharmaceuticals  (2011):|"Product Information. Zelboraf (vemurafenib)." Genentech  (2011):|"Product Information. Xalkori (crizotinib)." Pfizer U.S. Pharmaceuticals Group  (2011):|"Product Information. Mekinist (trametinib)." GlaxoSmithKline  (2013):|"Product Information. Zykadia (ceritinib)." Novartis Pharmaceuticals  (2014):|"Product Information. Zydelig (idelalisib)." Gilead Sciences  (2014):|"Product Information. Alecensa (alectinib)." Genentech  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38570, 18508, 'Cetuximab', 'Water-Electrolyte Imbalance', 'The use of certain EGFR inhibitors has been associated with progressive decreases in serum magnesium levels leading to severe cases of hypomagnesemia and accompanying electrolyte abnormalities, including hypocalcemia, and hypokalemia.  The onset of hypomagnesemia and accompanying electrolyte abnormalities occurred days to months after initiation of these agents.  Periodically monitor patients for hypomagnesemia, hypocalcemia, and hypokalemia, during and for at least 8 weeks following the completion of therapy.  Caution is recommended when using these agents in patients predisposed to electrolyte imbalances and those with a history of coronary artery disease, congestive heart failure, or arrhythmias.  Replete magnesium and other electrolytes as appropriate.', '3', '"Product Information. Erbitux (cetuximab)." Bristol-Myers Squibb  (2004):|"Product Information. Vectibix (panitumumab)." Amgen USA  (2006):|"Product Information. Portrazza (necitumumab)." Eli Lilly and Company  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38571, 18508, 'Cetuximab', 'Stevens-Johnson Syndrome', 'Cutaneous reactions, in some cases severe, have been reported with the use of EGFR inhibitors.  Monitor patients who develop dermatologic or soft tissue toxicities while receiving these agents for the development of inflammatory or infectious sequelae.  It is recommended to withhold treatment, and appropriate measures should be instituted as appropriate or discontinue the use of these agents for dermatologic or soft tissue toxicity associated with severe or life-threatening inflammatory or infectious complications.  Advise patients to wear sunscreen and hats and limit sun exposure while receiving therapy with these agents as exposure to sunlight can exacerbate dermatologic toxicities.', '3', '"Product Information. Iressa (gefitinib)." Astra-Zeneca Pharmaceuticals  (2003):|"Product Information. Erbitux (cetuximab)." Bristol-Myers Squibb  (2004):|"Product Information. Tarceva (erlotinib)." Genentech  (2004):|"Product Information. Vectibix (panitumumab)." Amgen USA  (2006):|"Product Information. Tykerb (lapatinib)." Novartis Pharmaceuticals  (2007):|"Product Information. Tagrisso (osimertinib)." Astra-Zeneca Pharmaceuticals  (2015):|"Product Information. Portrazza (necitumumab)." Eli Lilly and Company  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38572, 18508, 'Cetuximab', 'Eye Diseases', 'Some epidermal growth factor receptor (EGFR) inhibitors should be administered cautiously in patients with ocular disorders such as primary keratitis, ulcerative keratitis, or conjunctivitis.  It is recommended to interrupt or discontinue treatment with these agents if patients present with acute or worsening ocular disorders.', '3', '"Product Information. Iressa (gefitinib)." Astra-Zeneca Pharmaceuticals  (2003):|"Product Information. Erbitux (cetuximab)." Bristol-Myers Squibb  (2004):|"Product Information. Tarceva (erlotinib)." Genentech  (2004):|"Product Information. Vectibix (panitumumab)." Amgen USA  (2006):|"Product Information. Tykerb (lapatinib)." Novartis Pharmaceuticals  (2007):|"Product Information. Tagrisso (osimertinib)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38573, 18508, 'Cetuximab', 'Lung Diseases', 'The use of certain EGFR inhibitors has been associated with pulmonary toxicity.  Serious cases of interstitial lung disease (ILD), including fatal cases and interstitial pneumonitis or pulmonary fibrosis have been reported.  Caution is recommended when using these agents in patients with a history of interstitial pneumonitis or pulmonary fibrosis or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, and fever pending diagnostic evaluation.  If ILD is confirmed, permanently discontinue these agents and institute appropriate measures.', '3', '"Product Information. Iressa (gefitinib)." Astra-Zeneca Pharmaceuticals  (2003):|"Product Information. Erbitux (cetuximab)." Bristol-Myers Squibb  (2004):|"Product Information. Tarceva (erlotinib)." Genentech  (2004):|"Product Information. Vectibix (panitumumab)." Amgen USA  (2006):|"Product Information. Tykerb (lapatinib)." Novartis Pharmaceuticals  (2007):|"Product Information. Tagrisso (osimertinib)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38574, 18508, 'Cetuximab', 'Long QT Syndrome', 'QT prolongation was observed in patients treated with certain EGFR inhibitors.  These agents should be administered with caution in patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those who are taking medications known to prolong the QTc interval.  Serum electrolytes should be corrected prior to initiating therapy with these agents.  Periodic monitoring of ECGs and electrolytes is recommended in these patients.  Permanently discontinue the use of these agents in patients who develop QTc interval prolongation with signs/symptoms of life-threatening arrhythmia.', '3', '"Product Information. Erbitux (cetuximab)." Bristol-Myers Squibb  (2004):|"Product Information. Tykerb (lapatinib)." Novartis Pharmaceuticals  (2007):|"Product Information. Tagrisso (osimertinib)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38575, 18508, 'Cetuximab', 'Kidney Diseases', 'In clinical studies, renal failure occurred in 1% of patients with colorectal cancer treated with cetuximab.  Close monitoring is recommended in these patients.', '1', '"Product Information. Erbitux (cetuximab)." Bristol-Myers Squibb  (2004):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38576, 0, 'Cevimeline', 'Cardiovascular Diseases', 'Cevimeline may alter cardiac conduction and/or heart rate.  Patients with significant cardiovascular disease may be unable to compensate for transient changes in hemodynamics or rhythm induced by cevimeline.  Cevimeline should be used with caution and under close medical supervision in patients with a history of cardiovascular disease.', '3', '"Product Information. Evoxac (cevimeline)." Daiichi Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38577, 0, 'Cevimeline', 'Glaucoma', 'Cevimeline is contraindicated when miosis is undesirable, such in patients with narrow-angle (angle-closure) glaucoma or in acute iritis.', '3', '"Product Information. Evoxac (cevimeline)." Daiichi Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38578, 0, 'Cevimeline', 'Lung Diseases', 'The use of cevimeline is contraindicated in patients with uncontrolled asthma.  Cevimeline can potentially increase airway resistance, bronchial smooth muscle tone, and bronchial secretions.  This agent should be administered with caution and with close medical supervision in patients with controlled asthma, chronic bronchitis, or chronic obstructive pulmonary disease.', '3', '"Product Information. Evoxac (cevimeline)." Daiichi Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38579, 0, 'Cevimeline', 'Cholelithiasis', 'Cevimeline should be administered with caution in patients with a history of cholelithiasis.  Contractions of the gallbladder or biliary smooth muscle may precipitate complications such as cholecystitis, cholangitis and biliary obstruction.', '2', '"Product Information. Evoxac (cevimeline)." Daiichi Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38580, 0, 'Cevimeline', 'Nephrolithiasis', 'Cevimeline should be administered with caution to patients with a history of nephrolithiasis.  An increase in the ureteral smooth muscle tone may precipitate renal colic or ureteral reflux in patients with nephrolithiasis.', '2', '"Product Information. Evoxac (cevimeline)." Daiichi Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38581, 468, 'Albendazole', 'Bone Marrow Failure Disorders', 'Reversible leukopenia has been reported during albendazole therapy.  Rarely, granulocytopenia or pancytopenia have resulted in death.  Therapy with albendazole should be administered cautiously in patients with predisposition to myelosuppression.  Clinical monitoring of hematopoietic function prior to each cycle of albendazole and every two weeks during therapy is recommended.  Albendazole can be continued with a modest, non- progressive decrease in leukocyte count and absolute neutrophil count.', '3', 'Fernandez FJ, Rodriguezvidigal FF, Ledesma V, Cabanillas Y, Vagace JM "Aplastic anemia during treatment with albendazole." Am J Hematol 53 (1996):  53-4|"Product Information. Albenza (albendazole)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38582, 470, 'Albendazole', 'Bone Marrow Failure Disorders', 'Reversible leukopenia has been reported during albendazole therapy.  Rarely, granulocytopenia or pancytopenia have resulted in death.  Therapy with albendazole should be administered cautiously in patients with predisposition to myelosuppression.  Clinical monitoring of hematopoietic function prior to each cycle of albendazole and every two weeks during therapy is recommended.  Albendazole can be continued with a modest, non- progressive decrease in leukocyte count and absolute neutrophil count.', '3', 'Fernandez FJ, Rodriguezvidigal FF, Ledesma V, Cabanillas Y, Vagace JM "Aplastic anemia during treatment with albendazole." Am J Hematol 53 (1996):  53-4|"Product Information. Albenza (albendazole)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38583, 807, 'Albendazole', 'Bone Marrow Failure Disorders', 'Reversible leukopenia has been reported during albendazole therapy.  Rarely, granulocytopenia or pancytopenia have resulted in death.  Therapy with albendazole should be administered cautiously in patients with predisposition to myelosuppression.  Clinical monitoring of hematopoietic function prior to each cycle of albendazole and every two weeks during therapy is recommended.  Albendazole can be continued with a modest, non- progressive decrease in leukocyte count and absolute neutrophil count.', '3', 'Fernandez FJ, Rodriguezvidigal FF, Ledesma V, Cabanillas Y, Vagace JM "Aplastic anemia during treatment with albendazole." Am J Hematol 53 (1996):  53-4|"Product Information. Albenza (albendazole)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38584, 809, 'Albendazole', 'Bone Marrow Failure Disorders', 'Reversible leukopenia has been reported during albendazole therapy.  Rarely, granulocytopenia or pancytopenia have resulted in death.  Therapy with albendazole should be administered cautiously in patients with predisposition to myelosuppression.  Clinical monitoring of hematopoietic function prior to each cycle of albendazole and every two weeks during therapy is recommended.  Albendazole can be continued with a modest, non- progressive decrease in leukocyte count and absolute neutrophil count.', '3', 'Fernandez FJ, Rodriguezvidigal FF, Ledesma V, Cabanillas Y, Vagace JM "Aplastic anemia during treatment with albendazole." Am J Hematol 53 (1996):  53-4|"Product Information. Albenza (albendazole)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38585, 1381, 'Albendazole', 'Bone Marrow Failure Disorders', 'Reversible leukopenia has been reported during albendazole therapy.  Rarely, granulocytopenia or pancytopenia have resulted in death.  Therapy with albendazole should be administered cautiously in patients with predisposition to myelosuppression.  Clinical monitoring of hematopoietic function prior to each cycle of albendazole and every two weeks during therapy is recommended.  Albendazole can be continued with a modest, non- progressive decrease in leukocyte count and absolute neutrophil count.', '3', 'Fernandez FJ, Rodriguezvidigal FF, Ledesma V, Cabanillas Y, Vagace JM "Aplastic anemia during treatment with albendazole." Am J Hematol 53 (1996):  53-4|"Product Information. Albenza (albendazole)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38586, 12234, 'Albendazole', 'Bone Marrow Failure Disorders', 'Reversible leukopenia has been reported during albendazole therapy.  Rarely, granulocytopenia or pancytopenia have resulted in death.  Therapy with albendazole should be administered cautiously in patients with predisposition to myelosuppression.  Clinical monitoring of hematopoietic function prior to each cycle of albendazole and every two weeks during therapy is recommended.  Albendazole can be continued with a modest, non- progressive decrease in leukocyte count and absolute neutrophil count.', '3', 'Fernandez FJ, Rodriguezvidigal FF, Ledesma V, Cabanillas Y, Vagace JM "Aplastic anemia during treatment with albendazole." Am J Hematol 53 (1996):  53-4|"Product Information. Albenza (albendazole)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38587, 12236, 'Albendazole', 'Bone Marrow Failure Disorders', 'Reversible leukopenia has been reported during albendazole therapy.  Rarely, granulocytopenia or pancytopenia have resulted in death.  Therapy with albendazole should be administered cautiously in patients with predisposition to myelosuppression.  Clinical monitoring of hematopoietic function prior to each cycle of albendazole and every two weeks during therapy is recommended.  Albendazole can be continued with a modest, non- progressive decrease in leukocyte count and absolute neutrophil count.', '3', 'Fernandez FJ, Rodriguezvidigal FF, Ledesma V, Cabanillas Y, Vagace JM "Aplastic anemia during treatment with albendazole." Am J Hematol 53 (1996):  53-4|"Product Information. Albenza (albendazole)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38588, 13623, 'Albendazole', 'Bone Marrow Failure Disorders', 'Reversible leukopenia has been reported during albendazole therapy.  Rarely, granulocytopenia or pancytopenia have resulted in death.  Therapy with albendazole should be administered cautiously in patients with predisposition to myelosuppression.  Clinical monitoring of hematopoietic function prior to each cycle of albendazole and every two weeks during therapy is recommended.  Albendazole can be continued with a modest, non- progressive decrease in leukocyte count and absolute neutrophil count.', '3', 'Fernandez FJ, Rodriguezvidigal FF, Ledesma V, Cabanillas Y, Vagace JM "Aplastic anemia during treatment with albendazole." Am J Hematol 53 (1996):  53-4|"Product Information. Albenza (albendazole)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38589, 13624, 'Albendazole', 'Bone Marrow Failure Disorders', 'Reversible leukopenia has been reported during albendazole therapy.  Rarely, granulocytopenia or pancytopenia have resulted in death.  Therapy with albendazole should be administered cautiously in patients with predisposition to myelosuppression.  Clinical monitoring of hematopoietic function prior to each cycle of albendazole and every two weeks during therapy is recommended.  Albendazole can be continued with a modest, non- progressive decrease in leukocyte count and absolute neutrophil count.', '3', 'Fernandez FJ, Rodriguezvidigal FF, Ledesma V, Cabanillas Y, Vagace JM "Aplastic anemia during treatment with albendazole." Am J Hematol 53 (1996):  53-4|"Product Information. Albenza (albendazole)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38590, 13872, 'Albendazole', 'Bone Marrow Failure Disorders', 'Reversible leukopenia has been reported during albendazole therapy.  Rarely, granulocytopenia or pancytopenia have resulted in death.  Therapy with albendazole should be administered cautiously in patients with predisposition to myelosuppression.  Clinical monitoring of hematopoietic function prior to each cycle of albendazole and every two weeks during therapy is recommended.  Albendazole can be continued with a modest, non- progressive decrease in leukocyte count and absolute neutrophil count.', '3', 'Fernandez FJ, Rodriguezvidigal FF, Ledesma V, Cabanillas Y, Vagace JM "Aplastic anemia during treatment with albendazole." Am J Hematol 53 (1996):  53-4|"Product Information. Albenza (albendazole)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38591, 15064, 'Albendazole', 'Bone Marrow Failure Disorders', 'Reversible leukopenia has been reported during albendazole therapy.  Rarely, granulocytopenia or pancytopenia have resulted in death.  Therapy with albendazole should be administered cautiously in patients with predisposition to myelosuppression.  Clinical monitoring of hematopoietic function prior to each cycle of albendazole and every two weeks during therapy is recommended.  Albendazole can be continued with a modest, non- progressive decrease in leukocyte count and absolute neutrophil count.', '3', 'Fernandez FJ, Rodriguezvidigal FF, Ledesma V, Cabanillas Y, Vagace JM "Aplastic anemia during treatment with albendazole." Am J Hematol 53 (1996):  53-4|"Product Information. Albenza (albendazole)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38592, 468, 'Albendazole', 'Liver Diseases', 'Albendazole is converted to its biologically active metabolite and further metabolized to an inactive form by the liver.  Biliary excretion of albendazole is the primary route of elimination and biliary obstruction results in increased albendazole serum concentration and AUC.  Metabolism and therapeutic activity may be altered in patients with hepatic impairment.  Elevated liver transaminase levels have been reported in 16% of patients receiving albendazole.  Therapy with albendazole should be administered cautiously in patients with compromised hepatic function.  Clinical monitoring of hepatic function is recommended prior to initiation of each cycle of albendazole and at least every two weeks during therapy.  Patients with elevated liver enzyme test results are at increased risk for hepatotoxicity and bone marrow suppression.  Discontinue therapy if liver enzymes are significantly increased or if a clinically significant decrease in blood cell counts occur.', '2', 'Choudhuri G, Prasad RN "Jaundice due to albendazole." Indian J Gastroenterol 7 (1988):  245-6|Marriner SE, Morris DL, Dickson B, Bogan JA "Pharmacokinetics of albendazole in man." Eur J Clin Pharmacol 30 (1986):  705-8|"Product Information. Albenza (albendazole)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38593, 470, 'Albendazole', 'Liver Diseases', 'Albendazole is converted to its biologically active metabolite and further metabolized to an inactive form by the liver.  Biliary excretion of albendazole is the primary route of elimination and biliary obstruction results in increased albendazole serum concentration and AUC.  Metabolism and therapeutic activity may be altered in patients with hepatic impairment.  Elevated liver transaminase levels have been reported in 16% of patients receiving albendazole.  Therapy with albendazole should be administered cautiously in patients with compromised hepatic function.  Clinical monitoring of hepatic function is recommended prior to initiation of each cycle of albendazole and at least every two weeks during therapy.  Patients with elevated liver enzyme test results are at increased risk for hepatotoxicity and bone marrow suppression.  Discontinue therapy if liver enzymes are significantly increased or if a clinically significant decrease in blood cell counts occur.', '2', 'Choudhuri G, Prasad RN "Jaundice due to albendazole." Indian J Gastroenterol 7 (1988):  245-6|Marriner SE, Morris DL, Dickson B, Bogan JA "Pharmacokinetics of albendazole in man." Eur J Clin Pharmacol 30 (1986):  705-8|"Product Information. Albenza (albendazole)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38594, 807, 'Albendazole', 'Liver Diseases', 'Albendazole is converted to its biologically active metabolite and further metabolized to an inactive form by the liver.  Biliary excretion of albendazole is the primary route of elimination and biliary obstruction results in increased albendazole serum concentration and AUC.  Metabolism and therapeutic activity may be altered in patients with hepatic impairment.  Elevated liver transaminase levels have been reported in 16% of patients receiving albendazole.  Therapy with albendazole should be administered cautiously in patients with compromised hepatic function.  Clinical monitoring of hepatic function is recommended prior to initiation of each cycle of albendazole and at least every two weeks during therapy.  Patients with elevated liver enzyme test results are at increased risk for hepatotoxicity and bone marrow suppression.  Discontinue therapy if liver enzymes are significantly increased or if a clinically significant decrease in blood cell counts occur.', '2', 'Choudhuri G, Prasad RN "Jaundice due to albendazole." Indian J Gastroenterol 7 (1988):  245-6|Marriner SE, Morris DL, Dickson B, Bogan JA "Pharmacokinetics of albendazole in man." Eur J Clin Pharmacol 30 (1986):  705-8|"Product Information. Albenza (albendazole)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38595, 809, 'Albendazole', 'Liver Diseases', 'Albendazole is converted to its biologically active metabolite and further metabolized to an inactive form by the liver.  Biliary excretion of albendazole is the primary route of elimination and biliary obstruction results in increased albendazole serum concentration and AUC.  Metabolism and therapeutic activity may be altered in patients with hepatic impairment.  Elevated liver transaminase levels have been reported in 16% of patients receiving albendazole.  Therapy with albendazole should be administered cautiously in patients with compromised hepatic function.  Clinical monitoring of hepatic function is recommended prior to initiation of each cycle of albendazole and at least every two weeks during therapy.  Patients with elevated liver enzyme test results are at increased risk for hepatotoxicity and bone marrow suppression.  Discontinue therapy if liver enzymes are significantly increased or if a clinically significant decrease in blood cell counts occur.', '2', 'Choudhuri G, Prasad RN "Jaundice due to albendazole." Indian J Gastroenterol 7 (1988):  245-6|Marriner SE, Morris DL, Dickson B, Bogan JA "Pharmacokinetics of albendazole in man." Eur J Clin Pharmacol 30 (1986):  705-8|"Product Information. Albenza (albendazole)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38596, 1381, 'Albendazole', 'Liver Diseases', 'Albendazole is converted to its biologically active metabolite and further metabolized to an inactive form by the liver.  Biliary excretion of albendazole is the primary route of elimination and biliary obstruction results in increased albendazole serum concentration and AUC.  Metabolism and therapeutic activity may be altered in patients with hepatic impairment.  Elevated liver transaminase levels have been reported in 16% of patients receiving albendazole.  Therapy with albendazole should be administered cautiously in patients with compromised hepatic function.  Clinical monitoring of hepatic function is recommended prior to initiation of each cycle of albendazole and at least every two weeks during therapy.  Patients with elevated liver enzyme test results are at increased risk for hepatotoxicity and bone marrow suppression.  Discontinue therapy if liver enzymes are significantly increased or if a clinically significant decrease in blood cell counts occur.', '2', 'Choudhuri G, Prasad RN "Jaundice due to albendazole." Indian J Gastroenterol 7 (1988):  245-6|Marriner SE, Morris DL, Dickson B, Bogan JA "Pharmacokinetics of albendazole in man." Eur J Clin Pharmacol 30 (1986):  705-8|"Product Information. Albenza (albendazole)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38597, 12234, 'Albendazole', 'Liver Diseases', 'Albendazole is converted to its biologically active metabolite and further metabolized to an inactive form by the liver.  Biliary excretion of albendazole is the primary route of elimination and biliary obstruction results in increased albendazole serum concentration and AUC.  Metabolism and therapeutic activity may be altered in patients with hepatic impairment.  Elevated liver transaminase levels have been reported in 16% of patients receiving albendazole.  Therapy with albendazole should be administered cautiously in patients with compromised hepatic function.  Clinical monitoring of hepatic function is recommended prior to initiation of each cycle of albendazole and at least every two weeks during therapy.  Patients with elevated liver enzyme test results are at increased risk for hepatotoxicity and bone marrow suppression.  Discontinue therapy if liver enzymes are significantly increased or if a clinically significant decrease in blood cell counts occur.', '2', 'Choudhuri G, Prasad RN "Jaundice due to albendazole." Indian J Gastroenterol 7 (1988):  245-6|Marriner SE, Morris DL, Dickson B, Bogan JA "Pharmacokinetics of albendazole in man." Eur J Clin Pharmacol 30 (1986):  705-8|"Product Information. Albenza (albendazole)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38598, 12236, 'Albendazole', 'Liver Diseases', 'Albendazole is converted to its biologically active metabolite and further metabolized to an inactive form by the liver.  Biliary excretion of albendazole is the primary route of elimination and biliary obstruction results in increased albendazole serum concentration and AUC.  Metabolism and therapeutic activity may be altered in patients with hepatic impairment.  Elevated liver transaminase levels have been reported in 16% of patients receiving albendazole.  Therapy with albendazole should be administered cautiously in patients with compromised hepatic function.  Clinical monitoring of hepatic function is recommended prior to initiation of each cycle of albendazole and at least every two weeks during therapy.  Patients with elevated liver enzyme test results are at increased risk for hepatotoxicity and bone marrow suppression.  Discontinue therapy if liver enzymes are significantly increased or if a clinically significant decrease in blood cell counts occur.', '2', 'Choudhuri G, Prasad RN "Jaundice due to albendazole." Indian J Gastroenterol 7 (1988):  245-6|Marriner SE, Morris DL, Dickson B, Bogan JA "Pharmacokinetics of albendazole in man." Eur J Clin Pharmacol 30 (1986):  705-8|"Product Information. Albenza (albendazole)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38599, 13623, 'Albendazole', 'Liver Diseases', 'Albendazole is converted to its biologically active metabolite and further metabolized to an inactive form by the liver.  Biliary excretion of albendazole is the primary route of elimination and biliary obstruction results in increased albendazole serum concentration and AUC.  Metabolism and therapeutic activity may be altered in patients with hepatic impairment.  Elevated liver transaminase levels have been reported in 16% of patients receiving albendazole.  Therapy with albendazole should be administered cautiously in patients with compromised hepatic function.  Clinical monitoring of hepatic function is recommended prior to initiation of each cycle of albendazole and at least every two weeks during therapy.  Patients with elevated liver enzyme test results are at increased risk for hepatotoxicity and bone marrow suppression.  Discontinue therapy if liver enzymes are significantly increased or if a clinically significant decrease in blood cell counts occur.', '2', 'Choudhuri G, Prasad RN "Jaundice due to albendazole." Indian J Gastroenterol 7 (1988):  245-6|Marriner SE, Morris DL, Dickson B, Bogan JA "Pharmacokinetics of albendazole in man." Eur J Clin Pharmacol 30 (1986):  705-8|"Product Information. Albenza (albendazole)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38600, 13624, 'Albendazole', 'Liver Diseases', 'Albendazole is converted to its biologically active metabolite and further metabolized to an inactive form by the liver.  Biliary excretion of albendazole is the primary route of elimination and biliary obstruction results in increased albendazole serum concentration and AUC.  Metabolism and therapeutic activity may be altered in patients with hepatic impairment.  Elevated liver transaminase levels have been reported in 16% of patients receiving albendazole.  Therapy with albendazole should be administered cautiously in patients with compromised hepatic function.  Clinical monitoring of hepatic function is recommended prior to initiation of each cycle of albendazole and at least every two weeks during therapy.  Patients with elevated liver enzyme test results are at increased risk for hepatotoxicity and bone marrow suppression.  Discontinue therapy if liver enzymes are significantly increased or if a clinically significant decrease in blood cell counts occur.', '2', 'Choudhuri G, Prasad RN "Jaundice due to albendazole." Indian J Gastroenterol 7 (1988):  245-6|Marriner SE, Morris DL, Dickson B, Bogan JA "Pharmacokinetics of albendazole in man." Eur J Clin Pharmacol 30 (1986):  705-8|"Product Information. Albenza (albendazole)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38601, 13872, 'Albendazole', 'Liver Diseases', 'Albendazole is converted to its biologically active metabolite and further metabolized to an inactive form by the liver.  Biliary excretion of albendazole is the primary route of elimination and biliary obstruction results in increased albendazole serum concentration and AUC.  Metabolism and therapeutic activity may be altered in patients with hepatic impairment.  Elevated liver transaminase levels have been reported in 16% of patients receiving albendazole.  Therapy with albendazole should be administered cautiously in patients with compromised hepatic function.  Clinical monitoring of hepatic function is recommended prior to initiation of each cycle of albendazole and at least every two weeks during therapy.  Patients with elevated liver enzyme test results are at increased risk for hepatotoxicity and bone marrow suppression.  Discontinue therapy if liver enzymes are significantly increased or if a clinically significant decrease in blood cell counts occur.', '2', 'Choudhuri G, Prasad RN "Jaundice due to albendazole." Indian J Gastroenterol 7 (1988):  245-6|Marriner SE, Morris DL, Dickson B, Bogan JA "Pharmacokinetics of albendazole in man." Eur J Clin Pharmacol 30 (1986):  705-8|"Product Information. Albenza (albendazole)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38602, 15064, 'Albendazole', 'Liver Diseases', 'Albendazole is converted to its biologically active metabolite and further metabolized to an inactive form by the liver.  Biliary excretion of albendazole is the primary route of elimination and biliary obstruction results in increased albendazole serum concentration and AUC.  Metabolism and therapeutic activity may be altered in patients with hepatic impairment.  Elevated liver transaminase levels have been reported in 16% of patients receiving albendazole.  Therapy with albendazole should be administered cautiously in patients with compromised hepatic function.  Clinical monitoring of hepatic function is recommended prior to initiation of each cycle of albendazole and at least every two weeks during therapy.  Patients with elevated liver enzyme test results are at increased risk for hepatotoxicity and bone marrow suppression.  Discontinue therapy if liver enzymes are significantly increased or if a clinically significant decrease in blood cell counts occur.', '2', 'Choudhuri G, Prasad RN "Jaundice due to albendazole." Indian J Gastroenterol 7 (1988):  245-6|Marriner SE, Morris DL, Dickson B, Bogan JA "Pharmacokinetics of albendazole in man." Eur J Clin Pharmacol 30 (1986):  705-8|"Product Information. Albenza (albendazole)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38603, 468, 'Albendazole', 'Neurologic Manifestations', 'Albendazole therapy of neurocysticercosis can induce an inflammatory response within the CNS that precipitates seizures and cerebral hypertension.  Therapy with albendazole for neurocysticercosis should be administered cautiously in patients with or predisposition to seizures.  The use of corticosteroids during the first week of therapy to prevent cerebral hypertension and anticonvulsant therapy as required is recommended.', '2', 'Cruz I, Cruz ME, Carrasco F, Horton J "Neurocysticercosis: optimal dose treatment with albendazole." J Neurol Sci 133 (1995):  152-4|"Product Information. Albenza (albendazole)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38604, 470, 'Albendazole', 'Neurologic Manifestations', 'Albendazole therapy of neurocysticercosis can induce an inflammatory response within the CNS that precipitates seizures and cerebral hypertension.  Therapy with albendazole for neurocysticercosis should be administered cautiously in patients with or predisposition to seizures.  The use of corticosteroids during the first week of therapy to prevent cerebral hypertension and anticonvulsant therapy as required is recommended.', '2', 'Cruz I, Cruz ME, Carrasco F, Horton J "Neurocysticercosis: optimal dose treatment with albendazole." J Neurol Sci 133 (1995):  152-4|"Product Information. Albenza (albendazole)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38605, 807, 'Albendazole', 'Neurologic Manifestations', 'Albendazole therapy of neurocysticercosis can induce an inflammatory response within the CNS that precipitates seizures and cerebral hypertension.  Therapy with albendazole for neurocysticercosis should be administered cautiously in patients with or predisposition to seizures.  The use of corticosteroids during the first week of therapy to prevent cerebral hypertension and anticonvulsant therapy as required is recommended.', '2', 'Cruz I, Cruz ME, Carrasco F, Horton J "Neurocysticercosis: optimal dose treatment with albendazole." J Neurol Sci 133 (1995):  152-4|"Product Information. Albenza (albendazole)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38606, 809, 'Albendazole', 'Neurologic Manifestations', 'Albendazole therapy of neurocysticercosis can induce an inflammatory response within the CNS that precipitates seizures and cerebral hypertension.  Therapy with albendazole for neurocysticercosis should be administered cautiously in patients with or predisposition to seizures.  The use of corticosteroids during the first week of therapy to prevent cerebral hypertension and anticonvulsant therapy as required is recommended.', '2', 'Cruz I, Cruz ME, Carrasco F, Horton J "Neurocysticercosis: optimal dose treatment with albendazole." J Neurol Sci 133 (1995):  152-4|"Product Information. Albenza (albendazole)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38607, 1381, 'Albendazole', 'Neurologic Manifestations', 'Albendazole therapy of neurocysticercosis can induce an inflammatory response within the CNS that precipitates seizures and cerebral hypertension.  Therapy with albendazole for neurocysticercosis should be administered cautiously in patients with or predisposition to seizures.  The use of corticosteroids during the first week of therapy to prevent cerebral hypertension and anticonvulsant therapy as required is recommended.', '2', 'Cruz I, Cruz ME, Carrasco F, Horton J "Neurocysticercosis: optimal dose treatment with albendazole." J Neurol Sci 133 (1995):  152-4|"Product Information. Albenza (albendazole)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38608, 12234, 'Albendazole', 'Neurologic Manifestations', 'Albendazole therapy of neurocysticercosis can induce an inflammatory response within the CNS that precipitates seizures and cerebral hypertension.  Therapy with albendazole for neurocysticercosis should be administered cautiously in patients with or predisposition to seizures.  The use of corticosteroids during the first week of therapy to prevent cerebral hypertension and anticonvulsant therapy as required is recommended.', '2', 'Cruz I, Cruz ME, Carrasco F, Horton J "Neurocysticercosis: optimal dose treatment with albendazole." J Neurol Sci 133 (1995):  152-4|"Product Information. Albenza (albendazole)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38609, 12236, 'Albendazole', 'Neurologic Manifestations', 'Albendazole therapy of neurocysticercosis can induce an inflammatory response within the CNS that precipitates seizures and cerebral hypertension.  Therapy with albendazole for neurocysticercosis should be administered cautiously in patients with or predisposition to seizures.  The use of corticosteroids during the first week of therapy to prevent cerebral hypertension and anticonvulsant therapy as required is recommended.', '2', 'Cruz I, Cruz ME, Carrasco F, Horton J "Neurocysticercosis: optimal dose treatment with albendazole." J Neurol Sci 133 (1995):  152-4|"Product Information. Albenza (albendazole)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38610, 13623, 'Albendazole', 'Neurologic Manifestations', 'Albendazole therapy of neurocysticercosis can induce an inflammatory response within the CNS that precipitates seizures and cerebral hypertension.  Therapy with albendazole for neurocysticercosis should be administered cautiously in patients with or predisposition to seizures.  The use of corticosteroids during the first week of therapy to prevent cerebral hypertension and anticonvulsant therapy as required is recommended.', '2', 'Cruz I, Cruz ME, Carrasco F, Horton J "Neurocysticercosis: optimal dose treatment with albendazole." J Neurol Sci 133 (1995):  152-4|"Product Information. Albenza (albendazole)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38611, 13624, 'Albendazole', 'Neurologic Manifestations', 'Albendazole therapy of neurocysticercosis can induce an inflammatory response within the CNS that precipitates seizures and cerebral hypertension.  Therapy with albendazole for neurocysticercosis should be administered cautiously in patients with or predisposition to seizures.  The use of corticosteroids during the first week of therapy to prevent cerebral hypertension and anticonvulsant therapy as required is recommended.', '2', 'Cruz I, Cruz ME, Carrasco F, Horton J "Neurocysticercosis: optimal dose treatment with albendazole." J Neurol Sci 133 (1995):  152-4|"Product Information. Albenza (albendazole)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38612, 13872, 'Albendazole', 'Neurologic Manifestations', 'Albendazole therapy of neurocysticercosis can induce an inflammatory response within the CNS that precipitates seizures and cerebral hypertension.  Therapy with albendazole for neurocysticercosis should be administered cautiously in patients with or predisposition to seizures.  The use of corticosteroids during the first week of therapy to prevent cerebral hypertension and anticonvulsant therapy as required is recommended.', '2', 'Cruz I, Cruz ME, Carrasco F, Horton J "Neurocysticercosis: optimal dose treatment with albendazole." J Neurol Sci 133 (1995):  152-4|"Product Information. Albenza (albendazole)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38613, 15064, 'Albendazole', 'Neurologic Manifestations', 'Albendazole therapy of neurocysticercosis can induce an inflammatory response within the CNS that precipitates seizures and cerebral hypertension.  Therapy with albendazole for neurocysticercosis should be administered cautiously in patients with or predisposition to seizures.  The use of corticosteroids during the first week of therapy to prevent cerebral hypertension and anticonvulsant therapy as required is recommended.', '2', 'Cruz I, Cruz ME, Carrasco F, Horton J "Neurocysticercosis: optimal dose treatment with albendazole." J Neurol Sci 133 (1995):  152-4|"Product Information. Albenza (albendazole)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38614, 468, 'Albendazole', 'Kidney Diseases', 'The pharmacokinetics of albendazole in patients with impaired renal function have not been studied.  Caution is advised if used in these patients.', '2', '"Product Information. Albenza (albendazole)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38615, 470, 'Albendazole', 'Kidney Diseases', 'The pharmacokinetics of albendazole in patients with impaired renal function have not been studied.  Caution is advised if used in these patients.', '2', '"Product Information. Albenza (albendazole)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38616, 807, 'Albendazole', 'Kidney Diseases', 'The pharmacokinetics of albendazole in patients with impaired renal function have not been studied.  Caution is advised if used in these patients.', '2', '"Product Information. Albenza (albendazole)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38617, 809, 'Albendazole', 'Kidney Diseases', 'The pharmacokinetics of albendazole in patients with impaired renal function have not been studied.  Caution is advised if used in these patients.', '2', '"Product Information. Albenza (albendazole)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38618, 1381, 'Albendazole', 'Kidney Diseases', 'The pharmacokinetics of albendazole in patients with impaired renal function have not been studied.  Caution is advised if used in these patients.', '2', '"Product Information. Albenza (albendazole)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38619, 12234, 'Albendazole', 'Kidney Diseases', 'The pharmacokinetics of albendazole in patients with impaired renal function have not been studied.  Caution is advised if used in these patients.', '2', '"Product Information. Albenza (albendazole)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38620, 12236, 'Albendazole', 'Kidney Diseases', 'The pharmacokinetics of albendazole in patients with impaired renal function have not been studied.  Caution is advised if used in these patients.', '2', '"Product Information. Albenza (albendazole)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38621, 13623, 'Albendazole', 'Kidney Diseases', 'The pharmacokinetics of albendazole in patients with impaired renal function have not been studied.  Caution is advised if used in these patients.', '2', '"Product Information. Albenza (albendazole)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38622, 13624, 'Albendazole', 'Kidney Diseases', 'The pharmacokinetics of albendazole in patients with impaired renal function have not been studied.  Caution is advised if used in these patients.', '2', '"Product Information. Albenza (albendazole)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38623, 13872, 'Albendazole', 'Kidney Diseases', 'The pharmacokinetics of albendazole in patients with impaired renal function have not been studied.  Caution is advised if used in these patients.', '2', '"Product Information. Albenza (albendazole)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38624, 15064, 'Albendazole', 'Kidney Diseases', 'The pharmacokinetics of albendazole in patients with impaired renal function have not been studied.  Caution is advised if used in these patients.', '2', '"Product Information. Albenza (albendazole)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38625, 149, 'Chloramphenicol', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38626, 2499, 'Chloramphenicol', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38627, 2564, 'Chloramphenicol', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38628, 7921, 'Chloramphenicol', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38629, 8231, 'Chloramphenicol', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38630, 8232, 'Chloramphenicol', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38631, 9271, 'Chloramphenicol', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38632, 9313, 'Chloramphenicol', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38633, 9456, 'Chloramphenicol', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38634, 16245, 'Chloramphenicol', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38635, 16307, 'Chloramphenicol', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38636, 16308, 'Chloramphenicol', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38637, 18442, 'Chloramphenicol', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38638, 21029, 'Chloramphenicol', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38639, 21755, 'Chloramphenicol', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38640, 22814, 'Chloramphenicol', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38641, 22816, 'Chloramphenicol', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38642, 22817, 'Chloramphenicol', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38643, 24138, 'Chloramphenicol', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38644, 149, 'Chloramphenicol', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', 'Abrams SM, Degnan TJ, Vinciguerra V "Marrow aplasia following topical application of chloramphenicol eye ointment." Arch Intern Med 140 (1980):  576-7|Calderwood SB, Moellering RC "Common adverse effects of antibacterial agents on major organ systems." Surg Clin North Am 60 (1980):  65-81|Del Giacco GS, Petrini MT, Jannelli S, Carcassi U "Fatal bone marrow hypoplasia in a shepherd using chloramphenicol spray." Lancet 1 (1981):  945|Farber BF, Brody JP "Rapid development of aplastic anemia after intravenous chloramphenicol and cimetidine therapy." South Med J 74 (1981):  1257-8|Fraunfelder FT, Bagby GC, Kelly DJ "Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol." Am J Ophthalmol 93 (1982):  356-60|Alavi JB "Aplastic anemia associated with intravenous chloramphenicol." Am J Hematol 15 (1983):  375-9|West BC, DeVault GA Jr, Clement JC, Williams DM "Aplastic anemia associated with parenteral chloramphenicol: review of 10 cases, including the second case of possible increased risk with cimetidine." Rev Infect Dis 10 (1988):  1048-51|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Doona M, Walsh JB "Use of chloramphenicol as topical eye medication: time to cry halt? bone marrow aplasia also occurs with ocular use." BMJ 310 (1995):  1217-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38645, 2499, 'Chloramphenicol', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', 'Abrams SM, Degnan TJ, Vinciguerra V "Marrow aplasia following topical application of chloramphenicol eye ointment." Arch Intern Med 140 (1980):  576-7|Calderwood SB, Moellering RC "Common adverse effects of antibacterial agents on major organ systems." Surg Clin North Am 60 (1980):  65-81|Del Giacco GS, Petrini MT, Jannelli S, Carcassi U "Fatal bone marrow hypoplasia in a shepherd using chloramphenicol spray." Lancet 1 (1981):  945|Farber BF, Brody JP "Rapid development of aplastic anemia after intravenous chloramphenicol and cimetidine therapy." South Med J 74 (1981):  1257-8|Fraunfelder FT, Bagby GC, Kelly DJ "Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol." Am J Ophthalmol 93 (1982):  356-60|Alavi JB "Aplastic anemia associated with intravenous chloramphenicol." Am J Hematol 15 (1983):  375-9|West BC, DeVault GA Jr, Clement JC, Williams DM "Aplastic anemia associated with parenteral chloramphenicol: review of 10 cases, including the second case of possible increased risk with cimetidine." Rev Infect Dis 10 (1988):  1048-51|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Doona M, Walsh JB "Use of chloramphenicol as topical eye medication: time to cry halt? bone marrow aplasia also occurs with ocular use." BMJ 310 (1995):  1217-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38646, 2564, 'Chloramphenicol', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', 'Abrams SM, Degnan TJ, Vinciguerra V "Marrow aplasia following topical application of chloramphenicol eye ointment." Arch Intern Med 140 (1980):  576-7|Calderwood SB, Moellering RC "Common adverse effects of antibacterial agents on major organ systems." Surg Clin North Am 60 (1980):  65-81|Del Giacco GS, Petrini MT, Jannelli S, Carcassi U "Fatal bone marrow hypoplasia in a shepherd using chloramphenicol spray." Lancet 1 (1981):  945|Farber BF, Brody JP "Rapid development of aplastic anemia after intravenous chloramphenicol and cimetidine therapy." South Med J 74 (1981):  1257-8|Fraunfelder FT, Bagby GC, Kelly DJ "Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol." Am J Ophthalmol 93 (1982):  356-60|Alavi JB "Aplastic anemia associated with intravenous chloramphenicol." Am J Hematol 15 (1983):  375-9|West BC, DeVault GA Jr, Clement JC, Williams DM "Aplastic anemia associated with parenteral chloramphenicol: review of 10 cases, including the second case of possible increased risk with cimetidine." Rev Infect Dis 10 (1988):  1048-51|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Doona M, Walsh JB "Use of chloramphenicol as topical eye medication: time to cry halt? bone marrow aplasia also occurs with ocular use." BMJ 310 (1995):  1217-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38647, 7921, 'Chloramphenicol', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', 'Abrams SM, Degnan TJ, Vinciguerra V "Marrow aplasia following topical application of chloramphenicol eye ointment." Arch Intern Med 140 (1980):  576-7|Calderwood SB, Moellering RC "Common adverse effects of antibacterial agents on major organ systems." Surg Clin North Am 60 (1980):  65-81|Del Giacco GS, Petrini MT, Jannelli S, Carcassi U "Fatal bone marrow hypoplasia in a shepherd using chloramphenicol spray." Lancet 1 (1981):  945|Farber BF, Brody JP "Rapid development of aplastic anemia after intravenous chloramphenicol and cimetidine therapy." South Med J 74 (1981):  1257-8|Fraunfelder FT, Bagby GC, Kelly DJ "Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol." Am J Ophthalmol 93 (1982):  356-60|Alavi JB "Aplastic anemia associated with intravenous chloramphenicol." Am J Hematol 15 (1983):  375-9|West BC, DeVault GA Jr, Clement JC, Williams DM "Aplastic anemia associated with parenteral chloramphenicol: review of 10 cases, including the second case of possible increased risk with cimetidine." Rev Infect Dis 10 (1988):  1048-51|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Doona M, Walsh JB "Use of chloramphenicol as topical eye medication: time to cry halt? bone marrow aplasia also occurs with ocular use." BMJ 310 (1995):  1217-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38648, 8231, 'Chloramphenicol', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', 'Abrams SM, Degnan TJ, Vinciguerra V "Marrow aplasia following topical application of chloramphenicol eye ointment." Arch Intern Med 140 (1980):  576-7|Calderwood SB, Moellering RC "Common adverse effects of antibacterial agents on major organ systems." Surg Clin North Am 60 (1980):  65-81|Del Giacco GS, Petrini MT, Jannelli S, Carcassi U "Fatal bone marrow hypoplasia in a shepherd using chloramphenicol spray." Lancet 1 (1981):  945|Farber BF, Brody JP "Rapid development of aplastic anemia after intravenous chloramphenicol and cimetidine therapy." South Med J 74 (1981):  1257-8|Fraunfelder FT, Bagby GC, Kelly DJ "Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol." Am J Ophthalmol 93 (1982):  356-60|Alavi JB "Aplastic anemia associated with intravenous chloramphenicol." Am J Hematol 15 (1983):  375-9|West BC, DeVault GA Jr, Clement JC, Williams DM "Aplastic anemia associated with parenteral chloramphenicol: review of 10 cases, including the second case of possible increased risk with cimetidine." Rev Infect Dis 10 (1988):  1048-51|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Doona M, Walsh JB "Use of chloramphenicol as topical eye medication: time to cry halt? bone marrow aplasia also occurs with ocular use." BMJ 310 (1995):  1217-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38649, 8232, 'Chloramphenicol', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', 'Abrams SM, Degnan TJ, Vinciguerra V "Marrow aplasia following topical application of chloramphenicol eye ointment." Arch Intern Med 140 (1980):  576-7|Calderwood SB, Moellering RC "Common adverse effects of antibacterial agents on major organ systems." Surg Clin North Am 60 (1980):  65-81|Del Giacco GS, Petrini MT, Jannelli S, Carcassi U "Fatal bone marrow hypoplasia in a shepherd using chloramphenicol spray." Lancet 1 (1981):  945|Farber BF, Brody JP "Rapid development of aplastic anemia after intravenous chloramphenicol and cimetidine therapy." South Med J 74 (1981):  1257-8|Fraunfelder FT, Bagby GC, Kelly DJ "Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol." Am J Ophthalmol 93 (1982):  356-60|Alavi JB "Aplastic anemia associated with intravenous chloramphenicol." Am J Hematol 15 (1983):  375-9|West BC, DeVault GA Jr, Clement JC, Williams DM "Aplastic anemia associated with parenteral chloramphenicol: review of 10 cases, including the second case of possible increased risk with cimetidine." Rev Infect Dis 10 (1988):  1048-51|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Doona M, Walsh JB "Use of chloramphenicol as topical eye medication: time to cry halt? bone marrow aplasia also occurs with ocular use." BMJ 310 (1995):  1217-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38650, 9271, 'Chloramphenicol', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', 'Abrams SM, Degnan TJ, Vinciguerra V "Marrow aplasia following topical application of chloramphenicol eye ointment." Arch Intern Med 140 (1980):  576-7|Calderwood SB, Moellering RC "Common adverse effects of antibacterial agents on major organ systems." Surg Clin North Am 60 (1980):  65-81|Del Giacco GS, Petrini MT, Jannelli S, Carcassi U "Fatal bone marrow hypoplasia in a shepherd using chloramphenicol spray." Lancet 1 (1981):  945|Farber BF, Brody JP "Rapid development of aplastic anemia after intravenous chloramphenicol and cimetidine therapy." South Med J 74 (1981):  1257-8|Fraunfelder FT, Bagby GC, Kelly DJ "Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol." Am J Ophthalmol 93 (1982):  356-60|Alavi JB "Aplastic anemia associated with intravenous chloramphenicol." Am J Hematol 15 (1983):  375-9|West BC, DeVault GA Jr, Clement JC, Williams DM "Aplastic anemia associated with parenteral chloramphenicol: review of 10 cases, including the second case of possible increased risk with cimetidine." Rev Infect Dis 10 (1988):  1048-51|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Doona M, Walsh JB "Use of chloramphenicol as topical eye medication: time to cry halt? bone marrow aplasia also occurs with ocular use." BMJ 310 (1995):  1217-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38651, 9313, 'Chloramphenicol', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', 'Abrams SM, Degnan TJ, Vinciguerra V "Marrow aplasia following topical application of chloramphenicol eye ointment." Arch Intern Med 140 (1980):  576-7|Calderwood SB, Moellering RC "Common adverse effects of antibacterial agents on major organ systems." Surg Clin North Am 60 (1980):  65-81|Del Giacco GS, Petrini MT, Jannelli S, Carcassi U "Fatal bone marrow hypoplasia in a shepherd using chloramphenicol spray." Lancet 1 (1981):  945|Farber BF, Brody JP "Rapid development of aplastic anemia after intravenous chloramphenicol and cimetidine therapy." South Med J 74 (1981):  1257-8|Fraunfelder FT, Bagby GC, Kelly DJ "Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol." Am J Ophthalmol 93 (1982):  356-60|Alavi JB "Aplastic anemia associated with intravenous chloramphenicol." Am J Hematol 15 (1983):  375-9|West BC, DeVault GA Jr, Clement JC, Williams DM "Aplastic anemia associated with parenteral chloramphenicol: review of 10 cases, including the second case of possible increased risk with cimetidine." Rev Infect Dis 10 (1988):  1048-51|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Doona M, Walsh JB "Use of chloramphenicol as topical eye medication: time to cry halt? bone marrow aplasia also occurs with ocular use." BMJ 310 (1995):  1217-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38652, 9456, 'Chloramphenicol', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', 'Abrams SM, Degnan TJ, Vinciguerra V "Marrow aplasia following topical application of chloramphenicol eye ointment." Arch Intern Med 140 (1980):  576-7|Calderwood SB, Moellering RC "Common adverse effects of antibacterial agents on major organ systems." Surg Clin North Am 60 (1980):  65-81|Del Giacco GS, Petrini MT, Jannelli S, Carcassi U "Fatal bone marrow hypoplasia in a shepherd using chloramphenicol spray." Lancet 1 (1981):  945|Farber BF, Brody JP "Rapid development of aplastic anemia after intravenous chloramphenicol and cimetidine therapy." South Med J 74 (1981):  1257-8|Fraunfelder FT, Bagby GC, Kelly DJ "Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol." Am J Ophthalmol 93 (1982):  356-60|Alavi JB "Aplastic anemia associated with intravenous chloramphenicol." Am J Hematol 15 (1983):  375-9|West BC, DeVault GA Jr, Clement JC, Williams DM "Aplastic anemia associated with parenteral chloramphenicol: review of 10 cases, including the second case of possible increased risk with cimetidine." Rev Infect Dis 10 (1988):  1048-51|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Doona M, Walsh JB "Use of chloramphenicol as topical eye medication: time to cry halt? bone marrow aplasia also occurs with ocular use." BMJ 310 (1995):  1217-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38653, 16245, 'Chloramphenicol', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', 'Abrams SM, Degnan TJ, Vinciguerra V "Marrow aplasia following topical application of chloramphenicol eye ointment." Arch Intern Med 140 (1980):  576-7|Calderwood SB, Moellering RC "Common adverse effects of antibacterial agents on major organ systems." Surg Clin North Am 60 (1980):  65-81|Del Giacco GS, Petrini MT, Jannelli S, Carcassi U "Fatal bone marrow hypoplasia in a shepherd using chloramphenicol spray." Lancet 1 (1981):  945|Farber BF, Brody JP "Rapid development of aplastic anemia after intravenous chloramphenicol and cimetidine therapy." South Med J 74 (1981):  1257-8|Fraunfelder FT, Bagby GC, Kelly DJ "Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol." Am J Ophthalmol 93 (1982):  356-60|Alavi JB "Aplastic anemia associated with intravenous chloramphenicol." Am J Hematol 15 (1983):  375-9|West BC, DeVault GA Jr, Clement JC, Williams DM "Aplastic anemia associated with parenteral chloramphenicol: review of 10 cases, including the second case of possible increased risk with cimetidine." Rev Infect Dis 10 (1988):  1048-51|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Doona M, Walsh JB "Use of chloramphenicol as topical eye medication: time to cry halt? bone marrow aplasia also occurs with ocular use." BMJ 310 (1995):  1217-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38654, 16307, 'Chloramphenicol', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', 'Abrams SM, Degnan TJ, Vinciguerra V "Marrow aplasia following topical application of chloramphenicol eye ointment." Arch Intern Med 140 (1980):  576-7|Calderwood SB, Moellering RC "Common adverse effects of antibacterial agents on major organ systems." Surg Clin North Am 60 (1980):  65-81|Del Giacco GS, Petrini MT, Jannelli S, Carcassi U "Fatal bone marrow hypoplasia in a shepherd using chloramphenicol spray." Lancet 1 (1981):  945|Farber BF, Brody JP "Rapid development of aplastic anemia after intravenous chloramphenicol and cimetidine therapy." South Med J 74 (1981):  1257-8|Fraunfelder FT, Bagby GC, Kelly DJ "Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol." Am J Ophthalmol 93 (1982):  356-60|Alavi JB "Aplastic anemia associated with intravenous chloramphenicol." Am J Hematol 15 (1983):  375-9|West BC, DeVault GA Jr, Clement JC, Williams DM "Aplastic anemia associated with parenteral chloramphenicol: review of 10 cases, including the second case of possible increased risk with cimetidine." Rev Infect Dis 10 (1988):  1048-51|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Doona M, Walsh JB "Use of chloramphenicol as topical eye medication: time to cry halt? bone marrow aplasia also occurs with ocular use." BMJ 310 (1995):  1217-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38655, 16308, 'Chloramphenicol', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', 'Abrams SM, Degnan TJ, Vinciguerra V "Marrow aplasia following topical application of chloramphenicol eye ointment." Arch Intern Med 140 (1980):  576-7|Calderwood SB, Moellering RC "Common adverse effects of antibacterial agents on major organ systems." Surg Clin North Am 60 (1980):  65-81|Del Giacco GS, Petrini MT, Jannelli S, Carcassi U "Fatal bone marrow hypoplasia in a shepherd using chloramphenicol spray." Lancet 1 (1981):  945|Farber BF, Brody JP "Rapid development of aplastic anemia after intravenous chloramphenicol and cimetidine therapy." South Med J 74 (1981):  1257-8|Fraunfelder FT, Bagby GC, Kelly DJ "Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol." Am J Ophthalmol 93 (1982):  356-60|Alavi JB "Aplastic anemia associated with intravenous chloramphenicol." Am J Hematol 15 (1983):  375-9|West BC, DeVault GA Jr, Clement JC, Williams DM "Aplastic anemia associated with parenteral chloramphenicol: review of 10 cases, including the second case of possible increased risk with cimetidine." Rev Infect Dis 10 (1988):  1048-51|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Doona M, Walsh JB "Use of chloramphenicol as topical eye medication: time to cry halt? bone marrow aplasia also occurs with ocular use." BMJ 310 (1995):  1217-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38656, 18442, 'Chloramphenicol', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', 'Abrams SM, Degnan TJ, Vinciguerra V "Marrow aplasia following topical application of chloramphenicol eye ointment." Arch Intern Med 140 (1980):  576-7|Calderwood SB, Moellering RC "Common adverse effects of antibacterial agents on major organ systems." Surg Clin North Am 60 (1980):  65-81|Del Giacco GS, Petrini MT, Jannelli S, Carcassi U "Fatal bone marrow hypoplasia in a shepherd using chloramphenicol spray." Lancet 1 (1981):  945|Farber BF, Brody JP "Rapid development of aplastic anemia after intravenous chloramphenicol and cimetidine therapy." South Med J 74 (1981):  1257-8|Fraunfelder FT, Bagby GC, Kelly DJ "Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol." Am J Ophthalmol 93 (1982):  356-60|Alavi JB "Aplastic anemia associated with intravenous chloramphenicol." Am J Hematol 15 (1983):  375-9|West BC, DeVault GA Jr, Clement JC, Williams DM "Aplastic anemia associated with parenteral chloramphenicol: review of 10 cases, including the second case of possible increased risk with cimetidine." Rev Infect Dis 10 (1988):  1048-51|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Doona M, Walsh JB "Use of chloramphenicol as topical eye medication: time to cry halt? bone marrow aplasia also occurs with ocular use." BMJ 310 (1995):  1217-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38657, 21029, 'Chloramphenicol', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', 'Abrams SM, Degnan TJ, Vinciguerra V "Marrow aplasia following topical application of chloramphenicol eye ointment." Arch Intern Med 140 (1980):  576-7|Calderwood SB, Moellering RC "Common adverse effects of antibacterial agents on major organ systems." Surg Clin North Am 60 (1980):  65-81|Del Giacco GS, Petrini MT, Jannelli S, Carcassi U "Fatal bone marrow hypoplasia in a shepherd using chloramphenicol spray." Lancet 1 (1981):  945|Farber BF, Brody JP "Rapid development of aplastic anemia after intravenous chloramphenicol and cimetidine therapy." South Med J 74 (1981):  1257-8|Fraunfelder FT, Bagby GC, Kelly DJ "Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol." Am J Ophthalmol 93 (1982):  356-60|Alavi JB "Aplastic anemia associated with intravenous chloramphenicol." Am J Hematol 15 (1983):  375-9|West BC, DeVault GA Jr, Clement JC, Williams DM "Aplastic anemia associated with parenteral chloramphenicol: review of 10 cases, including the second case of possible increased risk with cimetidine." Rev Infect Dis 10 (1988):  1048-51|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Doona M, Walsh JB "Use of chloramphenicol as topical eye medication: time to cry halt? bone marrow aplasia also occurs with ocular use." BMJ 310 (1995):  1217-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38658, 21755, 'Chloramphenicol', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', 'Abrams SM, Degnan TJ, Vinciguerra V "Marrow aplasia following topical application of chloramphenicol eye ointment." Arch Intern Med 140 (1980):  576-7|Calderwood SB, Moellering RC "Common adverse effects of antibacterial agents on major organ systems." Surg Clin North Am 60 (1980):  65-81|Del Giacco GS, Petrini MT, Jannelli S, Carcassi U "Fatal bone marrow hypoplasia in a shepherd using chloramphenicol spray." Lancet 1 (1981):  945|Farber BF, Brody JP "Rapid development of aplastic anemia after intravenous chloramphenicol and cimetidine therapy." South Med J 74 (1981):  1257-8|Fraunfelder FT, Bagby GC, Kelly DJ "Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol." Am J Ophthalmol 93 (1982):  356-60|Alavi JB "Aplastic anemia associated with intravenous chloramphenicol." Am J Hematol 15 (1983):  375-9|West BC, DeVault GA Jr, Clement JC, Williams DM "Aplastic anemia associated with parenteral chloramphenicol: review of 10 cases, including the second case of possible increased risk with cimetidine." Rev Infect Dis 10 (1988):  1048-51|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Doona M, Walsh JB "Use of chloramphenicol as topical eye medication: time to cry halt? bone marrow aplasia also occurs with ocular use." BMJ 310 (1995):  1217-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38659, 22814, 'Chloramphenicol', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', 'Abrams SM, Degnan TJ, Vinciguerra V "Marrow aplasia following topical application of chloramphenicol eye ointment." Arch Intern Med 140 (1980):  576-7|Calderwood SB, Moellering RC "Common adverse effects of antibacterial agents on major organ systems." Surg Clin North Am 60 (1980):  65-81|Del Giacco GS, Petrini MT, Jannelli S, Carcassi U "Fatal bone marrow hypoplasia in a shepherd using chloramphenicol spray." Lancet 1 (1981):  945|Farber BF, Brody JP "Rapid development of aplastic anemia after intravenous chloramphenicol and cimetidine therapy." South Med J 74 (1981):  1257-8|Fraunfelder FT, Bagby GC, Kelly DJ "Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol." Am J Ophthalmol 93 (1982):  356-60|Alavi JB "Aplastic anemia associated with intravenous chloramphenicol." Am J Hematol 15 (1983):  375-9|West BC, DeVault GA Jr, Clement JC, Williams DM "Aplastic anemia associated with parenteral chloramphenicol: review of 10 cases, including the second case of possible increased risk with cimetidine." Rev Infect Dis 10 (1988):  1048-51|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Doona M, Walsh JB "Use of chloramphenicol as topical eye medication: time to cry halt? bone marrow aplasia also occurs with ocular use." BMJ 310 (1995):  1217-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38660, 22816, 'Chloramphenicol', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', 'Abrams SM, Degnan TJ, Vinciguerra V "Marrow aplasia following topical application of chloramphenicol eye ointment." Arch Intern Med 140 (1980):  576-7|Calderwood SB, Moellering RC "Common adverse effects of antibacterial agents on major organ systems." Surg Clin North Am 60 (1980):  65-81|Del Giacco GS, Petrini MT, Jannelli S, Carcassi U "Fatal bone marrow hypoplasia in a shepherd using chloramphenicol spray." Lancet 1 (1981):  945|Farber BF, Brody JP "Rapid development of aplastic anemia after intravenous chloramphenicol and cimetidine therapy." South Med J 74 (1981):  1257-8|Fraunfelder FT, Bagby GC, Kelly DJ "Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol." Am J Ophthalmol 93 (1982):  356-60|Alavi JB "Aplastic anemia associated with intravenous chloramphenicol." Am J Hematol 15 (1983):  375-9|West BC, DeVault GA Jr, Clement JC, Williams DM "Aplastic anemia associated with parenteral chloramphenicol: review of 10 cases, including the second case of possible increased risk with cimetidine." Rev Infect Dis 10 (1988):  1048-51|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Doona M, Walsh JB "Use of chloramphenicol as topical eye medication: time to cry halt? bone marrow aplasia also occurs with ocular use." BMJ 310 (1995):  1217-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38661, 22817, 'Chloramphenicol', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', 'Abrams SM, Degnan TJ, Vinciguerra V "Marrow aplasia following topical application of chloramphenicol eye ointment." Arch Intern Med 140 (1980):  576-7|Calderwood SB, Moellering RC "Common adverse effects of antibacterial agents on major organ systems." Surg Clin North Am 60 (1980):  65-81|Del Giacco GS, Petrini MT, Jannelli S, Carcassi U "Fatal bone marrow hypoplasia in a shepherd using chloramphenicol spray." Lancet 1 (1981):  945|Farber BF, Brody JP "Rapid development of aplastic anemia after intravenous chloramphenicol and cimetidine therapy." South Med J 74 (1981):  1257-8|Fraunfelder FT, Bagby GC, Kelly DJ "Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol." Am J Ophthalmol 93 (1982):  356-60|Alavi JB "Aplastic anemia associated with intravenous chloramphenicol." Am J Hematol 15 (1983):  375-9|West BC, DeVault GA Jr, Clement JC, Williams DM "Aplastic anemia associated with parenteral chloramphenicol: review of 10 cases, including the second case of possible increased risk with cimetidine." Rev Infect Dis 10 (1988):  1048-51|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Doona M, Walsh JB "Use of chloramphenicol as topical eye medication: time to cry halt? bone marrow aplasia also occurs with ocular use." BMJ 310 (1995):  1217-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38662, 24138, 'Chloramphenicol', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', 'Abrams SM, Degnan TJ, Vinciguerra V "Marrow aplasia following topical application of chloramphenicol eye ointment." Arch Intern Med 140 (1980):  576-7|Calderwood SB, Moellering RC "Common adverse effects of antibacterial agents on major organ systems." Surg Clin North Am 60 (1980):  65-81|Del Giacco GS, Petrini MT, Jannelli S, Carcassi U "Fatal bone marrow hypoplasia in a shepherd using chloramphenicol spray." Lancet 1 (1981):  945|Farber BF, Brody JP "Rapid development of aplastic anemia after intravenous chloramphenicol and cimetidine therapy." South Med J 74 (1981):  1257-8|Fraunfelder FT, Bagby GC, Kelly DJ "Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol." Am J Ophthalmol 93 (1982):  356-60|Alavi JB "Aplastic anemia associated with intravenous chloramphenicol." Am J Hematol 15 (1983):  375-9|West BC, DeVault GA Jr, Clement JC, Williams DM "Aplastic anemia associated with parenteral chloramphenicol: review of 10 cases, including the second case of possible increased risk with cimetidine." Rev Infect Dis 10 (1988):  1048-51|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Doona M, Walsh JB "Use of chloramphenicol as topical eye medication: time to cry halt? bone marrow aplasia also occurs with ocular use." BMJ 310 (1995):  1217-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38663, 149, 'Chloramphenicol', 'Liver Diseases', 'Chloramphenicol is primarily inactivated by glucuronyl transferase in the liver and eliminated in the urine as both parent drug and metabolites.  In adults with normal renal and hepatic function, only 5% to 15% of a dose of chloramphenicol is excreted unchanged by the kidney, but approximately 30% is excreted when chloramphenicol is administered intravenously as the sodium succinate ester.  However, the fraction of drug excreted unchanged may be highly variable, especially in neonates and children.  Therapy with chloramphenicol should be administered cautiously in patients with significantly impaired renal and/or hepatic function, since drug accumulation may occur in such patients.  The dosage should be reduced based on the degree of impairment as well as plasma drug concentrations.', '3', 'Azzollini F, Gazzaniga A, Lodola E, Natangelo R "Elimination of chloramphenicol and thiamphenicol in subjects with cirrhosis of the liver." Int J Clin Pharmacol Ther Toxicol 6 (1972):  130-4|Koup JR, Lau AH, Brodsky B, Slaughter RL "Chloramphenicol pharmacokinetics in hospitalized patients." Antimicrob Agents Chemother 15 (1979):  651-7|Slaughter RL, Pieper JA, Cerra FB, et al. "Chloramphenicol sodium succinate kinetics in critically ill patients." Clin Pharmacol Ther 28 (1979):  69-77|Nahata MC, Powell DA "Bioavailability and clearance of chloramphenicol after intravenous chloramphenicol succinate." Clin Pharmacol Ther 30 (1981):  368-72|Narang AP, Dattta DV, Nath N, Mathur VS "Pharmacokinetic study of chloramphenicol in patients with liver disease." Eur J Clin Pharmacol 20 (1981):  479-83|Burke JT, Wargin WA, Sheretz RJ, et al. "Pharmacokinetics of intravenous chloramphenicol sodium succinate in adult patients with normal renal and hepatic function." J Pharmacokinet Biopharm 10 (1982):  601-14|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38664, 2499, 'Chloramphenicol', 'Liver Diseases', 'Chloramphenicol is primarily inactivated by glucuronyl transferase in the liver and eliminated in the urine as both parent drug and metabolites.  In adults with normal renal and hepatic function, only 5% to 15% of a dose of chloramphenicol is excreted unchanged by the kidney, but approximately 30% is excreted when chloramphenicol is administered intravenously as the sodium succinate ester.  However, the fraction of drug excreted unchanged may be highly variable, especially in neonates and children.  Therapy with chloramphenicol should be administered cautiously in patients with significantly impaired renal and/or hepatic function, since drug accumulation may occur in such patients.  The dosage should be reduced based on the degree of impairment as well as plasma drug concentrations.', '3', 'Azzollini F, Gazzaniga A, Lodola E, Natangelo R "Elimination of chloramphenicol and thiamphenicol in subjects with cirrhosis of the liver." Int J Clin Pharmacol Ther Toxicol 6 (1972):  130-4|Koup JR, Lau AH, Brodsky B, Slaughter RL "Chloramphenicol pharmacokinetics in hospitalized patients." Antimicrob Agents Chemother 15 (1979):  651-7|Slaughter RL, Pieper JA, Cerra FB, et al. "Chloramphenicol sodium succinate kinetics in critically ill patients." Clin Pharmacol Ther 28 (1979):  69-77|Nahata MC, Powell DA "Bioavailability and clearance of chloramphenicol after intravenous chloramphenicol succinate." Clin Pharmacol Ther 30 (1981):  368-72|Narang AP, Dattta DV, Nath N, Mathur VS "Pharmacokinetic study of chloramphenicol in patients with liver disease." Eur J Clin Pharmacol 20 (1981):  479-83|Burke JT, Wargin WA, Sheretz RJ, et al. "Pharmacokinetics of intravenous chloramphenicol sodium succinate in adult patients with normal renal and hepatic function." J Pharmacokinet Biopharm 10 (1982):  601-14|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38665, 2564, 'Chloramphenicol', 'Liver Diseases', 'Chloramphenicol is primarily inactivated by glucuronyl transferase in the liver and eliminated in the urine as both parent drug and metabolites.  In adults with normal renal and hepatic function, only 5% to 15% of a dose of chloramphenicol is excreted unchanged by the kidney, but approximately 30% is excreted when chloramphenicol is administered intravenously as the sodium succinate ester.  However, the fraction of drug excreted unchanged may be highly variable, especially in neonates and children.  Therapy with chloramphenicol should be administered cautiously in patients with significantly impaired renal and/or hepatic function, since drug accumulation may occur in such patients.  The dosage should be reduced based on the degree of impairment as well as plasma drug concentrations.', '3', 'Azzollini F, Gazzaniga A, Lodola E, Natangelo R "Elimination of chloramphenicol and thiamphenicol in subjects with cirrhosis of the liver." Int J Clin Pharmacol Ther Toxicol 6 (1972):  130-4|Koup JR, Lau AH, Brodsky B, Slaughter RL "Chloramphenicol pharmacokinetics in hospitalized patients." Antimicrob Agents Chemother 15 (1979):  651-7|Slaughter RL, Pieper JA, Cerra FB, et al. "Chloramphenicol sodium succinate kinetics in critically ill patients." Clin Pharmacol Ther 28 (1979):  69-77|Nahata MC, Powell DA "Bioavailability and clearance of chloramphenicol after intravenous chloramphenicol succinate." Clin Pharmacol Ther 30 (1981):  368-72|Narang AP, Dattta DV, Nath N, Mathur VS "Pharmacokinetic study of chloramphenicol in patients with liver disease." Eur J Clin Pharmacol 20 (1981):  479-83|Burke JT, Wargin WA, Sheretz RJ, et al. "Pharmacokinetics of intravenous chloramphenicol sodium succinate in adult patients with normal renal and hepatic function." J Pharmacokinet Biopharm 10 (1982):  601-14|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38666, 7921, 'Chloramphenicol', 'Liver Diseases', 'Chloramphenicol is primarily inactivated by glucuronyl transferase in the liver and eliminated in the urine as both parent drug and metabolites.  In adults with normal renal and hepatic function, only 5% to 15% of a dose of chloramphenicol is excreted unchanged by the kidney, but approximately 30% is excreted when chloramphenicol is administered intravenously as the sodium succinate ester.  However, the fraction of drug excreted unchanged may be highly variable, especially in neonates and children.  Therapy with chloramphenicol should be administered cautiously in patients with significantly impaired renal and/or hepatic function, since drug accumulation may occur in such patients.  The dosage should be reduced based on the degree of impairment as well as plasma drug concentrations.', '3', 'Azzollini F, Gazzaniga A, Lodola E, Natangelo R "Elimination of chloramphenicol and thiamphenicol in subjects with cirrhosis of the liver." Int J Clin Pharmacol Ther Toxicol 6 (1972):  130-4|Koup JR, Lau AH, Brodsky B, Slaughter RL "Chloramphenicol pharmacokinetics in hospitalized patients." Antimicrob Agents Chemother 15 (1979):  651-7|Slaughter RL, Pieper JA, Cerra FB, et al. "Chloramphenicol sodium succinate kinetics in critically ill patients." Clin Pharmacol Ther 28 (1979):  69-77|Nahata MC, Powell DA "Bioavailability and clearance of chloramphenicol after intravenous chloramphenicol succinate." Clin Pharmacol Ther 30 (1981):  368-72|Narang AP, Dattta DV, Nath N, Mathur VS "Pharmacokinetic study of chloramphenicol in patients with liver disease." Eur J Clin Pharmacol 20 (1981):  479-83|Burke JT, Wargin WA, Sheretz RJ, et al. "Pharmacokinetics of intravenous chloramphenicol sodium succinate in adult patients with normal renal and hepatic function." J Pharmacokinet Biopharm 10 (1982):  601-14|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38667, 8231, 'Chloramphenicol', 'Liver Diseases', 'Chloramphenicol is primarily inactivated by glucuronyl transferase in the liver and eliminated in the urine as both parent drug and metabolites.  In adults with normal renal and hepatic function, only 5% to 15% of a dose of chloramphenicol is excreted unchanged by the kidney, but approximately 30% is excreted when chloramphenicol is administered intravenously as the sodium succinate ester.  However, the fraction of drug excreted unchanged may be highly variable, especially in neonates and children.  Therapy with chloramphenicol should be administered cautiously in patients with significantly impaired renal and/or hepatic function, since drug accumulation may occur in such patients.  The dosage should be reduced based on the degree of impairment as well as plasma drug concentrations.', '3', 'Azzollini F, Gazzaniga A, Lodola E, Natangelo R "Elimination of chloramphenicol and thiamphenicol in subjects with cirrhosis of the liver." Int J Clin Pharmacol Ther Toxicol 6 (1972):  130-4|Koup JR, Lau AH, Brodsky B, Slaughter RL "Chloramphenicol pharmacokinetics in hospitalized patients." Antimicrob Agents Chemother 15 (1979):  651-7|Slaughter RL, Pieper JA, Cerra FB, et al. "Chloramphenicol sodium succinate kinetics in critically ill patients." Clin Pharmacol Ther 28 (1979):  69-77|Nahata MC, Powell DA "Bioavailability and clearance of chloramphenicol after intravenous chloramphenicol succinate." Clin Pharmacol Ther 30 (1981):  368-72|Narang AP, Dattta DV, Nath N, Mathur VS "Pharmacokinetic study of chloramphenicol in patients with liver disease." Eur J Clin Pharmacol 20 (1981):  479-83|Burke JT, Wargin WA, Sheretz RJ, et al. "Pharmacokinetics of intravenous chloramphenicol sodium succinate in adult patients with normal renal and hepatic function." J Pharmacokinet Biopharm 10 (1982):  601-14|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38668, 8232, 'Chloramphenicol', 'Liver Diseases', 'Chloramphenicol is primarily inactivated by glucuronyl transferase in the liver and eliminated in the urine as both parent drug and metabolites.  In adults with normal renal and hepatic function, only 5% to 15% of a dose of chloramphenicol is excreted unchanged by the kidney, but approximately 30% is excreted when chloramphenicol is administered intravenously as the sodium succinate ester.  However, the fraction of drug excreted unchanged may be highly variable, especially in neonates and children.  Therapy with chloramphenicol should be administered cautiously in patients with significantly impaired renal and/or hepatic function, since drug accumulation may occur in such patients.  The dosage should be reduced based on the degree of impairment as well as plasma drug concentrations.', '3', 'Azzollini F, Gazzaniga A, Lodola E, Natangelo R "Elimination of chloramphenicol and thiamphenicol in subjects with cirrhosis of the liver." Int J Clin Pharmacol Ther Toxicol 6 (1972):  130-4|Koup JR, Lau AH, Brodsky B, Slaughter RL "Chloramphenicol pharmacokinetics in hospitalized patients." Antimicrob Agents Chemother 15 (1979):  651-7|Slaughter RL, Pieper JA, Cerra FB, et al. "Chloramphenicol sodium succinate kinetics in critically ill patients." Clin Pharmacol Ther 28 (1979):  69-77|Nahata MC, Powell DA "Bioavailability and clearance of chloramphenicol after intravenous chloramphenicol succinate." Clin Pharmacol Ther 30 (1981):  368-72|Narang AP, Dattta DV, Nath N, Mathur VS "Pharmacokinetic study of chloramphenicol in patients with liver disease." Eur J Clin Pharmacol 20 (1981):  479-83|Burke JT, Wargin WA, Sheretz RJ, et al. "Pharmacokinetics of intravenous chloramphenicol sodium succinate in adult patients with normal renal and hepatic function." J Pharmacokinet Biopharm 10 (1982):  601-14|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38669, 9271, 'Chloramphenicol', 'Liver Diseases', 'Chloramphenicol is primarily inactivated by glucuronyl transferase in the liver and eliminated in the urine as both parent drug and metabolites.  In adults with normal renal and hepatic function, only 5% to 15% of a dose of chloramphenicol is excreted unchanged by the kidney, but approximately 30% is excreted when chloramphenicol is administered intravenously as the sodium succinate ester.  However, the fraction of drug excreted unchanged may be highly variable, especially in neonates and children.  Therapy with chloramphenicol should be administered cautiously in patients with significantly impaired renal and/or hepatic function, since drug accumulation may occur in such patients.  The dosage should be reduced based on the degree of impairment as well as plasma drug concentrations.', '3', 'Azzollini F, Gazzaniga A, Lodola E, Natangelo R "Elimination of chloramphenicol and thiamphenicol in subjects with cirrhosis of the liver." Int J Clin Pharmacol Ther Toxicol 6 (1972):  130-4|Koup JR, Lau AH, Brodsky B, Slaughter RL "Chloramphenicol pharmacokinetics in hospitalized patients." Antimicrob Agents Chemother 15 (1979):  651-7|Slaughter RL, Pieper JA, Cerra FB, et al. "Chloramphenicol sodium succinate kinetics in critically ill patients." Clin Pharmacol Ther 28 (1979):  69-77|Nahata MC, Powell DA "Bioavailability and clearance of chloramphenicol after intravenous chloramphenicol succinate." Clin Pharmacol Ther 30 (1981):  368-72|Narang AP, Dattta DV, Nath N, Mathur VS "Pharmacokinetic study of chloramphenicol in patients with liver disease." Eur J Clin Pharmacol 20 (1981):  479-83|Burke JT, Wargin WA, Sheretz RJ, et al. "Pharmacokinetics of intravenous chloramphenicol sodium succinate in adult patients with normal renal and hepatic function." J Pharmacokinet Biopharm 10 (1982):  601-14|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38670, 9313, 'Chloramphenicol', 'Liver Diseases', 'Chloramphenicol is primarily inactivated by glucuronyl transferase in the liver and eliminated in the urine as both parent drug and metabolites.  In adults with normal renal and hepatic function, only 5% to 15% of a dose of chloramphenicol is excreted unchanged by the kidney, but approximately 30% is excreted when chloramphenicol is administered intravenously as the sodium succinate ester.  However, the fraction of drug excreted unchanged may be highly variable, especially in neonates and children.  Therapy with chloramphenicol should be administered cautiously in patients with significantly impaired renal and/or hepatic function, since drug accumulation may occur in such patients.  The dosage should be reduced based on the degree of impairment as well as plasma drug concentrations.', '3', 'Azzollini F, Gazzaniga A, Lodola E, Natangelo R "Elimination of chloramphenicol and thiamphenicol in subjects with cirrhosis of the liver." Int J Clin Pharmacol Ther Toxicol 6 (1972):  130-4|Koup JR, Lau AH, Brodsky B, Slaughter RL "Chloramphenicol pharmacokinetics in hospitalized patients." Antimicrob Agents Chemother 15 (1979):  651-7|Slaughter RL, Pieper JA, Cerra FB, et al. "Chloramphenicol sodium succinate kinetics in critically ill patients." Clin Pharmacol Ther 28 (1979):  69-77|Nahata MC, Powell DA "Bioavailability and clearance of chloramphenicol after intravenous chloramphenicol succinate." Clin Pharmacol Ther 30 (1981):  368-72|Narang AP, Dattta DV, Nath N, Mathur VS "Pharmacokinetic study of chloramphenicol in patients with liver disease." Eur J Clin Pharmacol 20 (1981):  479-83|Burke JT, Wargin WA, Sheretz RJ, et al. "Pharmacokinetics of intravenous chloramphenicol sodium succinate in adult patients with normal renal and hepatic function." J Pharmacokinet Biopharm 10 (1982):  601-14|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38671, 9456, 'Chloramphenicol', 'Liver Diseases', 'Chloramphenicol is primarily inactivated by glucuronyl transferase in the liver and eliminated in the urine as both parent drug and metabolites.  In adults with normal renal and hepatic function, only 5% to 15% of a dose of chloramphenicol is excreted unchanged by the kidney, but approximately 30% is excreted when chloramphenicol is administered intravenously as the sodium succinate ester.  However, the fraction of drug excreted unchanged may be highly variable, especially in neonates and children.  Therapy with chloramphenicol should be administered cautiously in patients with significantly impaired renal and/or hepatic function, since drug accumulation may occur in such patients.  The dosage should be reduced based on the degree of impairment as well as plasma drug concentrations.', '3', 'Azzollini F, Gazzaniga A, Lodola E, Natangelo R "Elimination of chloramphenicol and thiamphenicol in subjects with cirrhosis of the liver." Int J Clin Pharmacol Ther Toxicol 6 (1972):  130-4|Koup JR, Lau AH, Brodsky B, Slaughter RL "Chloramphenicol pharmacokinetics in hospitalized patients." Antimicrob Agents Chemother 15 (1979):  651-7|Slaughter RL, Pieper JA, Cerra FB, et al. "Chloramphenicol sodium succinate kinetics in critically ill patients." Clin Pharmacol Ther 28 (1979):  69-77|Nahata MC, Powell DA "Bioavailability and clearance of chloramphenicol after intravenous chloramphenicol succinate." Clin Pharmacol Ther 30 (1981):  368-72|Narang AP, Dattta DV, Nath N, Mathur VS "Pharmacokinetic study of chloramphenicol in patients with liver disease." Eur J Clin Pharmacol 20 (1981):  479-83|Burke JT, Wargin WA, Sheretz RJ, et al. "Pharmacokinetics of intravenous chloramphenicol sodium succinate in adult patients with normal renal and hepatic function." J Pharmacokinet Biopharm 10 (1982):  601-14|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38672, 16245, 'Chloramphenicol', 'Liver Diseases', 'Chloramphenicol is primarily inactivated by glucuronyl transferase in the liver and eliminated in the urine as both parent drug and metabolites.  In adults with normal renal and hepatic function, only 5% to 15% of a dose of chloramphenicol is excreted unchanged by the kidney, but approximately 30% is excreted when chloramphenicol is administered intravenously as the sodium succinate ester.  However, the fraction of drug excreted unchanged may be highly variable, especially in neonates and children.  Therapy with chloramphenicol should be administered cautiously in patients with significantly impaired renal and/or hepatic function, since drug accumulation may occur in such patients.  The dosage should be reduced based on the degree of impairment as well as plasma drug concentrations.', '3', 'Azzollini F, Gazzaniga A, Lodola E, Natangelo R "Elimination of chloramphenicol and thiamphenicol in subjects with cirrhosis of the liver." Int J Clin Pharmacol Ther Toxicol 6 (1972):  130-4|Koup JR, Lau AH, Brodsky B, Slaughter RL "Chloramphenicol pharmacokinetics in hospitalized patients." Antimicrob Agents Chemother 15 (1979):  651-7|Slaughter RL, Pieper JA, Cerra FB, et al. "Chloramphenicol sodium succinate kinetics in critically ill patients." Clin Pharmacol Ther 28 (1979):  69-77|Nahata MC, Powell DA "Bioavailability and clearance of chloramphenicol after intravenous chloramphenicol succinate." Clin Pharmacol Ther 30 (1981):  368-72|Narang AP, Dattta DV, Nath N, Mathur VS "Pharmacokinetic study of chloramphenicol in patients with liver disease." Eur J Clin Pharmacol 20 (1981):  479-83|Burke JT, Wargin WA, Sheretz RJ, et al. "Pharmacokinetics of intravenous chloramphenicol sodium succinate in adult patients with normal renal and hepatic function." J Pharmacokinet Biopharm 10 (1982):  601-14|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38673, 16307, 'Chloramphenicol', 'Liver Diseases', 'Chloramphenicol is primarily inactivated by glucuronyl transferase in the liver and eliminated in the urine as both parent drug and metabolites.  In adults with normal renal and hepatic function, only 5% to 15% of a dose of chloramphenicol is excreted unchanged by the kidney, but approximately 30% is excreted when chloramphenicol is administered intravenously as the sodium succinate ester.  However, the fraction of drug excreted unchanged may be highly variable, especially in neonates and children.  Therapy with chloramphenicol should be administered cautiously in patients with significantly impaired renal and/or hepatic function, since drug accumulation may occur in such patients.  The dosage should be reduced based on the degree of impairment as well as plasma drug concentrations.', '3', 'Azzollini F, Gazzaniga A, Lodola E, Natangelo R "Elimination of chloramphenicol and thiamphenicol in subjects with cirrhosis of the liver." Int J Clin Pharmacol Ther Toxicol 6 (1972):  130-4|Koup JR, Lau AH, Brodsky B, Slaughter RL "Chloramphenicol pharmacokinetics in hospitalized patients." Antimicrob Agents Chemother 15 (1979):  651-7|Slaughter RL, Pieper JA, Cerra FB, et al. "Chloramphenicol sodium succinate kinetics in critically ill patients." Clin Pharmacol Ther 28 (1979):  69-77|Nahata MC, Powell DA "Bioavailability and clearance of chloramphenicol after intravenous chloramphenicol succinate." Clin Pharmacol Ther 30 (1981):  368-72|Narang AP, Dattta DV, Nath N, Mathur VS "Pharmacokinetic study of chloramphenicol in patients with liver disease." Eur J Clin Pharmacol 20 (1981):  479-83|Burke JT, Wargin WA, Sheretz RJ, et al. "Pharmacokinetics of intravenous chloramphenicol sodium succinate in adult patients with normal renal and hepatic function." J Pharmacokinet Biopharm 10 (1982):  601-14|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38674, 16308, 'Chloramphenicol', 'Liver Diseases', 'Chloramphenicol is primarily inactivated by glucuronyl transferase in the liver and eliminated in the urine as both parent drug and metabolites.  In adults with normal renal and hepatic function, only 5% to 15% of a dose of chloramphenicol is excreted unchanged by the kidney, but approximately 30% is excreted when chloramphenicol is administered intravenously as the sodium succinate ester.  However, the fraction of drug excreted unchanged may be highly variable, especially in neonates and children.  Therapy with chloramphenicol should be administered cautiously in patients with significantly impaired renal and/or hepatic function, since drug accumulation may occur in such patients.  The dosage should be reduced based on the degree of impairment as well as plasma drug concentrations.', '3', 'Azzollini F, Gazzaniga A, Lodola E, Natangelo R "Elimination of chloramphenicol and thiamphenicol in subjects with cirrhosis of the liver." Int J Clin Pharmacol Ther Toxicol 6 (1972):  130-4|Koup JR, Lau AH, Brodsky B, Slaughter RL "Chloramphenicol pharmacokinetics in hospitalized patients." Antimicrob Agents Chemother 15 (1979):  651-7|Slaughter RL, Pieper JA, Cerra FB, et al. "Chloramphenicol sodium succinate kinetics in critically ill patients." Clin Pharmacol Ther 28 (1979):  69-77|Nahata MC, Powell DA "Bioavailability and clearance of chloramphenicol after intravenous chloramphenicol succinate." Clin Pharmacol Ther 30 (1981):  368-72|Narang AP, Dattta DV, Nath N, Mathur VS "Pharmacokinetic study of chloramphenicol in patients with liver disease." Eur J Clin Pharmacol 20 (1981):  479-83|Burke JT, Wargin WA, Sheretz RJ, et al. "Pharmacokinetics of intravenous chloramphenicol sodium succinate in adult patients with normal renal and hepatic function." J Pharmacokinet Biopharm 10 (1982):  601-14|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38675, 18442, 'Chloramphenicol', 'Liver Diseases', 'Chloramphenicol is primarily inactivated by glucuronyl transferase in the liver and eliminated in the urine as both parent drug and metabolites.  In adults with normal renal and hepatic function, only 5% to 15% of a dose of chloramphenicol is excreted unchanged by the kidney, but approximately 30% is excreted when chloramphenicol is administered intravenously as the sodium succinate ester.  However, the fraction of drug excreted unchanged may be highly variable, especially in neonates and children.  Therapy with chloramphenicol should be administered cautiously in patients with significantly impaired renal and/or hepatic function, since drug accumulation may occur in such patients.  The dosage should be reduced based on the degree of impairment as well as plasma drug concentrations.', '3', 'Azzollini F, Gazzaniga A, Lodola E, Natangelo R "Elimination of chloramphenicol and thiamphenicol in subjects with cirrhosis of the liver." Int J Clin Pharmacol Ther Toxicol 6 (1972):  130-4|Koup JR, Lau AH, Brodsky B, Slaughter RL "Chloramphenicol pharmacokinetics in hospitalized patients." Antimicrob Agents Chemother 15 (1979):  651-7|Slaughter RL, Pieper JA, Cerra FB, et al. "Chloramphenicol sodium succinate kinetics in critically ill patients." Clin Pharmacol Ther 28 (1979):  69-77|Nahata MC, Powell DA "Bioavailability and clearance of chloramphenicol after intravenous chloramphenicol succinate." Clin Pharmacol Ther 30 (1981):  368-72|Narang AP, Dattta DV, Nath N, Mathur VS "Pharmacokinetic study of chloramphenicol in patients with liver disease." Eur J Clin Pharmacol 20 (1981):  479-83|Burke JT, Wargin WA, Sheretz RJ, et al. "Pharmacokinetics of intravenous chloramphenicol sodium succinate in adult patients with normal renal and hepatic function." J Pharmacokinet Biopharm 10 (1982):  601-14|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38676, 21029, 'Chloramphenicol', 'Liver Diseases', 'Chloramphenicol is primarily inactivated by glucuronyl transferase in the liver and eliminated in the urine as both parent drug and metabolites.  In adults with normal renal and hepatic function, only 5% to 15% of a dose of chloramphenicol is excreted unchanged by the kidney, but approximately 30% is excreted when chloramphenicol is administered intravenously as the sodium succinate ester.  However, the fraction of drug excreted unchanged may be highly variable, especially in neonates and children.  Therapy with chloramphenicol should be administered cautiously in patients with significantly impaired renal and/or hepatic function, since drug accumulation may occur in such patients.  The dosage should be reduced based on the degree of impairment as well as plasma drug concentrations.', '3', 'Azzollini F, Gazzaniga A, Lodola E, Natangelo R "Elimination of chloramphenicol and thiamphenicol in subjects with cirrhosis of the liver." Int J Clin Pharmacol Ther Toxicol 6 (1972):  130-4|Koup JR, Lau AH, Brodsky B, Slaughter RL "Chloramphenicol pharmacokinetics in hospitalized patients." Antimicrob Agents Chemother 15 (1979):  651-7|Slaughter RL, Pieper JA, Cerra FB, et al. "Chloramphenicol sodium succinate kinetics in critically ill patients." Clin Pharmacol Ther 28 (1979):  69-77|Nahata MC, Powell DA "Bioavailability and clearance of chloramphenicol after intravenous chloramphenicol succinate." Clin Pharmacol Ther 30 (1981):  368-72|Narang AP, Dattta DV, Nath N, Mathur VS "Pharmacokinetic study of chloramphenicol in patients with liver disease." Eur J Clin Pharmacol 20 (1981):  479-83|Burke JT, Wargin WA, Sheretz RJ, et al. "Pharmacokinetics of intravenous chloramphenicol sodium succinate in adult patients with normal renal and hepatic function." J Pharmacokinet Biopharm 10 (1982):  601-14|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38677, 21755, 'Chloramphenicol', 'Liver Diseases', 'Chloramphenicol is primarily inactivated by glucuronyl transferase in the liver and eliminated in the urine as both parent drug and metabolites.  In adults with normal renal and hepatic function, only 5% to 15% of a dose of chloramphenicol is excreted unchanged by the kidney, but approximately 30% is excreted when chloramphenicol is administered intravenously as the sodium succinate ester.  However, the fraction of drug excreted unchanged may be highly variable, especially in neonates and children.  Therapy with chloramphenicol should be administered cautiously in patients with significantly impaired renal and/or hepatic function, since drug accumulation may occur in such patients.  The dosage should be reduced based on the degree of impairment as well as plasma drug concentrations.', '3', 'Azzollini F, Gazzaniga A, Lodola E, Natangelo R "Elimination of chloramphenicol and thiamphenicol in subjects with cirrhosis of the liver." Int J Clin Pharmacol Ther Toxicol 6 (1972):  130-4|Koup JR, Lau AH, Brodsky B, Slaughter RL "Chloramphenicol pharmacokinetics in hospitalized patients." Antimicrob Agents Chemother 15 (1979):  651-7|Slaughter RL, Pieper JA, Cerra FB, et al. "Chloramphenicol sodium succinate kinetics in critically ill patients." Clin Pharmacol Ther 28 (1979):  69-77|Nahata MC, Powell DA "Bioavailability and clearance of chloramphenicol after intravenous chloramphenicol succinate." Clin Pharmacol Ther 30 (1981):  368-72|Narang AP, Dattta DV, Nath N, Mathur VS "Pharmacokinetic study of chloramphenicol in patients with liver disease." Eur J Clin Pharmacol 20 (1981):  479-83|Burke JT, Wargin WA, Sheretz RJ, et al. "Pharmacokinetics of intravenous chloramphenicol sodium succinate in adult patients with normal renal and hepatic function." J Pharmacokinet Biopharm 10 (1982):  601-14|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38678, 22814, 'Chloramphenicol', 'Liver Diseases', 'Chloramphenicol is primarily inactivated by glucuronyl transferase in the liver and eliminated in the urine as both parent drug and metabolites.  In adults with normal renal and hepatic function, only 5% to 15% of a dose of chloramphenicol is excreted unchanged by the kidney, but approximately 30% is excreted when chloramphenicol is administered intravenously as the sodium succinate ester.  However, the fraction of drug excreted unchanged may be highly variable, especially in neonates and children.  Therapy with chloramphenicol should be administered cautiously in patients with significantly impaired renal and/or hepatic function, since drug accumulation may occur in such patients.  The dosage should be reduced based on the degree of impairment as well as plasma drug concentrations.', '3', 'Azzollini F, Gazzaniga A, Lodola E, Natangelo R "Elimination of chloramphenicol and thiamphenicol in subjects with cirrhosis of the liver." Int J Clin Pharmacol Ther Toxicol 6 (1972):  130-4|Koup JR, Lau AH, Brodsky B, Slaughter RL "Chloramphenicol pharmacokinetics in hospitalized patients." Antimicrob Agents Chemother 15 (1979):  651-7|Slaughter RL, Pieper JA, Cerra FB, et al. "Chloramphenicol sodium succinate kinetics in critically ill patients." Clin Pharmacol Ther 28 (1979):  69-77|Nahata MC, Powell DA "Bioavailability and clearance of chloramphenicol after intravenous chloramphenicol succinate." Clin Pharmacol Ther 30 (1981):  368-72|Narang AP, Dattta DV, Nath N, Mathur VS "Pharmacokinetic study of chloramphenicol in patients with liver disease." Eur J Clin Pharmacol 20 (1981):  479-83|Burke JT, Wargin WA, Sheretz RJ, et al. "Pharmacokinetics of intravenous chloramphenicol sodium succinate in adult patients with normal renal and hepatic function." J Pharmacokinet Biopharm 10 (1982):  601-14|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38679, 22816, 'Chloramphenicol', 'Liver Diseases', 'Chloramphenicol is primarily inactivated by glucuronyl transferase in the liver and eliminated in the urine as both parent drug and metabolites.  In adults with normal renal and hepatic function, only 5% to 15% of a dose of chloramphenicol is excreted unchanged by the kidney, but approximately 30% is excreted when chloramphenicol is administered intravenously as the sodium succinate ester.  However, the fraction of drug excreted unchanged may be highly variable, especially in neonates and children.  Therapy with chloramphenicol should be administered cautiously in patients with significantly impaired renal and/or hepatic function, since drug accumulation may occur in such patients.  The dosage should be reduced based on the degree of impairment as well as plasma drug concentrations.', '3', 'Azzollini F, Gazzaniga A, Lodola E, Natangelo R "Elimination of chloramphenicol and thiamphenicol in subjects with cirrhosis of the liver." Int J Clin Pharmacol Ther Toxicol 6 (1972):  130-4|Koup JR, Lau AH, Brodsky B, Slaughter RL "Chloramphenicol pharmacokinetics in hospitalized patients." Antimicrob Agents Chemother 15 (1979):  651-7|Slaughter RL, Pieper JA, Cerra FB, et al. "Chloramphenicol sodium succinate kinetics in critically ill patients." Clin Pharmacol Ther 28 (1979):  69-77|Nahata MC, Powell DA "Bioavailability and clearance of chloramphenicol after intravenous chloramphenicol succinate." Clin Pharmacol Ther 30 (1981):  368-72|Narang AP, Dattta DV, Nath N, Mathur VS "Pharmacokinetic study of chloramphenicol in patients with liver disease." Eur J Clin Pharmacol 20 (1981):  479-83|Burke JT, Wargin WA, Sheretz RJ, et al. "Pharmacokinetics of intravenous chloramphenicol sodium succinate in adult patients with normal renal and hepatic function." J Pharmacokinet Biopharm 10 (1982):  601-14|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38680, 22817, 'Chloramphenicol', 'Liver Diseases', 'Chloramphenicol is primarily inactivated by glucuronyl transferase in the liver and eliminated in the urine as both parent drug and metabolites.  In adults with normal renal and hepatic function, only 5% to 15% of a dose of chloramphenicol is excreted unchanged by the kidney, but approximately 30% is excreted when chloramphenicol is administered intravenously as the sodium succinate ester.  However, the fraction of drug excreted unchanged may be highly variable, especially in neonates and children.  Therapy with chloramphenicol should be administered cautiously in patients with significantly impaired renal and/or hepatic function, since drug accumulation may occur in such patients.  The dosage should be reduced based on the degree of impairment as well as plasma drug concentrations.', '3', 'Azzollini F, Gazzaniga A, Lodola E, Natangelo R "Elimination of chloramphenicol and thiamphenicol in subjects with cirrhosis of the liver." Int J Clin Pharmacol Ther Toxicol 6 (1972):  130-4|Koup JR, Lau AH, Brodsky B, Slaughter RL "Chloramphenicol pharmacokinetics in hospitalized patients." Antimicrob Agents Chemother 15 (1979):  651-7|Slaughter RL, Pieper JA, Cerra FB, et al. "Chloramphenicol sodium succinate kinetics in critically ill patients." Clin Pharmacol Ther 28 (1979):  69-77|Nahata MC, Powell DA "Bioavailability and clearance of chloramphenicol after intravenous chloramphenicol succinate." Clin Pharmacol Ther 30 (1981):  368-72|Narang AP, Dattta DV, Nath N, Mathur VS "Pharmacokinetic study of chloramphenicol in patients with liver disease." Eur J Clin Pharmacol 20 (1981):  479-83|Burke JT, Wargin WA, Sheretz RJ, et al. "Pharmacokinetics of intravenous chloramphenicol sodium succinate in adult patients with normal renal and hepatic function." J Pharmacokinet Biopharm 10 (1982):  601-14|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38681, 24138, 'Chloramphenicol', 'Liver Diseases', 'Chloramphenicol is primarily inactivated by glucuronyl transferase in the liver and eliminated in the urine as both parent drug and metabolites.  In adults with normal renal and hepatic function, only 5% to 15% of a dose of chloramphenicol is excreted unchanged by the kidney, but approximately 30% is excreted when chloramphenicol is administered intravenously as the sodium succinate ester.  However, the fraction of drug excreted unchanged may be highly variable, especially in neonates and children.  Therapy with chloramphenicol should be administered cautiously in patients with significantly impaired renal and/or hepatic function, since drug accumulation may occur in such patients.  The dosage should be reduced based on the degree of impairment as well as plasma drug concentrations.', '3', 'Azzollini F, Gazzaniga A, Lodola E, Natangelo R "Elimination of chloramphenicol and thiamphenicol in subjects with cirrhosis of the liver." Int J Clin Pharmacol Ther Toxicol 6 (1972):  130-4|Koup JR, Lau AH, Brodsky B, Slaughter RL "Chloramphenicol pharmacokinetics in hospitalized patients." Antimicrob Agents Chemother 15 (1979):  651-7|Slaughter RL, Pieper JA, Cerra FB, et al. "Chloramphenicol sodium succinate kinetics in critically ill patients." Clin Pharmacol Ther 28 (1979):  69-77|Nahata MC, Powell DA "Bioavailability and clearance of chloramphenicol after intravenous chloramphenicol succinate." Clin Pharmacol Ther 30 (1981):  368-72|Narang AP, Dattta DV, Nath N, Mathur VS "Pharmacokinetic study of chloramphenicol in patients with liver disease." Eur J Clin Pharmacol 20 (1981):  479-83|Burke JT, Wargin WA, Sheretz RJ, et al. "Pharmacokinetics of intravenous chloramphenicol sodium succinate in adult patients with normal renal and hepatic function." J Pharmacokinet Biopharm 10 (1982):  601-14|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38682, 149, 'Chloramphenicol (ophthalmic)', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', 'Abrams SM, Degnan TJ, Vinciguerra V "Marrow aplasia following topical application of chloramphenicol eye ointment." Arch Intern Med 140 (1980):  576-7|Calderwood SB, Moellering RC "Common adverse effects of antibacterial agents on major organ systems." Surg Clin North Am 60 (1980):  65-81|Del Giacco GS, Petrini MT, Jannelli S, Carcassi U "Fatal bone marrow hypoplasia in a shepherd using chloramphenicol spray." Lancet 1 (1981):  945|Farber BF, Brody JP "Rapid development of aplastic anemia after intravenous chloramphenicol and cimetidine therapy." South Med J 74 (1981):  1257-8|Fraunfelder FT, Bagby GC, Kelly DJ "Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol." Am J Ophthalmol 93 (1982):  356-60|Alavi JB "Aplastic anemia associated with intravenous chloramphenicol." Am J Hematol 15 (1983):  375-9|West BC, DeVault GA Jr, Clement JC, Williams DM "Aplastic anemia associated with parenteral chloramphenicol: review of 10 cases, including the second case of possible increased risk with cimetidine." Rev Infect Dis 10 (1988):  1048-51|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Doona M, Walsh JB "Use of chloramphenicol as topical eye medication: time to cry halt? bone marrow aplasia also occurs with ocular use." BMJ 310 (1995):  1217-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38683, 2499, 'Chloramphenicol (ophthalmic)', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', 'Abrams SM, Degnan TJ, Vinciguerra V "Marrow aplasia following topical application of chloramphenicol eye ointment." Arch Intern Med 140 (1980):  576-7|Calderwood SB, Moellering RC "Common adverse effects of antibacterial agents on major organ systems." Surg Clin North Am 60 (1980):  65-81|Del Giacco GS, Petrini MT, Jannelli S, Carcassi U "Fatal bone marrow hypoplasia in a shepherd using chloramphenicol spray." Lancet 1 (1981):  945|Farber BF, Brody JP "Rapid development of aplastic anemia after intravenous chloramphenicol and cimetidine therapy." South Med J 74 (1981):  1257-8|Fraunfelder FT, Bagby GC, Kelly DJ "Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol." Am J Ophthalmol 93 (1982):  356-60|Alavi JB "Aplastic anemia associated with intravenous chloramphenicol." Am J Hematol 15 (1983):  375-9|West BC, DeVault GA Jr, Clement JC, Williams DM "Aplastic anemia associated with parenteral chloramphenicol: review of 10 cases, including the second case of possible increased risk with cimetidine." Rev Infect Dis 10 (1988):  1048-51|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Doona M, Walsh JB "Use of chloramphenicol as topical eye medication: time to cry halt? bone marrow aplasia also occurs with ocular use." BMJ 310 (1995):  1217-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38684, 2564, 'Chloramphenicol (ophthalmic)', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', 'Abrams SM, Degnan TJ, Vinciguerra V "Marrow aplasia following topical application of chloramphenicol eye ointment." Arch Intern Med 140 (1980):  576-7|Calderwood SB, Moellering RC "Common adverse effects of antibacterial agents on major organ systems." Surg Clin North Am 60 (1980):  65-81|Del Giacco GS, Petrini MT, Jannelli S, Carcassi U "Fatal bone marrow hypoplasia in a shepherd using chloramphenicol spray." Lancet 1 (1981):  945|Farber BF, Brody JP "Rapid development of aplastic anemia after intravenous chloramphenicol and cimetidine therapy." South Med J 74 (1981):  1257-8|Fraunfelder FT, Bagby GC, Kelly DJ "Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol." Am J Ophthalmol 93 (1982):  356-60|Alavi JB "Aplastic anemia associated with intravenous chloramphenicol." Am J Hematol 15 (1983):  375-9|West BC, DeVault GA Jr, Clement JC, Williams DM "Aplastic anemia associated with parenteral chloramphenicol: review of 10 cases, including the second case of possible increased risk with cimetidine." Rev Infect Dis 10 (1988):  1048-51|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Doona M, Walsh JB "Use of chloramphenicol as topical eye medication: time to cry halt? bone marrow aplasia also occurs with ocular use." BMJ 310 (1995):  1217-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38685, 7921, 'Chloramphenicol (ophthalmic)', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', 'Abrams SM, Degnan TJ, Vinciguerra V "Marrow aplasia following topical application of chloramphenicol eye ointment." Arch Intern Med 140 (1980):  576-7|Calderwood SB, Moellering RC "Common adverse effects of antibacterial agents on major organ systems." Surg Clin North Am 60 (1980):  65-81|Del Giacco GS, Petrini MT, Jannelli S, Carcassi U "Fatal bone marrow hypoplasia in a shepherd using chloramphenicol spray." Lancet 1 (1981):  945|Farber BF, Brody JP "Rapid development of aplastic anemia after intravenous chloramphenicol and cimetidine therapy." South Med J 74 (1981):  1257-8|Fraunfelder FT, Bagby GC, Kelly DJ "Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol." Am J Ophthalmol 93 (1982):  356-60|Alavi JB "Aplastic anemia associated with intravenous chloramphenicol." Am J Hematol 15 (1983):  375-9|West BC, DeVault GA Jr, Clement JC, Williams DM "Aplastic anemia associated with parenteral chloramphenicol: review of 10 cases, including the second case of possible increased risk with cimetidine." Rev Infect Dis 10 (1988):  1048-51|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Doona M, Walsh JB "Use of chloramphenicol as topical eye medication: time to cry halt? bone marrow aplasia also occurs with ocular use." BMJ 310 (1995):  1217-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38686, 8231, 'Chloramphenicol (ophthalmic)', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', 'Abrams SM, Degnan TJ, Vinciguerra V "Marrow aplasia following topical application of chloramphenicol eye ointment." Arch Intern Med 140 (1980):  576-7|Calderwood SB, Moellering RC "Common adverse effects of antibacterial agents on major organ systems." Surg Clin North Am 60 (1980):  65-81|Del Giacco GS, Petrini MT, Jannelli S, Carcassi U "Fatal bone marrow hypoplasia in a shepherd using chloramphenicol spray." Lancet 1 (1981):  945|Farber BF, Brody JP "Rapid development of aplastic anemia after intravenous chloramphenicol and cimetidine therapy." South Med J 74 (1981):  1257-8|Fraunfelder FT, Bagby GC, Kelly DJ "Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol." Am J Ophthalmol 93 (1982):  356-60|Alavi JB "Aplastic anemia associated with intravenous chloramphenicol." Am J Hematol 15 (1983):  375-9|West BC, DeVault GA Jr, Clement JC, Williams DM "Aplastic anemia associated with parenteral chloramphenicol: review of 10 cases, including the second case of possible increased risk with cimetidine." Rev Infect Dis 10 (1988):  1048-51|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Doona M, Walsh JB "Use of chloramphenicol as topical eye medication: time to cry halt? bone marrow aplasia also occurs with ocular use." BMJ 310 (1995):  1217-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38687, 8232, 'Chloramphenicol (ophthalmic)', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', 'Abrams SM, Degnan TJ, Vinciguerra V "Marrow aplasia following topical application of chloramphenicol eye ointment." Arch Intern Med 140 (1980):  576-7|Calderwood SB, Moellering RC "Common adverse effects of antibacterial agents on major organ systems." Surg Clin North Am 60 (1980):  65-81|Del Giacco GS, Petrini MT, Jannelli S, Carcassi U "Fatal bone marrow hypoplasia in a shepherd using chloramphenicol spray." Lancet 1 (1981):  945|Farber BF, Brody JP "Rapid development of aplastic anemia after intravenous chloramphenicol and cimetidine therapy." South Med J 74 (1981):  1257-8|Fraunfelder FT, Bagby GC, Kelly DJ "Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol." Am J Ophthalmol 93 (1982):  356-60|Alavi JB "Aplastic anemia associated with intravenous chloramphenicol." Am J Hematol 15 (1983):  375-9|West BC, DeVault GA Jr, Clement JC, Williams DM "Aplastic anemia associated with parenteral chloramphenicol: review of 10 cases, including the second case of possible increased risk with cimetidine." Rev Infect Dis 10 (1988):  1048-51|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Doona M, Walsh JB "Use of chloramphenicol as topical eye medication: time to cry halt? bone marrow aplasia also occurs with ocular use." BMJ 310 (1995):  1217-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38688, 9271, 'Chloramphenicol (ophthalmic)', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', 'Abrams SM, Degnan TJ, Vinciguerra V "Marrow aplasia following topical application of chloramphenicol eye ointment." Arch Intern Med 140 (1980):  576-7|Calderwood SB, Moellering RC "Common adverse effects of antibacterial agents on major organ systems." Surg Clin North Am 60 (1980):  65-81|Del Giacco GS, Petrini MT, Jannelli S, Carcassi U "Fatal bone marrow hypoplasia in a shepherd using chloramphenicol spray." Lancet 1 (1981):  945|Farber BF, Brody JP "Rapid development of aplastic anemia after intravenous chloramphenicol and cimetidine therapy." South Med J 74 (1981):  1257-8|Fraunfelder FT, Bagby GC, Kelly DJ "Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol." Am J Ophthalmol 93 (1982):  356-60|Alavi JB "Aplastic anemia associated with intravenous chloramphenicol." Am J Hematol 15 (1983):  375-9|West BC, DeVault GA Jr, Clement JC, Williams DM "Aplastic anemia associated with parenteral chloramphenicol: review of 10 cases, including the second case of possible increased risk with cimetidine." Rev Infect Dis 10 (1988):  1048-51|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Doona M, Walsh JB "Use of chloramphenicol as topical eye medication: time to cry halt? bone marrow aplasia also occurs with ocular use." BMJ 310 (1995):  1217-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38689, 9313, 'Chloramphenicol (ophthalmic)', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', 'Abrams SM, Degnan TJ, Vinciguerra V "Marrow aplasia following topical application of chloramphenicol eye ointment." Arch Intern Med 140 (1980):  576-7|Calderwood SB, Moellering RC "Common adverse effects of antibacterial agents on major organ systems." Surg Clin North Am 60 (1980):  65-81|Del Giacco GS, Petrini MT, Jannelli S, Carcassi U "Fatal bone marrow hypoplasia in a shepherd using chloramphenicol spray." Lancet 1 (1981):  945|Farber BF, Brody JP "Rapid development of aplastic anemia after intravenous chloramphenicol and cimetidine therapy." South Med J 74 (1981):  1257-8|Fraunfelder FT, Bagby GC, Kelly DJ "Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol." Am J Ophthalmol 93 (1982):  356-60|Alavi JB "Aplastic anemia associated with intravenous chloramphenicol." Am J Hematol 15 (1983):  375-9|West BC, DeVault GA Jr, Clement JC, Williams DM "Aplastic anemia associated with parenteral chloramphenicol: review of 10 cases, including the second case of possible increased risk with cimetidine." Rev Infect Dis 10 (1988):  1048-51|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Doona M, Walsh JB "Use of chloramphenicol as topical eye medication: time to cry halt? bone marrow aplasia also occurs with ocular use." BMJ 310 (1995):  1217-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38690, 9456, 'Chloramphenicol (ophthalmic)', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', 'Abrams SM, Degnan TJ, Vinciguerra V "Marrow aplasia following topical application of chloramphenicol eye ointment." Arch Intern Med 140 (1980):  576-7|Calderwood SB, Moellering RC "Common adverse effects of antibacterial agents on major organ systems." Surg Clin North Am 60 (1980):  65-81|Del Giacco GS, Petrini MT, Jannelli S, Carcassi U "Fatal bone marrow hypoplasia in a shepherd using chloramphenicol spray." Lancet 1 (1981):  945|Farber BF, Brody JP "Rapid development of aplastic anemia after intravenous chloramphenicol and cimetidine therapy." South Med J 74 (1981):  1257-8|Fraunfelder FT, Bagby GC, Kelly DJ "Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol." Am J Ophthalmol 93 (1982):  356-60|Alavi JB "Aplastic anemia associated with intravenous chloramphenicol." Am J Hematol 15 (1983):  375-9|West BC, DeVault GA Jr, Clement JC, Williams DM "Aplastic anemia associated with parenteral chloramphenicol: review of 10 cases, including the second case of possible increased risk with cimetidine." Rev Infect Dis 10 (1988):  1048-51|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Doona M, Walsh JB "Use of chloramphenicol as topical eye medication: time to cry halt? bone marrow aplasia also occurs with ocular use." BMJ 310 (1995):  1217-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38691, 16245, 'Chloramphenicol (ophthalmic)', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', 'Abrams SM, Degnan TJ, Vinciguerra V "Marrow aplasia following topical application of chloramphenicol eye ointment." Arch Intern Med 140 (1980):  576-7|Calderwood SB, Moellering RC "Common adverse effects of antibacterial agents on major organ systems." Surg Clin North Am 60 (1980):  65-81|Del Giacco GS, Petrini MT, Jannelli S, Carcassi U "Fatal bone marrow hypoplasia in a shepherd using chloramphenicol spray." Lancet 1 (1981):  945|Farber BF, Brody JP "Rapid development of aplastic anemia after intravenous chloramphenicol and cimetidine therapy." South Med J 74 (1981):  1257-8|Fraunfelder FT, Bagby GC, Kelly DJ "Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol." Am J Ophthalmol 93 (1982):  356-60|Alavi JB "Aplastic anemia associated with intravenous chloramphenicol." Am J Hematol 15 (1983):  375-9|West BC, DeVault GA Jr, Clement JC, Williams DM "Aplastic anemia associated with parenteral chloramphenicol: review of 10 cases, including the second case of possible increased risk with cimetidine." Rev Infect Dis 10 (1988):  1048-51|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Doona M, Walsh JB "Use of chloramphenicol as topical eye medication: time to cry halt? bone marrow aplasia also occurs with ocular use." BMJ 310 (1995):  1217-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38692, 16307, 'Chloramphenicol (ophthalmic)', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', 'Abrams SM, Degnan TJ, Vinciguerra V "Marrow aplasia following topical application of chloramphenicol eye ointment." Arch Intern Med 140 (1980):  576-7|Calderwood SB, Moellering RC "Common adverse effects of antibacterial agents on major organ systems." Surg Clin North Am 60 (1980):  65-81|Del Giacco GS, Petrini MT, Jannelli S, Carcassi U "Fatal bone marrow hypoplasia in a shepherd using chloramphenicol spray." Lancet 1 (1981):  945|Farber BF, Brody JP "Rapid development of aplastic anemia after intravenous chloramphenicol and cimetidine therapy." South Med J 74 (1981):  1257-8|Fraunfelder FT, Bagby GC, Kelly DJ "Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol." Am J Ophthalmol 93 (1982):  356-60|Alavi JB "Aplastic anemia associated with intravenous chloramphenicol." Am J Hematol 15 (1983):  375-9|West BC, DeVault GA Jr, Clement JC, Williams DM "Aplastic anemia associated with parenteral chloramphenicol: review of 10 cases, including the second case of possible increased risk with cimetidine." Rev Infect Dis 10 (1988):  1048-51|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Doona M, Walsh JB "Use of chloramphenicol as topical eye medication: time to cry halt? bone marrow aplasia also occurs with ocular use." BMJ 310 (1995):  1217-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38693, 16308, 'Chloramphenicol (ophthalmic)', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', 'Abrams SM, Degnan TJ, Vinciguerra V "Marrow aplasia following topical application of chloramphenicol eye ointment." Arch Intern Med 140 (1980):  576-7|Calderwood SB, Moellering RC "Common adverse effects of antibacterial agents on major organ systems." Surg Clin North Am 60 (1980):  65-81|Del Giacco GS, Petrini MT, Jannelli S, Carcassi U "Fatal bone marrow hypoplasia in a shepherd using chloramphenicol spray." Lancet 1 (1981):  945|Farber BF, Brody JP "Rapid development of aplastic anemia after intravenous chloramphenicol and cimetidine therapy." South Med J 74 (1981):  1257-8|Fraunfelder FT, Bagby GC, Kelly DJ "Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol." Am J Ophthalmol 93 (1982):  356-60|Alavi JB "Aplastic anemia associated with intravenous chloramphenicol." Am J Hematol 15 (1983):  375-9|West BC, DeVault GA Jr, Clement JC, Williams DM "Aplastic anemia associated with parenteral chloramphenicol: review of 10 cases, including the second case of possible increased risk with cimetidine." Rev Infect Dis 10 (1988):  1048-51|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Doona M, Walsh JB "Use of chloramphenicol as topical eye medication: time to cry halt? bone marrow aplasia also occurs with ocular use." BMJ 310 (1995):  1217-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38694, 18442, 'Chloramphenicol (ophthalmic)', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', 'Abrams SM, Degnan TJ, Vinciguerra V "Marrow aplasia following topical application of chloramphenicol eye ointment." Arch Intern Med 140 (1980):  576-7|Calderwood SB, Moellering RC "Common adverse effects of antibacterial agents on major organ systems." Surg Clin North Am 60 (1980):  65-81|Del Giacco GS, Petrini MT, Jannelli S, Carcassi U "Fatal bone marrow hypoplasia in a shepherd using chloramphenicol spray." Lancet 1 (1981):  945|Farber BF, Brody JP "Rapid development of aplastic anemia after intravenous chloramphenicol and cimetidine therapy." South Med J 74 (1981):  1257-8|Fraunfelder FT, Bagby GC, Kelly DJ "Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol." Am J Ophthalmol 93 (1982):  356-60|Alavi JB "Aplastic anemia associated with intravenous chloramphenicol." Am J Hematol 15 (1983):  375-9|West BC, DeVault GA Jr, Clement JC, Williams DM "Aplastic anemia associated with parenteral chloramphenicol: review of 10 cases, including the second case of possible increased risk with cimetidine." Rev Infect Dis 10 (1988):  1048-51|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Doona M, Walsh JB "Use of chloramphenicol as topical eye medication: time to cry halt? bone marrow aplasia also occurs with ocular use." BMJ 310 (1995):  1217-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38695, 21029, 'Chloramphenicol (ophthalmic)', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', 'Abrams SM, Degnan TJ, Vinciguerra V "Marrow aplasia following topical application of chloramphenicol eye ointment." Arch Intern Med 140 (1980):  576-7|Calderwood SB, Moellering RC "Common adverse effects of antibacterial agents on major organ systems." Surg Clin North Am 60 (1980):  65-81|Del Giacco GS, Petrini MT, Jannelli S, Carcassi U "Fatal bone marrow hypoplasia in a shepherd using chloramphenicol spray." Lancet 1 (1981):  945|Farber BF, Brody JP "Rapid development of aplastic anemia after intravenous chloramphenicol and cimetidine therapy." South Med J 74 (1981):  1257-8|Fraunfelder FT, Bagby GC, Kelly DJ "Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol." Am J Ophthalmol 93 (1982):  356-60|Alavi JB "Aplastic anemia associated with intravenous chloramphenicol." Am J Hematol 15 (1983):  375-9|West BC, DeVault GA Jr, Clement JC, Williams DM "Aplastic anemia associated with parenteral chloramphenicol: review of 10 cases, including the second case of possible increased risk with cimetidine." Rev Infect Dis 10 (1988):  1048-51|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Doona M, Walsh JB "Use of chloramphenicol as topical eye medication: time to cry halt? bone marrow aplasia also occurs with ocular use." BMJ 310 (1995):  1217-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38696, 21755, 'Chloramphenicol (ophthalmic)', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', 'Abrams SM, Degnan TJ, Vinciguerra V "Marrow aplasia following topical application of chloramphenicol eye ointment." Arch Intern Med 140 (1980):  576-7|Calderwood SB, Moellering RC "Common adverse effects of antibacterial agents on major organ systems." Surg Clin North Am 60 (1980):  65-81|Del Giacco GS, Petrini MT, Jannelli S, Carcassi U "Fatal bone marrow hypoplasia in a shepherd using chloramphenicol spray." Lancet 1 (1981):  945|Farber BF, Brody JP "Rapid development of aplastic anemia after intravenous chloramphenicol and cimetidine therapy." South Med J 74 (1981):  1257-8|Fraunfelder FT, Bagby GC, Kelly DJ "Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol." Am J Ophthalmol 93 (1982):  356-60|Alavi JB "Aplastic anemia associated with intravenous chloramphenicol." Am J Hematol 15 (1983):  375-9|West BC, DeVault GA Jr, Clement JC, Williams DM "Aplastic anemia associated with parenteral chloramphenicol: review of 10 cases, including the second case of possible increased risk with cimetidine." Rev Infect Dis 10 (1988):  1048-51|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Doona M, Walsh JB "Use of chloramphenicol as topical eye medication: time to cry halt? bone marrow aplasia also occurs with ocular use." BMJ 310 (1995):  1217-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38697, 22814, 'Chloramphenicol (ophthalmic)', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', 'Abrams SM, Degnan TJ, Vinciguerra V "Marrow aplasia following topical application of chloramphenicol eye ointment." Arch Intern Med 140 (1980):  576-7|Calderwood SB, Moellering RC "Common adverse effects of antibacterial agents on major organ systems." Surg Clin North Am 60 (1980):  65-81|Del Giacco GS, Petrini MT, Jannelli S, Carcassi U "Fatal bone marrow hypoplasia in a shepherd using chloramphenicol spray." Lancet 1 (1981):  945|Farber BF, Brody JP "Rapid development of aplastic anemia after intravenous chloramphenicol and cimetidine therapy." South Med J 74 (1981):  1257-8|Fraunfelder FT, Bagby GC, Kelly DJ "Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol." Am J Ophthalmol 93 (1982):  356-60|Alavi JB "Aplastic anemia associated with intravenous chloramphenicol." Am J Hematol 15 (1983):  375-9|West BC, DeVault GA Jr, Clement JC, Williams DM "Aplastic anemia associated with parenteral chloramphenicol: review of 10 cases, including the second case of possible increased risk with cimetidine." Rev Infect Dis 10 (1988):  1048-51|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Doona M, Walsh JB "Use of chloramphenicol as topical eye medication: time to cry halt? bone marrow aplasia also occurs with ocular use." BMJ 310 (1995):  1217-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38698, 22816, 'Chloramphenicol (ophthalmic)', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', 'Abrams SM, Degnan TJ, Vinciguerra V "Marrow aplasia following topical application of chloramphenicol eye ointment." Arch Intern Med 140 (1980):  576-7|Calderwood SB, Moellering RC "Common adverse effects of antibacterial agents on major organ systems." Surg Clin North Am 60 (1980):  65-81|Del Giacco GS, Petrini MT, Jannelli S, Carcassi U "Fatal bone marrow hypoplasia in a shepherd using chloramphenicol spray." Lancet 1 (1981):  945|Farber BF, Brody JP "Rapid development of aplastic anemia after intravenous chloramphenicol and cimetidine therapy." South Med J 74 (1981):  1257-8|Fraunfelder FT, Bagby GC, Kelly DJ "Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol." Am J Ophthalmol 93 (1982):  356-60|Alavi JB "Aplastic anemia associated with intravenous chloramphenicol." Am J Hematol 15 (1983):  375-9|West BC, DeVault GA Jr, Clement JC, Williams DM "Aplastic anemia associated with parenteral chloramphenicol: review of 10 cases, including the second case of possible increased risk with cimetidine." Rev Infect Dis 10 (1988):  1048-51|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Doona M, Walsh JB "Use of chloramphenicol as topical eye medication: time to cry halt? bone marrow aplasia also occurs with ocular use." BMJ 310 (1995):  1217-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38699, 22817, 'Chloramphenicol (ophthalmic)', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', 'Abrams SM, Degnan TJ, Vinciguerra V "Marrow aplasia following topical application of chloramphenicol eye ointment." Arch Intern Med 140 (1980):  576-7|Calderwood SB, Moellering RC "Common adverse effects of antibacterial agents on major organ systems." Surg Clin North Am 60 (1980):  65-81|Del Giacco GS, Petrini MT, Jannelli S, Carcassi U "Fatal bone marrow hypoplasia in a shepherd using chloramphenicol spray." Lancet 1 (1981):  945|Farber BF, Brody JP "Rapid development of aplastic anemia after intravenous chloramphenicol and cimetidine therapy." South Med J 74 (1981):  1257-8|Fraunfelder FT, Bagby GC, Kelly DJ "Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol." Am J Ophthalmol 93 (1982):  356-60|Alavi JB "Aplastic anemia associated with intravenous chloramphenicol." Am J Hematol 15 (1983):  375-9|West BC, DeVault GA Jr, Clement JC, Williams DM "Aplastic anemia associated with parenteral chloramphenicol: review of 10 cases, including the second case of possible increased risk with cimetidine." Rev Infect Dis 10 (1988):  1048-51|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Doona M, Walsh JB "Use of chloramphenicol as topical eye medication: time to cry halt? bone marrow aplasia also occurs with ocular use." BMJ 310 (1995):  1217-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38700, 24138, 'Chloramphenicol (ophthalmic)', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', 'Abrams SM, Degnan TJ, Vinciguerra V "Marrow aplasia following topical application of chloramphenicol eye ointment." Arch Intern Med 140 (1980):  576-7|Calderwood SB, Moellering RC "Common adverse effects of antibacterial agents on major organ systems." Surg Clin North Am 60 (1980):  65-81|Del Giacco GS, Petrini MT, Jannelli S, Carcassi U "Fatal bone marrow hypoplasia in a shepherd using chloramphenicol spray." Lancet 1 (1981):  945|Farber BF, Brody JP "Rapid development of aplastic anemia after intravenous chloramphenicol and cimetidine therapy." South Med J 74 (1981):  1257-8|Fraunfelder FT, Bagby GC, Kelly DJ "Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol." Am J Ophthalmol 93 (1982):  356-60|Alavi JB "Aplastic anemia associated with intravenous chloramphenicol." Am J Hematol 15 (1983):  375-9|West BC, DeVault GA Jr, Clement JC, Williams DM "Aplastic anemia associated with parenteral chloramphenicol: review of 10 cases, including the second case of possible increased risk with cimetidine." Rev Infect Dis 10 (1988):  1048-51|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Doona M, Walsh JB "Use of chloramphenicol as topical eye medication: time to cry halt? bone marrow aplasia also occurs with ocular use." BMJ 310 (1995):  1217-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38701, 7225, 'Chlorambucil', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38702, 7225, 'Chlorambucil', 'Bone Marrow Failure Disorders', 'Chlorambucil can severely suppress bone marrow function.  It induces a slowly progressive lymphopenia and dose-related neutropenia.  Thrombocytopenia and anemia may also occur.  Irreversible bone marrow suppression has been reported and is associated with a total dose of or > 6.5 mg/kg in one course of continuous dosing.  Therapy with chlorambucil should be administered cautiously and at a reduced dosage in patients whose bone marrow reserve may be depressed by prior chemotherapy or irradiation or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitoring of hematopoietic function is recommended.', '3', '"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38703, 7225, 'Chlorambucil', 'Hepatic Insufficiency', 'No formal studies have been conducted in patients with hepatic impairment.  As chlorambucil is primarily metabolized in the liver, patients with hepatic impairment should be closely monitored for toxicity.  A dose reduction may be considered in patients with hepatic impairment when treated with chlorambucil.', '2', '"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38704, 7225, 'Chlorambucil', 'Lung Diseases', 'Interstitial pneumonitis and/or fibrosis have been reported during chlorambucil therapy.  Pulmonary complications may not be reversible in all patients.  Patients should be instructed to immediately report signs and symptoms of pulmonary dysfunction such as cough, dyspnea or congestion.  Therapy with chlorambucil should be administered cautiously in patients with or predisposed to pulmonary dysfunction.', '2', '"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38705, 7225, 'Chlorambucil', 'Seizures', 'An increased risk of seizures has been reported in patients administered high pulse doses of chlorambucil and in children with nephrotic syndromes.  Focal and/or generalized seizures have been reported rarely at daily therapeutic doses. Therapy with chlorambucil should be administered cautiously in patients with a history of seizure disorders or head trauma.', '2', '"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38706, 149, 'Chloramphenicol (otic)', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', 'Abrams SM, Degnan TJ, Vinciguerra V "Marrow aplasia following topical application of chloramphenicol eye ointment." Arch Intern Med 140 (1980):  576-7|Calderwood SB, Moellering RC "Common adverse effects of antibacterial agents on major organ systems." Surg Clin North Am 60 (1980):  65-81|Del Giacco GS, Petrini MT, Jannelli S, Carcassi U "Fatal bone marrow hypoplasia in a shepherd using chloramphenicol spray." Lancet 1 (1981):  945|Farber BF, Brody JP "Rapid development of aplastic anemia after intravenous chloramphenicol and cimetidine therapy." South Med J 74 (1981):  1257-8|Fraunfelder FT, Bagby GC, Kelly DJ "Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol." Am J Ophthalmol 93 (1982):  356-60|Alavi JB "Aplastic anemia associated with intravenous chloramphenicol." Am J Hematol 15 (1983):  375-9|West BC, DeVault GA Jr, Clement JC, Williams DM "Aplastic anemia associated with parenteral chloramphenicol: review of 10 cases, including the second case of possible increased risk with cimetidine." Rev Infect Dis 10 (1988):  1048-51|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Doona M, Walsh JB "Use of chloramphenicol as topical eye medication: time to cry halt? bone marrow aplasia also occurs with ocular use." BMJ 310 (1995):  1217-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38707, 2499, 'Chloramphenicol (otic)', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', 'Abrams SM, Degnan TJ, Vinciguerra V "Marrow aplasia following topical application of chloramphenicol eye ointment." Arch Intern Med 140 (1980):  576-7|Calderwood SB, Moellering RC "Common adverse effects of antibacterial agents on major organ systems." Surg Clin North Am 60 (1980):  65-81|Del Giacco GS, Petrini MT, Jannelli S, Carcassi U "Fatal bone marrow hypoplasia in a shepherd using chloramphenicol spray." Lancet 1 (1981):  945|Farber BF, Brody JP "Rapid development of aplastic anemia after intravenous chloramphenicol and cimetidine therapy." South Med J 74 (1981):  1257-8|Fraunfelder FT, Bagby GC, Kelly DJ "Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol." Am J Ophthalmol 93 (1982):  356-60|Alavi JB "Aplastic anemia associated with intravenous chloramphenicol." Am J Hematol 15 (1983):  375-9|West BC, DeVault GA Jr, Clement JC, Williams DM "Aplastic anemia associated with parenteral chloramphenicol: review of 10 cases, including the second case of possible increased risk with cimetidine." Rev Infect Dis 10 (1988):  1048-51|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Doona M, Walsh JB "Use of chloramphenicol as topical eye medication: time to cry halt? bone marrow aplasia also occurs with ocular use." BMJ 310 (1995):  1217-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38708, 2564, 'Chloramphenicol (otic)', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', 'Abrams SM, Degnan TJ, Vinciguerra V "Marrow aplasia following topical application of chloramphenicol eye ointment." Arch Intern Med 140 (1980):  576-7|Calderwood SB, Moellering RC "Common adverse effects of antibacterial agents on major organ systems." Surg Clin North Am 60 (1980):  65-81|Del Giacco GS, Petrini MT, Jannelli S, Carcassi U "Fatal bone marrow hypoplasia in a shepherd using chloramphenicol spray." Lancet 1 (1981):  945|Farber BF, Brody JP "Rapid development of aplastic anemia after intravenous chloramphenicol and cimetidine therapy." South Med J 74 (1981):  1257-8|Fraunfelder FT, Bagby GC, Kelly DJ "Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol." Am J Ophthalmol 93 (1982):  356-60|Alavi JB "Aplastic anemia associated with intravenous chloramphenicol." Am J Hematol 15 (1983):  375-9|West BC, DeVault GA Jr, Clement JC, Williams DM "Aplastic anemia associated with parenteral chloramphenicol: review of 10 cases, including the second case of possible increased risk with cimetidine." Rev Infect Dis 10 (1988):  1048-51|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Doona M, Walsh JB "Use of chloramphenicol as topical eye medication: time to cry halt? bone marrow aplasia also occurs with ocular use." BMJ 310 (1995):  1217-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38709, 7921, 'Chloramphenicol (otic)', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', 'Abrams SM, Degnan TJ, Vinciguerra V "Marrow aplasia following topical application of chloramphenicol eye ointment." Arch Intern Med 140 (1980):  576-7|Calderwood SB, Moellering RC "Common adverse effects of antibacterial agents on major organ systems." Surg Clin North Am 60 (1980):  65-81|Del Giacco GS, Petrini MT, Jannelli S, Carcassi U "Fatal bone marrow hypoplasia in a shepherd using chloramphenicol spray." Lancet 1 (1981):  945|Farber BF, Brody JP "Rapid development of aplastic anemia after intravenous chloramphenicol and cimetidine therapy." South Med J 74 (1981):  1257-8|Fraunfelder FT, Bagby GC, Kelly DJ "Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol." Am J Ophthalmol 93 (1982):  356-60|Alavi JB "Aplastic anemia associated with intravenous chloramphenicol." Am J Hematol 15 (1983):  375-9|West BC, DeVault GA Jr, Clement JC, Williams DM "Aplastic anemia associated with parenteral chloramphenicol: review of 10 cases, including the second case of possible increased risk with cimetidine." Rev Infect Dis 10 (1988):  1048-51|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Doona M, Walsh JB "Use of chloramphenicol as topical eye medication: time to cry halt? bone marrow aplasia also occurs with ocular use." BMJ 310 (1995):  1217-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38710, 8231, 'Chloramphenicol (otic)', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', 'Abrams SM, Degnan TJ, Vinciguerra V "Marrow aplasia following topical application of chloramphenicol eye ointment." Arch Intern Med 140 (1980):  576-7|Calderwood SB, Moellering RC "Common adverse effects of antibacterial agents on major organ systems." Surg Clin North Am 60 (1980):  65-81|Del Giacco GS, Petrini MT, Jannelli S, Carcassi U "Fatal bone marrow hypoplasia in a shepherd using chloramphenicol spray." Lancet 1 (1981):  945|Farber BF, Brody JP "Rapid development of aplastic anemia after intravenous chloramphenicol and cimetidine therapy." South Med J 74 (1981):  1257-8|Fraunfelder FT, Bagby GC, Kelly DJ "Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol." Am J Ophthalmol 93 (1982):  356-60|Alavi JB "Aplastic anemia associated with intravenous chloramphenicol." Am J Hematol 15 (1983):  375-9|West BC, DeVault GA Jr, Clement JC, Williams DM "Aplastic anemia associated with parenteral chloramphenicol: review of 10 cases, including the second case of possible increased risk with cimetidine." Rev Infect Dis 10 (1988):  1048-51|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Doona M, Walsh JB "Use of chloramphenicol as topical eye medication: time to cry halt? bone marrow aplasia also occurs with ocular use." BMJ 310 (1995):  1217-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38711, 8232, 'Chloramphenicol (otic)', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', 'Abrams SM, Degnan TJ, Vinciguerra V "Marrow aplasia following topical application of chloramphenicol eye ointment." Arch Intern Med 140 (1980):  576-7|Calderwood SB, Moellering RC "Common adverse effects of antibacterial agents on major organ systems." Surg Clin North Am 60 (1980):  65-81|Del Giacco GS, Petrini MT, Jannelli S, Carcassi U "Fatal bone marrow hypoplasia in a shepherd using chloramphenicol spray." Lancet 1 (1981):  945|Farber BF, Brody JP "Rapid development of aplastic anemia after intravenous chloramphenicol and cimetidine therapy." South Med J 74 (1981):  1257-8|Fraunfelder FT, Bagby GC, Kelly DJ "Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol." Am J Ophthalmol 93 (1982):  356-60|Alavi JB "Aplastic anemia associated with intravenous chloramphenicol." Am J Hematol 15 (1983):  375-9|West BC, DeVault GA Jr, Clement JC, Williams DM "Aplastic anemia associated with parenteral chloramphenicol: review of 10 cases, including the second case of possible increased risk with cimetidine." Rev Infect Dis 10 (1988):  1048-51|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Doona M, Walsh JB "Use of chloramphenicol as topical eye medication: time to cry halt? bone marrow aplasia also occurs with ocular use." BMJ 310 (1995):  1217-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38712, 9271, 'Chloramphenicol (otic)', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', 'Abrams SM, Degnan TJ, Vinciguerra V "Marrow aplasia following topical application of chloramphenicol eye ointment." Arch Intern Med 140 (1980):  576-7|Calderwood SB, Moellering RC "Common adverse effects of antibacterial agents on major organ systems." Surg Clin North Am 60 (1980):  65-81|Del Giacco GS, Petrini MT, Jannelli S, Carcassi U "Fatal bone marrow hypoplasia in a shepherd using chloramphenicol spray." Lancet 1 (1981):  945|Farber BF, Brody JP "Rapid development of aplastic anemia after intravenous chloramphenicol and cimetidine therapy." South Med J 74 (1981):  1257-8|Fraunfelder FT, Bagby GC, Kelly DJ "Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol." Am J Ophthalmol 93 (1982):  356-60|Alavi JB "Aplastic anemia associated with intravenous chloramphenicol." Am J Hematol 15 (1983):  375-9|West BC, DeVault GA Jr, Clement JC, Williams DM "Aplastic anemia associated with parenteral chloramphenicol: review of 10 cases, including the second case of possible increased risk with cimetidine." Rev Infect Dis 10 (1988):  1048-51|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Doona M, Walsh JB "Use of chloramphenicol as topical eye medication: time to cry halt? bone marrow aplasia also occurs with ocular use." BMJ 310 (1995):  1217-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38713, 9313, 'Chloramphenicol (otic)', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', 'Abrams SM, Degnan TJ, Vinciguerra V "Marrow aplasia following topical application of chloramphenicol eye ointment." Arch Intern Med 140 (1980):  576-7|Calderwood SB, Moellering RC "Common adverse effects of antibacterial agents on major organ systems." Surg Clin North Am 60 (1980):  65-81|Del Giacco GS, Petrini MT, Jannelli S, Carcassi U "Fatal bone marrow hypoplasia in a shepherd using chloramphenicol spray." Lancet 1 (1981):  945|Farber BF, Brody JP "Rapid development of aplastic anemia after intravenous chloramphenicol and cimetidine therapy." South Med J 74 (1981):  1257-8|Fraunfelder FT, Bagby GC, Kelly DJ "Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol." Am J Ophthalmol 93 (1982):  356-60|Alavi JB "Aplastic anemia associated with intravenous chloramphenicol." Am J Hematol 15 (1983):  375-9|West BC, DeVault GA Jr, Clement JC, Williams DM "Aplastic anemia associated with parenteral chloramphenicol: review of 10 cases, including the second case of possible increased risk with cimetidine." Rev Infect Dis 10 (1988):  1048-51|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Doona M, Walsh JB "Use of chloramphenicol as topical eye medication: time to cry halt? bone marrow aplasia also occurs with ocular use." BMJ 310 (1995):  1217-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38714, 9456, 'Chloramphenicol (otic)', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', 'Abrams SM, Degnan TJ, Vinciguerra V "Marrow aplasia following topical application of chloramphenicol eye ointment." Arch Intern Med 140 (1980):  576-7|Calderwood SB, Moellering RC "Common adverse effects of antibacterial agents on major organ systems." Surg Clin North Am 60 (1980):  65-81|Del Giacco GS, Petrini MT, Jannelli S, Carcassi U "Fatal bone marrow hypoplasia in a shepherd using chloramphenicol spray." Lancet 1 (1981):  945|Farber BF, Brody JP "Rapid development of aplastic anemia after intravenous chloramphenicol and cimetidine therapy." South Med J 74 (1981):  1257-8|Fraunfelder FT, Bagby GC, Kelly DJ "Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol." Am J Ophthalmol 93 (1982):  356-60|Alavi JB "Aplastic anemia associated with intravenous chloramphenicol." Am J Hematol 15 (1983):  375-9|West BC, DeVault GA Jr, Clement JC, Williams DM "Aplastic anemia associated with parenteral chloramphenicol: review of 10 cases, including the second case of possible increased risk with cimetidine." Rev Infect Dis 10 (1988):  1048-51|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Doona M, Walsh JB "Use of chloramphenicol as topical eye medication: time to cry halt? bone marrow aplasia also occurs with ocular use." BMJ 310 (1995):  1217-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38715, 16245, 'Chloramphenicol (otic)', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', 'Abrams SM, Degnan TJ, Vinciguerra V "Marrow aplasia following topical application of chloramphenicol eye ointment." Arch Intern Med 140 (1980):  576-7|Calderwood SB, Moellering RC "Common adverse effects of antibacterial agents on major organ systems." Surg Clin North Am 60 (1980):  65-81|Del Giacco GS, Petrini MT, Jannelli S, Carcassi U "Fatal bone marrow hypoplasia in a shepherd using chloramphenicol spray." Lancet 1 (1981):  945|Farber BF, Brody JP "Rapid development of aplastic anemia after intravenous chloramphenicol and cimetidine therapy." South Med J 74 (1981):  1257-8|Fraunfelder FT, Bagby GC, Kelly DJ "Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol." Am J Ophthalmol 93 (1982):  356-60|Alavi JB "Aplastic anemia associated with intravenous chloramphenicol." Am J Hematol 15 (1983):  375-9|West BC, DeVault GA Jr, Clement JC, Williams DM "Aplastic anemia associated with parenteral chloramphenicol: review of 10 cases, including the second case of possible increased risk with cimetidine." Rev Infect Dis 10 (1988):  1048-51|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Doona M, Walsh JB "Use of chloramphenicol as topical eye medication: time to cry halt? bone marrow aplasia also occurs with ocular use." BMJ 310 (1995):  1217-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38716, 16307, 'Chloramphenicol (otic)', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', 'Abrams SM, Degnan TJ, Vinciguerra V "Marrow aplasia following topical application of chloramphenicol eye ointment." Arch Intern Med 140 (1980):  576-7|Calderwood SB, Moellering RC "Common adverse effects of antibacterial agents on major organ systems." Surg Clin North Am 60 (1980):  65-81|Del Giacco GS, Petrini MT, Jannelli S, Carcassi U "Fatal bone marrow hypoplasia in a shepherd using chloramphenicol spray." Lancet 1 (1981):  945|Farber BF, Brody JP "Rapid development of aplastic anemia after intravenous chloramphenicol and cimetidine therapy." South Med J 74 (1981):  1257-8|Fraunfelder FT, Bagby GC, Kelly DJ "Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol." Am J Ophthalmol 93 (1982):  356-60|Alavi JB "Aplastic anemia associated with intravenous chloramphenicol." Am J Hematol 15 (1983):  375-9|West BC, DeVault GA Jr, Clement JC, Williams DM "Aplastic anemia associated with parenteral chloramphenicol: review of 10 cases, including the second case of possible increased risk with cimetidine." Rev Infect Dis 10 (1988):  1048-51|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Doona M, Walsh JB "Use of chloramphenicol as topical eye medication: time to cry halt? bone marrow aplasia also occurs with ocular use." BMJ 310 (1995):  1217-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38717, 16308, 'Chloramphenicol (otic)', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', 'Abrams SM, Degnan TJ, Vinciguerra V "Marrow aplasia following topical application of chloramphenicol eye ointment." Arch Intern Med 140 (1980):  576-7|Calderwood SB, Moellering RC "Common adverse effects of antibacterial agents on major organ systems." Surg Clin North Am 60 (1980):  65-81|Del Giacco GS, Petrini MT, Jannelli S, Carcassi U "Fatal bone marrow hypoplasia in a shepherd using chloramphenicol spray." Lancet 1 (1981):  945|Farber BF, Brody JP "Rapid development of aplastic anemia after intravenous chloramphenicol and cimetidine therapy." South Med J 74 (1981):  1257-8|Fraunfelder FT, Bagby GC, Kelly DJ "Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol." Am J Ophthalmol 93 (1982):  356-60|Alavi JB "Aplastic anemia associated with intravenous chloramphenicol." Am J Hematol 15 (1983):  375-9|West BC, DeVault GA Jr, Clement JC, Williams DM "Aplastic anemia associated with parenteral chloramphenicol: review of 10 cases, including the second case of possible increased risk with cimetidine." Rev Infect Dis 10 (1988):  1048-51|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Doona M, Walsh JB "Use of chloramphenicol as topical eye medication: time to cry halt? bone marrow aplasia also occurs with ocular use." BMJ 310 (1995):  1217-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38718, 18442, 'Chloramphenicol (otic)', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', 'Abrams SM, Degnan TJ, Vinciguerra V "Marrow aplasia following topical application of chloramphenicol eye ointment." Arch Intern Med 140 (1980):  576-7|Calderwood SB, Moellering RC "Common adverse effects of antibacterial agents on major organ systems." Surg Clin North Am 60 (1980):  65-81|Del Giacco GS, Petrini MT, Jannelli S, Carcassi U "Fatal bone marrow hypoplasia in a shepherd using chloramphenicol spray." Lancet 1 (1981):  945|Farber BF, Brody JP "Rapid development of aplastic anemia after intravenous chloramphenicol and cimetidine therapy." South Med J 74 (1981):  1257-8|Fraunfelder FT, Bagby GC, Kelly DJ "Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol." Am J Ophthalmol 93 (1982):  356-60|Alavi JB "Aplastic anemia associated with intravenous chloramphenicol." Am J Hematol 15 (1983):  375-9|West BC, DeVault GA Jr, Clement JC, Williams DM "Aplastic anemia associated with parenteral chloramphenicol: review of 10 cases, including the second case of possible increased risk with cimetidine." Rev Infect Dis 10 (1988):  1048-51|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Doona M, Walsh JB "Use of chloramphenicol as topical eye medication: time to cry halt? bone marrow aplasia also occurs with ocular use." BMJ 310 (1995):  1217-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38719, 21029, 'Chloramphenicol (otic)', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', 'Abrams SM, Degnan TJ, Vinciguerra V "Marrow aplasia following topical application of chloramphenicol eye ointment." Arch Intern Med 140 (1980):  576-7|Calderwood SB, Moellering RC "Common adverse effects of antibacterial agents on major organ systems." Surg Clin North Am 60 (1980):  65-81|Del Giacco GS, Petrini MT, Jannelli S, Carcassi U "Fatal bone marrow hypoplasia in a shepherd using chloramphenicol spray." Lancet 1 (1981):  945|Farber BF, Brody JP "Rapid development of aplastic anemia after intravenous chloramphenicol and cimetidine therapy." South Med J 74 (1981):  1257-8|Fraunfelder FT, Bagby GC, Kelly DJ "Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol." Am J Ophthalmol 93 (1982):  356-60|Alavi JB "Aplastic anemia associated with intravenous chloramphenicol." Am J Hematol 15 (1983):  375-9|West BC, DeVault GA Jr, Clement JC, Williams DM "Aplastic anemia associated with parenteral chloramphenicol: review of 10 cases, including the second case of possible increased risk with cimetidine." Rev Infect Dis 10 (1988):  1048-51|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Doona M, Walsh JB "Use of chloramphenicol as topical eye medication: time to cry halt? bone marrow aplasia also occurs with ocular use." BMJ 310 (1995):  1217-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38720, 21755, 'Chloramphenicol (otic)', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', 'Abrams SM, Degnan TJ, Vinciguerra V "Marrow aplasia following topical application of chloramphenicol eye ointment." Arch Intern Med 140 (1980):  576-7|Calderwood SB, Moellering RC "Common adverse effects of antibacterial agents on major organ systems." Surg Clin North Am 60 (1980):  65-81|Del Giacco GS, Petrini MT, Jannelli S, Carcassi U "Fatal bone marrow hypoplasia in a shepherd using chloramphenicol spray." Lancet 1 (1981):  945|Farber BF, Brody JP "Rapid development of aplastic anemia after intravenous chloramphenicol and cimetidine therapy." South Med J 74 (1981):  1257-8|Fraunfelder FT, Bagby GC, Kelly DJ "Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol." Am J Ophthalmol 93 (1982):  356-60|Alavi JB "Aplastic anemia associated with intravenous chloramphenicol." Am J Hematol 15 (1983):  375-9|West BC, DeVault GA Jr, Clement JC, Williams DM "Aplastic anemia associated with parenteral chloramphenicol: review of 10 cases, including the second case of possible increased risk with cimetidine." Rev Infect Dis 10 (1988):  1048-51|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Doona M, Walsh JB "Use of chloramphenicol as topical eye medication: time to cry halt? bone marrow aplasia also occurs with ocular use." BMJ 310 (1995):  1217-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38721, 22814, 'Chloramphenicol (otic)', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', 'Abrams SM, Degnan TJ, Vinciguerra V "Marrow aplasia following topical application of chloramphenicol eye ointment." Arch Intern Med 140 (1980):  576-7|Calderwood SB, Moellering RC "Common adverse effects of antibacterial agents on major organ systems." Surg Clin North Am 60 (1980):  65-81|Del Giacco GS, Petrini MT, Jannelli S, Carcassi U "Fatal bone marrow hypoplasia in a shepherd using chloramphenicol spray." Lancet 1 (1981):  945|Farber BF, Brody JP "Rapid development of aplastic anemia after intravenous chloramphenicol and cimetidine therapy." South Med J 74 (1981):  1257-8|Fraunfelder FT, Bagby GC, Kelly DJ "Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol." Am J Ophthalmol 93 (1982):  356-60|Alavi JB "Aplastic anemia associated with intravenous chloramphenicol." Am J Hematol 15 (1983):  375-9|West BC, DeVault GA Jr, Clement JC, Williams DM "Aplastic anemia associated with parenteral chloramphenicol: review of 10 cases, including the second case of possible increased risk with cimetidine." Rev Infect Dis 10 (1988):  1048-51|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Doona M, Walsh JB "Use of chloramphenicol as topical eye medication: time to cry halt? bone marrow aplasia also occurs with ocular use." BMJ 310 (1995):  1217-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38722, 22816, 'Chloramphenicol (otic)', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', 'Abrams SM, Degnan TJ, Vinciguerra V "Marrow aplasia following topical application of chloramphenicol eye ointment." Arch Intern Med 140 (1980):  576-7|Calderwood SB, Moellering RC "Common adverse effects of antibacterial agents on major organ systems." Surg Clin North Am 60 (1980):  65-81|Del Giacco GS, Petrini MT, Jannelli S, Carcassi U "Fatal bone marrow hypoplasia in a shepherd using chloramphenicol spray." Lancet 1 (1981):  945|Farber BF, Brody JP "Rapid development of aplastic anemia after intravenous chloramphenicol and cimetidine therapy." South Med J 74 (1981):  1257-8|Fraunfelder FT, Bagby GC, Kelly DJ "Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol." Am J Ophthalmol 93 (1982):  356-60|Alavi JB "Aplastic anemia associated with intravenous chloramphenicol." Am J Hematol 15 (1983):  375-9|West BC, DeVault GA Jr, Clement JC, Williams DM "Aplastic anemia associated with parenteral chloramphenicol: review of 10 cases, including the second case of possible increased risk with cimetidine." Rev Infect Dis 10 (1988):  1048-51|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Doona M, Walsh JB "Use of chloramphenicol as topical eye medication: time to cry halt? bone marrow aplasia also occurs with ocular use." BMJ 310 (1995):  1217-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38723, 22817, 'Chloramphenicol (otic)', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', 'Abrams SM, Degnan TJ, Vinciguerra V "Marrow aplasia following topical application of chloramphenicol eye ointment." Arch Intern Med 140 (1980):  576-7|Calderwood SB, Moellering RC "Common adverse effects of antibacterial agents on major organ systems." Surg Clin North Am 60 (1980):  65-81|Del Giacco GS, Petrini MT, Jannelli S, Carcassi U "Fatal bone marrow hypoplasia in a shepherd using chloramphenicol spray." Lancet 1 (1981):  945|Farber BF, Brody JP "Rapid development of aplastic anemia after intravenous chloramphenicol and cimetidine therapy." South Med J 74 (1981):  1257-8|Fraunfelder FT, Bagby GC, Kelly DJ "Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol." Am J Ophthalmol 93 (1982):  356-60|Alavi JB "Aplastic anemia associated with intravenous chloramphenicol." Am J Hematol 15 (1983):  375-9|West BC, DeVault GA Jr, Clement JC, Williams DM "Aplastic anemia associated with parenteral chloramphenicol: review of 10 cases, including the second case of possible increased risk with cimetidine." Rev Infect Dis 10 (1988):  1048-51|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Doona M, Walsh JB "Use of chloramphenicol as topical eye medication: time to cry halt? bone marrow aplasia also occurs with ocular use." BMJ 310 (1995):  1217-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38724, 24138, 'Chloramphenicol (otic)', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', 'Abrams SM, Degnan TJ, Vinciguerra V "Marrow aplasia following topical application of chloramphenicol eye ointment." Arch Intern Med 140 (1980):  576-7|Calderwood SB, Moellering RC "Common adverse effects of antibacterial agents on major organ systems." Surg Clin North Am 60 (1980):  65-81|Del Giacco GS, Petrini MT, Jannelli S, Carcassi U "Fatal bone marrow hypoplasia in a shepherd using chloramphenicol spray." Lancet 1 (1981):  945|Farber BF, Brody JP "Rapid development of aplastic anemia after intravenous chloramphenicol and cimetidine therapy." South Med J 74 (1981):  1257-8|Fraunfelder FT, Bagby GC, Kelly DJ "Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol." Am J Ophthalmol 93 (1982):  356-60|Alavi JB "Aplastic anemia associated with intravenous chloramphenicol." Am J Hematol 15 (1983):  375-9|West BC, DeVault GA Jr, Clement JC, Williams DM "Aplastic anemia associated with parenteral chloramphenicol: review of 10 cases, including the second case of possible increased risk with cimetidine." Rev Infect Dis 10 (1988):  1048-51|"Product Information. Chloromycetin (chloramphenicol)." Parke-Davis  (2002):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Doona M, Walsh JB "Use of chloramphenicol as topical eye medication: time to cry halt? bone marrow aplasia also occurs with ocular use." BMJ 310 (1995):  1217-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38725, 149, 'Chloramphenicol (otic)', 'Tympanic Membrane Perforation', 'The use of chloramphenicol otic preparations is contraindicated in patients with a perforated tympanic membrane.  The risk of ototoxicity may be increased if medication enters the middle ear.', '3', 'Iqbal SM, Srivatsav CBP "Chloramphenicol ototoxicity." J Laryngol Otol 98 (1984):  523-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38726, 2499, 'Chloramphenicol (otic)', 'Tympanic Membrane Perforation', 'The use of chloramphenicol otic preparations is contraindicated in patients with a perforated tympanic membrane.  The risk of ototoxicity may be increased if medication enters the middle ear.', '3', 'Iqbal SM, Srivatsav CBP "Chloramphenicol ototoxicity." J Laryngol Otol 98 (1984):  523-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38727, 2564, 'Chloramphenicol (otic)', 'Tympanic Membrane Perforation', 'The use of chloramphenicol otic preparations is contraindicated in patients with a perforated tympanic membrane.  The risk of ototoxicity may be increased if medication enters the middle ear.', '3', 'Iqbal SM, Srivatsav CBP "Chloramphenicol ototoxicity." J Laryngol Otol 98 (1984):  523-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38728, 7921, 'Chloramphenicol (otic)', 'Tympanic Membrane Perforation', 'The use of chloramphenicol otic preparations is contraindicated in patients with a perforated tympanic membrane.  The risk of ototoxicity may be increased if medication enters the middle ear.', '3', 'Iqbal SM, Srivatsav CBP "Chloramphenicol ototoxicity." J Laryngol Otol 98 (1984):  523-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38729, 8231, 'Chloramphenicol (otic)', 'Tympanic Membrane Perforation', 'The use of chloramphenicol otic preparations is contraindicated in patients with a perforated tympanic membrane.  The risk of ototoxicity may be increased if medication enters the middle ear.', '3', 'Iqbal SM, Srivatsav CBP "Chloramphenicol ototoxicity." J Laryngol Otol 98 (1984):  523-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38730, 8232, 'Chloramphenicol (otic)', 'Tympanic Membrane Perforation', 'The use of chloramphenicol otic preparations is contraindicated in patients with a perforated tympanic membrane.  The risk of ototoxicity may be increased if medication enters the middle ear.', '3', 'Iqbal SM, Srivatsav CBP "Chloramphenicol ototoxicity." J Laryngol Otol 98 (1984):  523-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38731, 9271, 'Chloramphenicol (otic)', 'Tympanic Membrane Perforation', 'The use of chloramphenicol otic preparations is contraindicated in patients with a perforated tympanic membrane.  The risk of ototoxicity may be increased if medication enters the middle ear.', '3', 'Iqbal SM, Srivatsav CBP "Chloramphenicol ototoxicity." J Laryngol Otol 98 (1984):  523-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38732, 9313, 'Chloramphenicol (otic)', 'Tympanic Membrane Perforation', 'The use of chloramphenicol otic preparations is contraindicated in patients with a perforated tympanic membrane.  The risk of ototoxicity may be increased if medication enters the middle ear.', '3', 'Iqbal SM, Srivatsav CBP "Chloramphenicol ototoxicity." J Laryngol Otol 98 (1984):  523-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38733, 9456, 'Chloramphenicol (otic)', 'Tympanic Membrane Perforation', 'The use of chloramphenicol otic preparations is contraindicated in patients with a perforated tympanic membrane.  The risk of ototoxicity may be increased if medication enters the middle ear.', '3', 'Iqbal SM, Srivatsav CBP "Chloramphenicol ototoxicity." J Laryngol Otol 98 (1984):  523-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38734, 16245, 'Chloramphenicol (otic)', 'Tympanic Membrane Perforation', 'The use of chloramphenicol otic preparations is contraindicated in patients with a perforated tympanic membrane.  The risk of ototoxicity may be increased if medication enters the middle ear.', '3', 'Iqbal SM, Srivatsav CBP "Chloramphenicol ototoxicity." J Laryngol Otol 98 (1984):  523-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38735, 16307, 'Chloramphenicol (otic)', 'Tympanic Membrane Perforation', 'The use of chloramphenicol otic preparations is contraindicated in patients with a perforated tympanic membrane.  The risk of ototoxicity may be increased if medication enters the middle ear.', '3', 'Iqbal SM, Srivatsav CBP "Chloramphenicol ototoxicity." J Laryngol Otol 98 (1984):  523-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38736, 16308, 'Chloramphenicol (otic)', 'Tympanic Membrane Perforation', 'The use of chloramphenicol otic preparations is contraindicated in patients with a perforated tympanic membrane.  The risk of ototoxicity may be increased if medication enters the middle ear.', '3', 'Iqbal SM, Srivatsav CBP "Chloramphenicol ototoxicity." J Laryngol Otol 98 (1984):  523-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38737, 18442, 'Chloramphenicol (otic)', 'Tympanic Membrane Perforation', 'The use of chloramphenicol otic preparations is contraindicated in patients with a perforated tympanic membrane.  The risk of ototoxicity may be increased if medication enters the middle ear.', '3', 'Iqbal SM, Srivatsav CBP "Chloramphenicol ototoxicity." J Laryngol Otol 98 (1984):  523-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38738, 21029, 'Chloramphenicol (otic)', 'Tympanic Membrane Perforation', 'The use of chloramphenicol otic preparations is contraindicated in patients with a perforated tympanic membrane.  The risk of ototoxicity may be increased if medication enters the middle ear.', '3', 'Iqbal SM, Srivatsav CBP "Chloramphenicol ototoxicity." J Laryngol Otol 98 (1984):  523-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38739, 21755, 'Chloramphenicol (otic)', 'Tympanic Membrane Perforation', 'The use of chloramphenicol otic preparations is contraindicated in patients with a perforated tympanic membrane.  The risk of ototoxicity may be increased if medication enters the middle ear.', '3', 'Iqbal SM, Srivatsav CBP "Chloramphenicol ototoxicity." J Laryngol Otol 98 (1984):  523-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38740, 22814, 'Chloramphenicol (otic)', 'Tympanic Membrane Perforation', 'The use of chloramphenicol otic preparations is contraindicated in patients with a perforated tympanic membrane.  The risk of ototoxicity may be increased if medication enters the middle ear.', '3', 'Iqbal SM, Srivatsav CBP "Chloramphenicol ototoxicity." J Laryngol Otol 98 (1984):  523-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38741, 22816, 'Chloramphenicol (otic)', 'Tympanic Membrane Perforation', 'The use of chloramphenicol otic preparations is contraindicated in patients with a perforated tympanic membrane.  The risk of ototoxicity may be increased if medication enters the middle ear.', '3', 'Iqbal SM, Srivatsav CBP "Chloramphenicol ototoxicity." J Laryngol Otol 98 (1984):  523-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38742, 22817, 'Chloramphenicol (otic)', 'Tympanic Membrane Perforation', 'The use of chloramphenicol otic preparations is contraindicated in patients with a perforated tympanic membrane.  The risk of ototoxicity may be increased if medication enters the middle ear.', '3', 'Iqbal SM, Srivatsav CBP "Chloramphenicol ototoxicity." J Laryngol Otol 98 (1984):  523-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38743, 24138, 'Chloramphenicol (otic)', 'Tympanic Membrane Perforation', 'The use of chloramphenicol otic preparations is contraindicated in patients with a perforated tympanic membrane.  The risk of ototoxicity may be increased if medication enters the middle ear.', '3', 'Iqbal SM, Srivatsav CBP "Chloramphenicol ototoxicity." J Laryngol Otol 98 (1984):  523-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38744, 2938, 'Chlordiazepoxide', 'Alcoholic Intoxication', 'The use of benzodiazepines with alcohol is not recommended.  Patients with acute alcohol intoxication exhibit depressed vital signs.  The central nervous system depressant effects of benzodiazepines may be additive with those of alcohol, and severe respiratory depression and death may occur.  Therapy with benzodiazepines should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Xanax (alprazolam)." Pharmacia and Upjohn  (2002):|"Product Information. Valium (diazepam)." Roche Laboratories  (2002):|"Product Information. Ativan (lorazepam)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Serax (oxazepam)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Restoril (temazepam)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Halcion (triazolam)." Pharmacia and Upjohn  (2001):|"Product Information. Dalmane (flurazepam)." Roche Laboratories  (2001):|"Product Information. Tranxene (clorazepate)." Abbott Pharmaceutical  (2001):|"Product Information. Klonopin (clonazepam)." Roche Laboratories  (2001):|"Product Information. Prosom (estazolam)." Abbott Pharmaceutical  (2022):|"Product Information. Librium (chlordiazepoxide)." Roche Laboratories  (2001):|"Product Information. Doral (quazepam)." Wallace Laboratories  (2001):|"Product Information. Versed (midazolam)." Roche Laboratories  (2001):|"Product Information. Onfi (clobazam)." Lundbeck Inc  (2011):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38745, 2938, 'Chlordiazepoxide', 'Glaucoma, Angle-Closure', 'The manufacturers consider the use of benzodiazepines to be contraindicated in patients with acute angle-closure glaucoma or untreated open-angle glaucoma.  These agents do not possess anticholinergic activity but have very rarely been associated with increased intraocular pressure.', '3', '"Product Information. Xanax (alprazolam)." Pharmacia and Upjohn  (2002):|"Product Information. Valium (diazepam)." Roche Laboratories  (2002):|"Product Information. Ativan (lorazepam)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Serax (oxazepam)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Restoril (temazepam)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Halcion (triazolam)." Pharmacia and Upjohn  (2001):|"Product Information. Dalmane (flurazepam)." Roche Laboratories  (2001):|"Product Information. Tranxene (clorazepate)." Abbott Pharmaceutical  (2001):|"Product Information. Klonopin (clonazepam)." Roche Laboratories  (2001):|"Product Information. Prosom (estazolam)." Abbott Pharmaceutical  (2022):|"Product Information. Librium (chlordiazepoxide)." Roche Laboratories  (2001):|"Product Information. Doral (quazepam)." Wallace Laboratories  (2001):|"Product Information. Versed (midazolam)." Roche Laboratories  (2001):|Fraunfelder FT, Fraunfelder FW; Randall JA "Drug-Induced Ocular Side Effects" Boston, MA: Butterworth-Heinemann  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38746, 2938, 'Chlordiazepoxide', 'Substance-Related Disorders', 'Benzodiazepines have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use and/or excessive dosages.  However, abrupt cessation following continual use of as few as 6 weeks at therapeutic levels has occasionally precipitated withdrawal symptoms.  Addiction- prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance when treated with benzodiazepines.  It may be prudent to refrain from dispensing large quantities of medication to these patients.  After prolonged use or if dependency is suspected, withdrawal of benzodiazepine therapy should be undertaken gradually using a dosage- tapering schedule.  If withdrawal symptoms occur, temporary reinstitution of benzodiazepines may be necessary.', '3', '"Product Information. Xanax (alprazolam)." Pharmacia and Upjohn  (2002):|"Product Information. Valium (diazepam)." Roche Laboratories  (2002):|"Product Information. Ativan (lorazepam)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Serax (oxazepam)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Restoril (temazepam)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Halcion (triazolam)." Pharmacia and Upjohn  (2001):|"Product Information. Dalmane (flurazepam)." Roche Laboratories  (2001):|"Product Information. Tranxene (clorazepate)." Abbott Pharmaceutical  (2001):|"Product Information. Klonopin (clonazepam)." Roche Laboratories  (2001):|"Product Information. Prosom (estazolam)." Abbott Pharmaceutical  (2022):|"Product Information. Librium (chlordiazepoxide)." Roche Laboratories  (2001):|"Product Information. Doral (quazepam)." Wallace Laboratories  (2001):|"Product Information. Onfi (clobazam)." Lundbeck Inc  (2011):|"Product Information. Byfavo (remimazolam)." Acacia Pharma, Inc  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38747, 2938, 'Chlordiazepoxide', 'Liver Diseases', 'Benzodiazepines are metabolized by the liver, and the metabolites are excreted in the urine.  Chlordiazepoxide, clorazepate, diazepam, flurazepam and quazepam undergo oxidative N-dealkylation to active metabolites that are substantially longer-acting than the parent compound.  These metabolites then undergo further biotransformation to pharmacologically inactive products before excretion by the kidney.  Therapy with benzodiazepines should be administered cautiously at lower initial dosages in patients with impaired renal and/or hepatic function.  Agents that are converted to weakly active, short-acting, or inactive metabolites may be preferable in hepatic impairment.  Lorazepam, oxazepam and temazepam are conjugated to inactive metabolites, while alprazolam, estazolam and triazolam undergo hydroxylation to weakly active or inactive metabolites.', '3', 'Sellers EM, Greenblatt DJ, Giles HG, et al. "Chlordiazepoxide and oxazepam disposition in cirrhosis." Clin Pharmacol Ther 26 (1979):  240-6|Hicks R, Dysken MW, Davis JM, et al. "The pharmacokinetics of psychotropic medication in the elderly: a review." J Clin Psychiatry 42 (1981):  374-85|Murray TG, Chiang ST, Koepke HH, Walker BR "Renal disease, age, and oxazepam kinetics." Clin Pharmacol Ther 30 (1981):  805-9|Hoyumpa AM "Disposition and elimination of minor tranquilizers in the aged and in patients with liver disease." South Med J 71 (1978):  23-8|Kraus JW, Desmond PV, Marshall JP, Johnson RF, Schenker S, Wilkinson GR "Effects of age and liver disease on disposition of lorazepam." Clin Pharmacol Ther 24 (1978):  411-9|Verbeeck RK, Tjandramaga TB, de Schepper PJ, Verberckmoes R "Impaired elimination of lorazepam following subchronic administration in two patients with renal failure." Br J Clin Pharmacol 12 (1981):  749-50|Greenblatt DJ "Clinical pharmacokinetics of oxazepam and lorazepam." Clin Pharmacokinet 6 (1981):  89-105|Morrison G, Chiang ST, Koepke HH, Walker BR "Effect of renal impairment and hemodialysis on lorazepam kinetics." Clin Pharmacol Ther 35 (1984):  646-52|Klotz U, Avant GR, Hoyumpa A, Schenker S, Wikinson GR "The effects of age and liver disease on the disposition and elimination of diazepam in adult man." J Clin Invest 55 (1975):  347-59|Cutler RE, Blair AD "Pharmacokinetics of diazepam in normal and uremic humans." Clin Pharmacol Ther 25 (1979):  219-20|Ochs HR, Greenblatt DJ, Kaschell HJ, Klehr U, Divoll M, Abernathy DR "Diazepam kinetics in patients with renal insufficiency or hyperthyroidism." Br J Clin Pharmacol 12 (1981):  829-32|Schmith VD, Piraino B, Smith RB, Kroboth PD "Alprazolam in end-stage renal disease: I. Pharmacokinetics." J Clin Pharmacol 31 (1991):  571-9|Dehlin O, Kullingsjo H, Liden A, Agrell B, Moser G, Olsen I "Pharmacokinetics of alprazolam in geriatric patients with neurotic depression." Pharmacol Toxicol 68 (1991):  121-4|Sellers EM, Greenblatt DJ, Giles HG, et al. "Chlordiazepoxide and oxazepam disposition in cirrhosis." Clin Pharmacol Ther 26 (1979):  240-6|Morgan DD, Robinson JD, Mendenhall CL "Clinical pharmacokinetics of chlordiazepoxide in patients with alcoholic hepatitis." Eur J Clin Pharmacol 19 (1981):  279-85|Tedesco FJ, Mills LR "Diazepam (valium) hepatitis." Dig Dis Sci 27 (1982):  470-2|de Silva JAF, Strojny N "Determination of flurazepam and its major biotransformation products in blood and urine by spectrophotofluorometry and spectrophotometry." J Pharm Sci 60 (1971):  1303-14|Kaplan SA, de Silva JAF, Jack ML, et al. "Blood level profile in man following chronic oral administration of flurazepam hydrochloride." J Pharm Sci 62 (1973):  1932-5|Greenblatt DJ, Divoll M, Harmatz JJ "Kinetics and clinical effects of flurazepam in young and elderly noninsomniacs." Clin Pharmacol Ther 30 (1981):  475-86|Ghabrial H, Desmond PV, Watson KJ, et al. "The effects of age and chronic liver disease on the elimination of temazepam." Eur J Clin Pharmacol 30 (1986):  93-7|Busch U, Molzahn M, Bozler G, Koss FW "Pharmacokinetics of oxazepam following multiple administration in volunteers and patients with chronic renal disease." Arzneimittelforschung 31 (1981):  1507-11|Juhl RP, Van Thiel DH, Dittert LW, Smith RB "Alprazolam pharmacokinetics in alcoholic liver disease." J Clin Pharmacol 24 (1984):  113-9|Johnson J, Padilla BG, Carter J, Holt JH, Ozawa T "Adverse effects of flurazepam in a hemodialysis patient." J Am Assoc Nephrol Nurses Tech 4 (1977):  93-5|Kroboth PD, Smith RB, Rault R, Silver MR, Sorkin MI, Puschett JB, Juhl RP "Effects of end-stage renal disease and aluminum hydroxide on temazepam kinetics." Clin Pharmacol Ther 37 (1985):  453-9|Wilensky AJ, Levy RH, Troupin AS, Moretti-Ojemann L "Clorazepate kinetics in treated epileptics." Clin Pharmacol Ther 24 (1978):  22-30|Greenblatt DJ, Divoll MK, Soong MH, Boxenbaum HG, Harmatz JS, Shader RI "Desmethyldiazepam pharmacokinetics: studies following intravenous and oral desmethyldiazepam, oral clorazepate, and intravenous diazepam." J Clin Pharmacol 28 (1988):  853-9|Ochs HR, Rauh HW, Greenblatt DJ, Kaschell HJ "Clorazepate dipotassium and diazepam in renal insufficiency: serum concentrations and protein binding of diazepam and desmethyldiazepam." Nephron 37 (1984):  100-4|Roberts RK, Wilkinson GR, Branch RA, Schenker S "Effect of age and parenchymal liver disease on the disposition and elimination of chlordiazepoxide (librium)." Gastroenterology 75 (1978):  479-85|Kroboth PD, Smith RB, Silver MR, Rault R, Sorkin MI, Puschett JB, Juhl RP "Effects of end stage renal disease and aluminium hydroxide on triazolam pharmacokinetics." Br J Clin Pharmacol 19 (1985):  839-42|Kroboth PD, Smith RB, Van Thiel DH, Juhl RP "Nighttime dosing of triazolam in patients with liver disease and normal subjects: kinetics and daytime effects." J Clin Pharmacol 27 (1987):  555-60|Hilbert JM, Chung M, Radwanski E, Gural R, Symchowicz S, Zampaglione N "Quazepam kinetics in the elderly." Clin Pharmacol Ther 36 (1984):  566-9|Chung M, Hilbert JM, Gural RP, Radwanski E, Symchowicz S, Zampaglione N "Multiple-dose quazepam kinetics." Clin Pharmacol Ther 35 (1984):  520-4|Gustavson LE, Carrigan PJ "The clinical pharmacokinetics of single doses of estazolam." Am J Med 88 (1990):  s2-5|Allen MD, Greenblatt DJ, Arnold JD "Single- and multiple-dose kinetics of estazolam, a triazolo benzodiazepine." Psychopharmacology (Berl) 66 (1979):  267-74|"Product Information. Xanax (alprazolam)." Pharmacia and Upjohn  (2002):|"Product Information. Valium (diazepam)." Roche Laboratories  (2002):|"Product Information. Ativan (lorazepam)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Serax (oxazepam)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Restoril (temazepam)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Halcion (triazolam)." Pharmacia and Upjohn  (2001):|"Product Information. Dalmane (flurazepam)." Roche Laboratories  (2001):|"Product Information. Tranxene (clorazepate)." Abbott Pharmaceutical  (2001):|"Product Information. Klonopin (clonazepam)." Roche Laboratories  (2001):|"Product Information. Prosom (estazolam)." Abbott Pharmaceutical  (2022):|"Product Information. Librium (chlordiazepoxide)." Roche Laboratories  (2001):|"Product Information. Doral (quazepam)." Wallace Laboratories  (2001):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38748, 2938, 'Chlordiazepoxide', 'Respiratory Insufficiency', 'Benzodiazepines may cause respiratory depression and apnea, usually when given in high dosages and/or by intravenous administration.  However, some patients may be susceptible at commonly used dosages, including the elderly, debilitated or severely ill patients, those receiving other CNS depressants, and those with limited ventilatory reserve, chronic pulmonary insufficiency or other respiratory disorders.  Therapy with benzodiazepines should be administered cautiously in these patients.  Appropriate monitoring and individualization of dosage are particularly important, and equipment for resuscitation should be immediately available if the parenteral route is used.  Benzodiazepines, especially injectable formulations, should generally be avoided in patients with sleep apnea, severe respiratory insufficiency, or hypoxia.', '3', 'Iber FL, Livak A, Kruss DM "Apnea and cardiopulmonary arrest during and after endoscopy." J Clin Gastroenterol 14 (1992):  109-13|Cohen S, Khan A "Respiratory distress with use of lorazepam in mania." J Clin Psychopharmacol 7 (1987):  199-200|Donaldson D, Gibson G "System complications with intravenous diazepam." Oral Surg Oral Med Oral Patho 49 (1980):  126-30|Eldridge PR, Punt JA "Risks associated with giving benzodiazepines to patients with acute neurological injuries." Br Med J 300 (1990):  1189-90|Man GC, Hsu K, Sproule BJ "Effect of alprazolam on exercise and dyspnea in patients with chronic obstructive pulmonary disease." Chest 90 (1986):  832-6|Mendelson WB, Weingartner H, Greenblatt DJ, Garnett D, Gillin JC "A clinical study of flurazepam." Sleep 5 (1982):  350-60|"Product Information. Xanax (alprazolam)." Pharmacia and Upjohn  (2002):|"Product Information. Valium (diazepam)." Roche Laboratories  (2002):|"Product Information. Ativan (lorazepam)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Serax (oxazepam)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Restoril (temazepam)." Sandoz Pharmaceuticals Corporation  (2001):|Pierce MW, Shu VS, Groves LJ "Safety of estazolam. The United States clinical experience." Am J Med 88 (1990):  s12-7|Skatrud JB, Badr S, Begle RL, Juan D "Ventilatory response to single, high dose estazolam in healthy humans." J Clin Pharmacol 30 (1990):  543-8|Sullivan RJ, Jr "Respiratory depression requiring ventilatory support following 0.5 mg of triazolam." J Am Geriatr Soc 37 (1989):  450-2|"Product Information. Halcion (triazolam)." Pharmacia and Upjohn  (2001):|"Product Information. Dalmane (flurazepam)." Roche Laboratories  (2001):|Model DG, Berry DJ "Effects of chlordiazepoxide in respiratory failure due to chronic bronchitis." Lancet 2 (1974):  869-70|Dixon D "Respiratory depression following midazolam." Anaesthesia 40 (1985):  922|Yakel DL, Jr  Whittaker SE, Elstad MR "Midazolam-induced angioedema and bronchoconstriction." Crit Care Med 20 (1992):  307-8|Berggren L, Eriksson I, Mollenholt P, Sunzel M "Changes in respiratory pattern after repeated doses of diazepam and midazolam in healthy subjects." Acta Anaesthesiol Scand 31 (1987):  667-72|Taylor JW, Simon KB "Possible intramuscular midazolam-associated cardiorespiratory arrest and death." DICP 24 (1990):  695-7|Munoz HR, Dagnino JA, Rufs JA, Bugedo GJ "Benzodiazepine premedication causes hypoxemia during spinal anesthesia in geriatric patients." Reg Anesth 17 (1992):  139-42|"Product Information. Tranxene (clorazepate)." Abbott Pharmaceutical  (2001):|"Product Information. Klonopin (clonazepam)." Roche Laboratories  (2001):|"Product Information. Prosom (estazolam)." Abbott Pharmaceutical  (2022):|"Product Information. Librium (chlordiazepoxide)." Roche Laboratories  (2001):|Murphy PJ, Erskine R, Langton JA "The effect of intravenously administered diazepam, midazolam and flumazenil on the sensitivity of upper airway reflexes." Anaesthesia 49 (1994):  105-10|"Product Information. Doral (quazepam)." Wallace Laboratories  (2001):|"Product Information. Versed (midazolam)." Roche Laboratories  (2001):|Berry RB, Kouchi K, Bower J, Prosise G, Light RW "Triazolam in patients with obstructive sleep apnea." Am J Respir Crit Care Med 151 (1995):  450-4|"Product Information. Byfavo (remimazolam)." Acacia Pharma, Inc  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38749, 2938, 'Chlordiazepoxide', 'Seizures', 'The use of benzodiazepines in patients with seizure disorders may increase the incidence or precipitate the onset of generalized tonic-clonic seizures (grand mal).  Appropriate anticonvulsant medication might need to be initiated or the dosage increased.  Abrupt cessation of benzodiazepine therapy may precipitate seizures and other withdrawal symptoms, particularly after prolonged use and/or excessive dosages.  Status epilepticus may occur in patients with a history of seizures withdrawn rapidly from benzodiazepine therapy.  Following chronic administration, cessation of benzodiazepine therapy should occur gradually with incrementally reduced dosages.  Patients should be advised not to discontinue medication without first consulting with the physician.', '3', 'Ananth J "Abstinence syndrome from therapeutic doses of oxazepam." Can J Psychiatry 28 (1983):  592|Wilbur R, Kulik AV "Abstinence syndrome from therapeutic doses of oxazepam." Can J Psychiatry 28 (1983):  298-300|Busto U, Sellers EM, Naranjo CA, et al. "Withdrawal reaction after long-term therapeutic use of benzodiazepines." N Engl J Med 315 (1986):  854-9|Hersch EL, Billings RF "Acute confusional state with status petit mal as a withdrawal syndrome: and five year follow-up." Can J Psychiatry 33 (1988):  157-9|Howe JG "Lorazepam withdrawal seizures." Br Med J 280 (1980):  1163-4|Kales A, Bixler EO, Soldatos CR, Jacoby JA, Kales JD "Lorazepam: effects on sleep and withdrawal phenomena." Pharmacology 32 (1986):  121-30|Robinson GM, Sellers EM "Diazepam withdrawal seizures." Can Med Assoc J 126 (1982):  944-5|Browne JL, Hauge KJ "A review of alprazolam withdrawal." Drug Intell Clin Pharm 20 (1986):  837-41|Ghadirian AM, Gauthier S, Wong T "Convulsions in patients abruptly withdrawn from clonazepam while receiving neuroleptic medication ." Am J Psychiatry 144 (1987):  686|Hauser P, Devinsky O, De Bellis M, Theodore WH, Post RM "Benzodiazepine withdrawal delirium with catatonic features. Occurrence in patients with partial seizure disorders." Arch Neurol 46 (1989):  696-9|Specht U, Boenigk HE, Wolf P "Discontinuation of clonazepam after long-term treatment." Epilepsia 30 (1989):  458-63|Alvarez N, Hartford E, Doubt C "Epileptic seizures induced by clonazepam." Clin Electroencephalogr 12 (1981):  57-65|Berlin RM, Conell LJ "Withdrawal symptoms after long-term treatment with therapeutic doses of flurazepam: a case report." Am J Psychiatry 140 (1983):  488-90|Bond WS, Schwartz M "Withdrawal reactions after long-term treatment with flurazepam." Clin Pharm 3 (1984):  316-8|"Product Information. Xanax (alprazolam)." Pharmacia and Upjohn  (2002):|"Product Information. Valium (diazepam)." Roche Laboratories  (2002):|"Product Information. Ativan (lorazepam)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Serax (oxazepam)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Restoril (temazepam)." Sandoz Pharmaceuticals Corporation  (2001):|Tien AY, Gujavarty KS "Seizure following withdrawal from triazolam." Am J Psychiatry 142 (1985):  1516-7|Patterson WM "Triazolam withdrawal." J Clin Psychiatry 49 (1988):  369|Schneider LS, Syapin PJ, Pawluczyk S "Seizures following triazolam withdrawal despite benzodiazepine treatment." J Clin Psychiatry 48 (1987):  418-9|"Product Information. Halcion (triazolam)." Pharmacia and Upjohn  (2001):|"Product Information. Dalmane (flurazepam)." Roche Laboratories  (2001):|Ryan GP, Boisse NR "Experimental induction of benzodiazepine tolerance and physical dependence." J Pharmacol Exp Ther 226 (1983):  100-7|Petursson H, Lader MH "Benzodiazepine dependence." Br J Addict 76 (1981):  133-45|Finley PR, Nolan PE, Jr "Precipitation of benzodiazepine withdrawal following sudden discontinuation of midazolam." DICP 23 (1989):  151-2|"Product Information. Tranxene (clorazepate)." Abbott Pharmaceutical  (2001):|"Product Information. Klonopin (clonazepam)." Roche Laboratories  (2001):|"Product Information. Prosom (estazolam)." Abbott Pharmaceutical  (2022):|"Product Information. Librium (chlordiazepoxide)." Roche Laboratories  (2001):|Roy-Byrne PP, Sullivan MD, Cowley DS, Ries RK "Adjunctive treatment of benzodiazepine discontinuation syndromes - a review." J Psychiatr Res 27 Suppl (1993):  143-53|"Product Information. Doral (quazepam)." Wallace Laboratories  (2001):|"Product Information. Versed (midazolam)." Roche Laboratories  (2001):|Frattola L, Garreau M, Piolti R, Bassi S, Albizzati MG, Borghi C, Morselli PL "Comparison of the efficacy, safety and withdrawal of alpidem and alprazolam in anxious patients." Br J Psychiatry 165 (1994):  94-100', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38750, 2938, 'Chlordiazepoxide', 'Hypotension', 'Benzodiazepines should not be administered by injection to patients in shock or coma.  The hypnotic and hypotensive effects of these agents may be prolonged and intensified in such patients.', '3', '"Product Information. Valium (diazepam)." Roche Laboratories  (2002):|"Product Information. Ativan (lorazepam)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Librium (chlordiazepoxide)." Roche Laboratories  (2001):|"Product Information. Versed (midazolam)." Roche Laboratories  (2001):|"Product Information. Byfavo (remimazolam)." Acacia Pharma, Inc  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38751, 2938, 'Chlordiazepoxide', 'Depressive Disorder', 'Benzodiazepines depress the central nervous system and may cause or exacerbate mental depression and cause suicidal behavior and ideation.  Episodes of mania and hypomania have also been reported in depressed patients treated with some of these agents.  Therapy with benzodiazepines should be administered cautiously in patients with a history of depression or other psychiatric disorders.  Patients should be monitored for any changes in mood or behavior.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '2', '"Product Information. Xanax (alprazolam)." Pharmacia and Upjohn  (2002):|"Product Information. Valium (diazepam)." Roche Laboratories  (2002):|"Product Information. Ativan (lorazepam)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Serax (oxazepam)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Restoril (temazepam)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Halcion (triazolam)." Pharmacia and Upjohn  (2001):|"Product Information. Dalmane (flurazepam)." Roche Laboratories  (2001):|"Product Information. Tranxene (clorazepate)." Abbott Pharmaceutical  (2001):|"Product Information. Klonopin (clonazepam)." Roche Laboratories  (2001):|"Product Information. Prosom (estazolam)." Abbott Pharmaceutical  (2022):|"Product Information. Librium (chlordiazepoxide)." Roche Laboratories  (2001):|"Product Information. Doral (quazepam)." Wallace Laboratories  (2001):|"Product Information. Onfi (clobazam)." Lundbeck Inc  (2011):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38752, 2938, 'Chlordiazepoxide', 'Obesity', 'The plasma half-lives of benzodiazepines may be prolonged in obese patients, presumably due to increased distribution into fat.  Marked increases in distribution (> 100%) have been reported for diazepam and midazolam, and moderate increases (25% to 100%) for alprazolam, lorazepam, and oxazepam.  Therapy with benzodiazepines should be administered cautiously in obese patients, with careful monitoring of CNS status.  Longer dosing intervals may be appropriate.  When dosing by weight, loading doses should be based on actual body weight, while maintenance dose should be based on ideal body weight to avoid toxicity.', '2', '"Product Information. Xanax (alprazolam)." Pharmacia and Upjohn  (2002):|"Product Information. Valium (diazepam)." Roche Laboratories  (2002):|"Product Information. Ativan (lorazepam)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Serax (oxazepam)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Restoril (temazepam)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Halcion (triazolam)." Pharmacia and Upjohn  (2001):|"Product Information. Dalmane (flurazepam)." Roche Laboratories  (2001):|"Product Information. Tranxene (clorazepate)." Abbott Pharmaceutical  (2001):|"Product Information. Klonopin (clonazepam)." Roche Laboratories  (2001):|"Product Information. Prosom (estazolam)." Abbott Pharmaceutical  (2022):|"Product Information. Librium (chlordiazepoxide)." Roche Laboratories  (2001):|"Product Information. Doral (quazepam)." Wallace Laboratories  (2001):|"Product Information. Versed (midazolam)." Roche Laboratories  (2001):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38753, 2938, 'Chlordiazepoxide', 'Psychotic Disorders', 'Paradoxical reactions, including excitability, irritability, aggressive behavior, agitation, nervousness, hostility, anxiety, sleep disturbances, nightmares and vivid dreams, have been reported with the use of benzodiazepines in psychiatric patients and pediatric patients with hyperactive aggressive disorders.  Such patients should be monitored for signs of paradoxical stimulation during therapy with benzodiazepines.  The manufacturers do not recommend the use of benzodiazepines for the treatment of psychosis.', '2', 'French AP "Dangerously aggressive behavior as a side effect of alprazolam." Am J Psychiatry 146 (1989):  276|Goodman WK, Charney DS "A case of alprazolam, but not lorazepam, inducing manic symptoms." J Clin Psychiatry 48 (1987):  117-8|Edwards JG, Inman WH, Pearce GL, Rawson NS "Prescription-event monitoring of 10,895 patients treated with alprazolam." Br J Psychiatry 158 (1991):  387-92|Wysowski DK, Barash D "Adverse behavioral reactions attributed to triazolam in the Food and Drug Administration''s Spontaneous Reporting System." Arch Intern Med 151 (1991):  2003-8|Bixler EO, Kales A, Brubaker BH, Kales JD "Adverse reactions to benzodiazepine hypnotics: spontaneous reporting system." Pharmacology 35 (1987):  286-300|Cohen LS, Rosenbaum JF "Clonazepam: new uses and potential problems." J Clin Psychiatry 48 (1987):  50-6|White MC, Silverman JJ, Harbison JW "Psychosis associated with clonazepam therapy for blepharospasm." J Nerv Ment Dis 170 (1982):  117-9|Dorevitch A "Mania associated with clonazepam." DICP 25 (1991):  938-9|Marchevsky S, Isaacs G, Nitzan I "Behavioral disinhibition with clonazepam." Gen Hosp Psychiatry 10 (1988):  447|Binder RL "Three case reports of behavioral disinhibition with clonazepam." Gen Hosp Psychiatry 9 (1987):  151-3|Koczerginski D, Kennedy SH, Swinson RP "Clonazepam and lithium--a toxic combination in the treatment of mania?" Int Clin Psychopharmacol 4 (1989):  195-9|Fava M, Borofsky GF "Sexual disinhibition during treatment with a benzodiazepine: a case report." Int J Psychiatry Med 21 (1991):  99-104|Cunningham TA "Letter: Adverse reaction to flurazepam." Can Med Assoc J 112 (1975):  805|Pollack MH "Clonazepam: a review of open clinical trials." J Clin Psychiatry 48 (1987):  12-5|"Product Information. Xanax (alprazolam)." Pharmacia and Upjohn  (2002):|"Product Information. Valium (diazepam)." Roche Laboratories  (2002):|"Product Information. Ativan (lorazepam)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Serax (oxazepam)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Restoril (temazepam)." Sandoz Pharmaceuticals Corporation  (2001):|Karch FE "Rage reaction associated with clorazepate dipotassium." Ann Intern Med 91 (1979):  61-2|Weilburg JB, Sachs G, Falk WE "Triazolam-induced brief episodes of secondary mania in a depressed patient." J Clin Psychiatry 48 (1987):  492-3|Rothschild AJ "Disinhibition, amnestic reactions, and other adverse reactions secondary to triazolam: a review of the literature." J Clin Psychiatry 53 (1992):  69-79|Schogt B, Conn D "Paranoid symptoms associated with triazolam." Can J Psychiatry 30 (1985):  462-3|"Product Information. Halcion (triazolam)." Pharmacia and Upjohn  (2001):|"Product Information. Dalmane (flurazepam)." Roche Laboratories  (2001):|Viscott DS "Chlordiazepoxide and hallucinations. Report of cases." Arch Gen Psychiatry 19 (1968):  370-6|Fiset L, Milgrom P, Beirne OR, Roy-Byrne P "Disinhibition of behaviors with midazolam: report of a case." J Oral Maxillofac Surg 50 (1992):  645-9|Lobo BL, Miwa LJ "Midazolam disinhibition reaction." Drug Intell Clin Pharm 22 (1988):  725|"Product Information. Tranxene (clorazepate)." Abbott Pharmaceutical  (2001):|"Product Information. Klonopin (clonazepam)." Roche Laboratories  (2001):|"Product Information. Prosom (estazolam)." Abbott Pharmaceutical  (2022):|"Product Information. Librium (chlordiazepoxide)." Roche Laboratories  (2001):|Rush CR, Higgins ST, Hughes JR, Bickel WK "A comparison of the acute behavioral effects of triazolam and temazepam in normal volunteers." Psychopharmacology (Berl) 112 (1993):  407-14|"Product Information. Doral (quazepam)." Wallace Laboratories  (2001):|"Product Information. Versed (midazolam)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38754, 2938, 'Chlordiazepoxide', 'Porphyrias', 'There have been isolated reports associating the use of chlordiazepoxide with exacerbation of porphyria.  Therapy with chlordiazepoxide should be administered cautiously in patients with porphyria.', '2', '"Product Information. Librium (chlordiazepoxide)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38755, 24890, 'Chenodeoxycholic acid', 'Liver Diseases', 'Chenodeoxycholic acid is contraindicated in the presence of known hepatocyte dysfunction or bile ductal abnormalities such as intrahepatic cholestasis, primary biliary cirrhosis or sclerosing cholangitis; a gallbladder confirmed as non-visualizing after two consecutive single doses of dye; radiopaque stones; or gallstone complications or compelling reasons for gallbladder surgery including unremitting acute cholecystitis, cholangitis, biliary obstruction, gallstone pancreatitis, or biliary gastrointestinal fistula.', '3', '"Product Information. Chenodal (chenodeoxycholic acid)." Manchester Pharmaceutical  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38756, 0, 'Albiglutide', 'Pancreatitis', 'The use of GLP-1 receptor agonists has been associated with rare reports of acute pancreatitis.  Other antidiabetic therapies should be considered in patients with a previous history of pancreatitis, although it is not known if they are at increased risk.  Patients receiving treatment with GLP-1 receptor agonists should be observed carefully for signs and symptoms of pancreatitis.  If this diagnosis is suspected, the treatment should be discontinued immediately and appropriate management should be initiated.  Treatment with GLP-1 receptor agonists should be permanently discontinued if pancreatitis is confirmed.', '3', '"Product Information. Byetta (exenatide)." Amylin Pharmaceuticals Inc  (2005):|"Product Information. Tanzeum (albiglutide)." GlaxoSmithKline  (2014):|"Product Information. Trulicity (dulaglutide)." Eli Lilly and Company  (2014):|"Product Information. Saxenda (liraglutide)." Novo Nordisk Pharmaceuticals Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38757, 0, 'Albiglutide', 'Thyroid Neoplasms', 'GLP-1 receptor agonist antidiabetic drugs are contraindicated in patients with a personal or family history of medullary thyroid carcinoma and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN2).  Carcinogenicity studies in rodents and limited postmarketing data suggest that GLP-1 inhibitors may cause a dose-related and treatment duration-related increase in risk of thyroid C-cell tumors, although a causal relationship has not been established.', '3', '"Product Information. Byetta (exenatide)." Amylin Pharmaceuticals Inc  (2005):|"Product Information. Victoza (liraglutide)." Novo Nordisk Pharmaceuticals Inc  (2010):|"Product Information. Tanzeum (albiglutide)." GlaxoSmithKline  (2014):|"Product Information. Trulicity (dulaglutide)." Eli Lilly and Company  (2014):|"Product Information. Saxenda (liraglutide)." Novo Nordisk Pharmaceuticals Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38758, 0, 'Albiglutide', 'Kidney Diseases', 'There have been reports of acute renal failure and worsening of chronic renal failure sometimes requiring hemodialysis in patients treated with GLP-1 receptor inhibitors.  Some of these events occurred in patients without known underlying renal disease.  These drugs should be used with caution in patients with renal impairment, especially during treatment initiation or dose escalation.  Patients should be monitored, especially if they report severe gastrointestinal reactions such as nausea, vomiting, diarrhea, or dehydration.  The frequency of gastrointestinal events is increased as renal function declines.  There is limited clinical experience with most of these drugs in patients with severe renal impairment.', '2', '"Product Information. Symlin (pramlintide)." Amphastar Pharmaceuticals Inc  (2005):|"Product Information. Byetta (exenatide)." Amylin Pharmaceuticals Inc  (2005):|"Product Information. Victoza (liraglutide)." Novo Nordisk Pharmaceuticals Inc  (2010):|"Product Information. Trulicity (dulaglutide)." Eli Lilly and Company  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38759, 306, 'Chloroquine', 'Toxic Optic Neuropathy', 'The use of 4-aminoquinolines is generally considered contraindicated in the presence of retinal or visual field changes, whether attributable to 4-aminoquinoline compounds or to any other etiology.  However, in the treatment of acute attacks of malaria caused by susceptible strains of plasmodia, these agents may be considered if potential benefits are anticipated to outweigh the risks.  4-aminoquinolines are oculotoxic and can cause dose-related, irreversible retinal damage and vision loss during and up to several years after long-term or high-dose therapy (e.g., in the treatment of systemic lupus erythematosus or rheumatoid arthritis).  Ophthalmologic monitoring, including visual acuity, expert slit-lamp, funduscopic, and visual field tests, is recommended at baseline and every three months during prolonged use.  Therapy should be discontinued immediately if abnormalities develop in visual acuity, visual field, or retinal macular areas (e.g., pigmentary changes, loss of foveal reflex), or if the patient experiences visual symptoms such as light flashes and streaks that are not fully explainable by difficulties of accommodation or corneal opacities.  Other common symptoms that may indicate retinopathy include nyctalopia, photophobia, blurred distance vision, difficulty reading or seeing (e.g., words or letters disappearing or parts of objects missing; misty vision; fog before the eyes), and missing or blacked out areas in the central or peripheral visual field.  Retinal changes and visual disturbances may progress even after cessation of therapy.  However, in a number of patients, early retinopathy (macular pigmentation sometimes with central field defects) diminished or regressed completely after therapy was discontinued.  Paracentral scotoma to red targets, sometimes termed premaculopathy, is indicative of early retinal dysfunction and is usually reversible with cessation of therapy.', '3', 'Sassani JW, Brucker AJ, Cobbs W, Campbell C "Progressive chloroquine retinopathy." Ann Ophthalmol 15 (1983):  19-22|Ehrenfeld M, Nesher R, Merin S "Delayed-onset chloroquine retinopathy." Br J Ophthalmol 70 (1986):  281-3|Frisk-Holmberg M, Bergkvist Y, Domeij-Nyberg B, et al. "Chloroquine serum concentration and side effects: evidence for dose-dependent kinetics." Clin Pharmacol Ther 25 (1979):  345-50|Craig GL, Buchanan WW "Antirheumatic drugs: clinical pharmacology and therapeutic use." Drugs 20 (1980):  453-84|"Product Information. Aralen (chloroquine)." Sanofi Winthrop Pharmaceuticals  (2002):|Goldstein JH "Effects of drugs on cornea, conjunctiva, and lids." Int Ophthalmol Clin 11 (1971):  13-34|"Product Information. Plaquenil (hydroxychloroquine)." Apothecon Inc  (2022):|Puavilai S, Kunavisarut S, Vatanasuk M, Timpatanapong P, Sriwong ST, Janwitayanujit S, Nantiruj K, Totemchokchyakarn K, Ruangkanchana "Ocular toxicity of chloroquine among Thai patients." Int J Dermatol 38 (1999):  934-7', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38760, 2506, 'Chloroquine', 'Toxic Optic Neuropathy', 'The use of 4-aminoquinolines is generally considered contraindicated in the presence of retinal or visual field changes, whether attributable to 4-aminoquinoline compounds or to any other etiology.  However, in the treatment of acute attacks of malaria caused by susceptible strains of plasmodia, these agents may be considered if potential benefits are anticipated to outweigh the risks.  4-aminoquinolines are oculotoxic and can cause dose-related, irreversible retinal damage and vision loss during and up to several years after long-term or high-dose therapy (e.g., in the treatment of systemic lupus erythematosus or rheumatoid arthritis).  Ophthalmologic monitoring, including visual acuity, expert slit-lamp, funduscopic, and visual field tests, is recommended at baseline and every three months during prolonged use.  Therapy should be discontinued immediately if abnormalities develop in visual acuity, visual field, or retinal macular areas (e.g., pigmentary changes, loss of foveal reflex), or if the patient experiences visual symptoms such as light flashes and streaks that are not fully explainable by difficulties of accommodation or corneal opacities.  Other common symptoms that may indicate retinopathy include nyctalopia, photophobia, blurred distance vision, difficulty reading or seeing (e.g., words or letters disappearing or parts of objects missing; misty vision; fog before the eyes), and missing or blacked out areas in the central or peripheral visual field.  Retinal changes and visual disturbances may progress even after cessation of therapy.  However, in a number of patients, early retinopathy (macular pigmentation sometimes with central field defects) diminished or regressed completely after therapy was discontinued.  Paracentral scotoma to red targets, sometimes termed premaculopathy, is indicative of early retinal dysfunction and is usually reversible with cessation of therapy.', '3', 'Sassani JW, Brucker AJ, Cobbs W, Campbell C "Progressive chloroquine retinopathy." Ann Ophthalmol 15 (1983):  19-22|Ehrenfeld M, Nesher R, Merin S "Delayed-onset chloroquine retinopathy." Br J Ophthalmol 70 (1986):  281-3|Frisk-Holmberg M, Bergkvist Y, Domeij-Nyberg B, et al. "Chloroquine serum concentration and side effects: evidence for dose-dependent kinetics." Clin Pharmacol Ther 25 (1979):  345-50|Craig GL, Buchanan WW "Antirheumatic drugs: clinical pharmacology and therapeutic use." Drugs 20 (1980):  453-84|"Product Information. Aralen (chloroquine)." Sanofi Winthrop Pharmaceuticals  (2002):|Goldstein JH "Effects of drugs on cornea, conjunctiva, and lids." Int Ophthalmol Clin 11 (1971):  13-34|"Product Information. Plaquenil (hydroxychloroquine)." Apothecon Inc  (2022):|Puavilai S, Kunavisarut S, Vatanasuk M, Timpatanapong P, Sriwong ST, Janwitayanujit S, Nantiruj K, Totemchokchyakarn K, Ruangkanchana "Ocular toxicity of chloroquine among Thai patients." Int J Dermatol 38 (1999):  934-7', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38761, 16253, 'Chloroquine', 'Toxic Optic Neuropathy', 'The use of 4-aminoquinolines is generally considered contraindicated in the presence of retinal or visual field changes, whether attributable to 4-aminoquinoline compounds or to any other etiology.  However, in the treatment of acute attacks of malaria caused by susceptible strains of plasmodia, these agents may be considered if potential benefits are anticipated to outweigh the risks.  4-aminoquinolines are oculotoxic and can cause dose-related, irreversible retinal damage and vision loss during and up to several years after long-term or high-dose therapy (e.g., in the treatment of systemic lupus erythematosus or rheumatoid arthritis).  Ophthalmologic monitoring, including visual acuity, expert slit-lamp, funduscopic, and visual field tests, is recommended at baseline and every three months during prolonged use.  Therapy should be discontinued immediately if abnormalities develop in visual acuity, visual field, or retinal macular areas (e.g., pigmentary changes, loss of foveal reflex), or if the patient experiences visual symptoms such as light flashes and streaks that are not fully explainable by difficulties of accommodation or corneal opacities.  Other common symptoms that may indicate retinopathy include nyctalopia, photophobia, blurred distance vision, difficulty reading or seeing (e.g., words or letters disappearing or parts of objects missing; misty vision; fog before the eyes), and missing or blacked out areas in the central or peripheral visual field.  Retinal changes and visual disturbances may progress even after cessation of therapy.  However, in a number of patients, early retinopathy (macular pigmentation sometimes with central field defects) diminished or regressed completely after therapy was discontinued.  Paracentral scotoma to red targets, sometimes termed premaculopathy, is indicative of early retinal dysfunction and is usually reversible with cessation of therapy.', '3', 'Sassani JW, Brucker AJ, Cobbs W, Campbell C "Progressive chloroquine retinopathy." Ann Ophthalmol 15 (1983):  19-22|Ehrenfeld M, Nesher R, Merin S "Delayed-onset chloroquine retinopathy." Br J Ophthalmol 70 (1986):  281-3|Frisk-Holmberg M, Bergkvist Y, Domeij-Nyberg B, et al. "Chloroquine serum concentration and side effects: evidence for dose-dependent kinetics." Clin Pharmacol Ther 25 (1979):  345-50|Craig GL, Buchanan WW "Antirheumatic drugs: clinical pharmacology and therapeutic use." Drugs 20 (1980):  453-84|"Product Information. Aralen (chloroquine)." Sanofi Winthrop Pharmaceuticals  (2002):|Goldstein JH "Effects of drugs on cornea, conjunctiva, and lids." Int Ophthalmol Clin 11 (1971):  13-34|"Product Information. Plaquenil (hydroxychloroquine)." Apothecon Inc  (2022):|Puavilai S, Kunavisarut S, Vatanasuk M, Timpatanapong P, Sriwong ST, Janwitayanujit S, Nantiruj K, Totemchokchyakarn K, Ruangkanchana "Ocular toxicity of chloroquine among Thai patients." Int J Dermatol 38 (1999):  934-7', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38762, 16254, 'Chloroquine', 'Toxic Optic Neuropathy', 'The use of 4-aminoquinolines is generally considered contraindicated in the presence of retinal or visual field changes, whether attributable to 4-aminoquinoline compounds or to any other etiology.  However, in the treatment of acute attacks of malaria caused by susceptible strains of plasmodia, these agents may be considered if potential benefits are anticipated to outweigh the risks.  4-aminoquinolines are oculotoxic and can cause dose-related, irreversible retinal damage and vision loss during and up to several years after long-term or high-dose therapy (e.g., in the treatment of systemic lupus erythematosus or rheumatoid arthritis).  Ophthalmologic monitoring, including visual acuity, expert slit-lamp, funduscopic, and visual field tests, is recommended at baseline and every three months during prolonged use.  Therapy should be discontinued immediately if abnormalities develop in visual acuity, visual field, or retinal macular areas (e.g., pigmentary changes, loss of foveal reflex), or if the patient experiences visual symptoms such as light flashes and streaks that are not fully explainable by difficulties of accommodation or corneal opacities.  Other common symptoms that may indicate retinopathy include nyctalopia, photophobia, blurred distance vision, difficulty reading or seeing (e.g., words or letters disappearing or parts of objects missing; misty vision; fog before the eyes), and missing or blacked out areas in the central or peripheral visual field.  Retinal changes and visual disturbances may progress even after cessation of therapy.  However, in a number of patients, early retinopathy (macular pigmentation sometimes with central field defects) diminished or regressed completely after therapy was discontinued.  Paracentral scotoma to red targets, sometimes termed premaculopathy, is indicative of early retinal dysfunction and is usually reversible with cessation of therapy.', '3', 'Sassani JW, Brucker AJ, Cobbs W, Campbell C "Progressive chloroquine retinopathy." Ann Ophthalmol 15 (1983):  19-22|Ehrenfeld M, Nesher R, Merin S "Delayed-onset chloroquine retinopathy." Br J Ophthalmol 70 (1986):  281-3|Frisk-Holmberg M, Bergkvist Y, Domeij-Nyberg B, et al. "Chloroquine serum concentration and side effects: evidence for dose-dependent kinetics." Clin Pharmacol Ther 25 (1979):  345-50|Craig GL, Buchanan WW "Antirheumatic drugs: clinical pharmacology and therapeutic use." Drugs 20 (1980):  453-84|"Product Information. Aralen (chloroquine)." Sanofi Winthrop Pharmaceuticals  (2002):|Goldstein JH "Effects of drugs on cornea, conjunctiva, and lids." Int Ophthalmol Clin 11 (1971):  13-34|"Product Information. Plaquenil (hydroxychloroquine)." Apothecon Inc  (2022):|Puavilai S, Kunavisarut S, Vatanasuk M, Timpatanapong P, Sriwong ST, Janwitayanujit S, Nantiruj K, Totemchokchyakarn K, Ruangkanchana "Ocular toxicity of chloroquine among Thai patients." Int J Dermatol 38 (1999):  934-7', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38763, 22238, 'Chloroquine', 'Toxic Optic Neuropathy', 'The use of 4-aminoquinolines is generally considered contraindicated in the presence of retinal or visual field changes, whether attributable to 4-aminoquinoline compounds or to any other etiology.  However, in the treatment of acute attacks of malaria caused by susceptible strains of plasmodia, these agents may be considered if potential benefits are anticipated to outweigh the risks.  4-aminoquinolines are oculotoxic and can cause dose-related, irreversible retinal damage and vision loss during and up to several years after long-term or high-dose therapy (e.g., in the treatment of systemic lupus erythematosus or rheumatoid arthritis).  Ophthalmologic monitoring, including visual acuity, expert slit-lamp, funduscopic, and visual field tests, is recommended at baseline and every three months during prolonged use.  Therapy should be discontinued immediately if abnormalities develop in visual acuity, visual field, or retinal macular areas (e.g., pigmentary changes, loss of foveal reflex), or if the patient experiences visual symptoms such as light flashes and streaks that are not fully explainable by difficulties of accommodation or corneal opacities.  Other common symptoms that may indicate retinopathy include nyctalopia, photophobia, blurred distance vision, difficulty reading or seeing (e.g., words or letters disappearing or parts of objects missing; misty vision; fog before the eyes), and missing or blacked out areas in the central or peripheral visual field.  Retinal changes and visual disturbances may progress even after cessation of therapy.  However, in a number of patients, early retinopathy (macular pigmentation sometimes with central field defects) diminished or regressed completely after therapy was discontinued.  Paracentral scotoma to red targets, sometimes termed premaculopathy, is indicative of early retinal dysfunction and is usually reversible with cessation of therapy.', '3', 'Sassani JW, Brucker AJ, Cobbs W, Campbell C "Progressive chloroquine retinopathy." Ann Ophthalmol 15 (1983):  19-22|Ehrenfeld M, Nesher R, Merin S "Delayed-onset chloroquine retinopathy." Br J Ophthalmol 70 (1986):  281-3|Frisk-Holmberg M, Bergkvist Y, Domeij-Nyberg B, et al. "Chloroquine serum concentration and side effects: evidence for dose-dependent kinetics." Clin Pharmacol Ther 25 (1979):  345-50|Craig GL, Buchanan WW "Antirheumatic drugs: clinical pharmacology and therapeutic use." Drugs 20 (1980):  453-84|"Product Information. Aralen (chloroquine)." Sanofi Winthrop Pharmaceuticals  (2002):|Goldstein JH "Effects of drugs on cornea, conjunctiva, and lids." Int Ophthalmol Clin 11 (1971):  13-34|"Product Information. Plaquenil (hydroxychloroquine)." Apothecon Inc  (2022):|Puavilai S, Kunavisarut S, Vatanasuk M, Timpatanapong P, Sriwong ST, Janwitayanujit S, Nantiruj K, Totemchokchyakarn K, Ruangkanchana "Ocular toxicity of chloroquine among Thai patients." Int J Dermatol 38 (1999):  934-7', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38764, 306, 'Chloroquine', 'Porphyrias', 'The use of aminoquinolines in patients with porphyria may exacerbate the condition.  Aminoquinolines should not be used in these patients unless the potential benefits are anticipated to outweigh the risks.', '3', '"Product Information. Aralen (chloroquine)." Sanofi Winthrop Pharmaceuticals  (2002):|Liu AC "Hepatotoxic reaction to chloroquine phosphate in a patient with previously unrecognized porphyria cutanea tarda." West J Med 162 (1995):  548-51|"Product Information. Plaquenil (hydroxychloroquine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38765, 2506, 'Chloroquine', 'Porphyrias', 'The use of aminoquinolines in patients with porphyria may exacerbate the condition.  Aminoquinolines should not be used in these patients unless the potential benefits are anticipated to outweigh the risks.', '3', '"Product Information. Aralen (chloroquine)." Sanofi Winthrop Pharmaceuticals  (2002):|Liu AC "Hepatotoxic reaction to chloroquine phosphate in a patient with previously unrecognized porphyria cutanea tarda." West J Med 162 (1995):  548-51|"Product Information. Plaquenil (hydroxychloroquine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38766, 16253, 'Chloroquine', 'Porphyrias', 'The use of aminoquinolines in patients with porphyria may exacerbate the condition.  Aminoquinolines should not be used in these patients unless the potential benefits are anticipated to outweigh the risks.', '3', '"Product Information. Aralen (chloroquine)." Sanofi Winthrop Pharmaceuticals  (2002):|Liu AC "Hepatotoxic reaction to chloroquine phosphate in a patient with previously unrecognized porphyria cutanea tarda." West J Med 162 (1995):  548-51|"Product Information. Plaquenil (hydroxychloroquine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38767, 16254, 'Chloroquine', 'Porphyrias', 'The use of aminoquinolines in patients with porphyria may exacerbate the condition.  Aminoquinolines should not be used in these patients unless the potential benefits are anticipated to outweigh the risks.', '3', '"Product Information. Aralen (chloroquine)." Sanofi Winthrop Pharmaceuticals  (2002):|Liu AC "Hepatotoxic reaction to chloroquine phosphate in a patient with previously unrecognized porphyria cutanea tarda." West J Med 162 (1995):  548-51|"Product Information. Plaquenil (hydroxychloroquine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38768, 22238, 'Chloroquine', 'Porphyrias', 'The use of aminoquinolines in patients with porphyria may exacerbate the condition.  Aminoquinolines should not be used in these patients unless the potential benefits are anticipated to outweigh the risks.', '3', '"Product Information. Aralen (chloroquine)." Sanofi Winthrop Pharmaceuticals  (2002):|Liu AC "Hepatotoxic reaction to chloroquine phosphate in a patient with previously unrecognized porphyria cutanea tarda." West J Med 162 (1995):  548-51|"Product Information. Plaquenil (hydroxychloroquine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38769, 306, 'Chloroquine', 'Arrhythmias, Cardiac', 'The use of 4-aminoquinolines such as hydroxychloroquine and chloroquine prolong the QT interval.  Ventricular arrhythmias and torsades de pointes have been reported in patients taking these agents.  Care should be exercised in patients with a prolonged QT interval at baseline or at increased risk for arrythmia.  A baseline electrocardiogram should be obtained to assess for QT interval prolongation and other abnormalities.  It is recommended to use appropriate diagnostic tools such as ECG to monitor patients during therapy.', '2', '"Product Information. Plaquenil (hydroxychloroquine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38770, 2506, 'Chloroquine', 'Arrhythmias, Cardiac', 'The use of 4-aminoquinolines such as hydroxychloroquine and chloroquine prolong the QT interval.  Ventricular arrhythmias and torsades de pointes have been reported in patients taking these agents.  Care should be exercised in patients with a prolonged QT interval at baseline or at increased risk for arrythmia.  A baseline electrocardiogram should be obtained to assess for QT interval prolongation and other abnormalities.  It is recommended to use appropriate diagnostic tools such as ECG to monitor patients during therapy.', '2', '"Product Information. Plaquenil (hydroxychloroquine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38771, 16253, 'Chloroquine', 'Arrhythmias, Cardiac', 'The use of 4-aminoquinolines such as hydroxychloroquine and chloroquine prolong the QT interval.  Ventricular arrhythmias and torsades de pointes have been reported in patients taking these agents.  Care should be exercised in patients with a prolonged QT interval at baseline or at increased risk for arrythmia.  A baseline electrocardiogram should be obtained to assess for QT interval prolongation and other abnormalities.  It is recommended to use appropriate diagnostic tools such as ECG to monitor patients during therapy.', '2', '"Product Information. Plaquenil (hydroxychloroquine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38772, 16254, 'Chloroquine', 'Arrhythmias, Cardiac', 'The use of 4-aminoquinolines such as hydroxychloroquine and chloroquine prolong the QT interval.  Ventricular arrhythmias and torsades de pointes have been reported in patients taking these agents.  Care should be exercised in patients with a prolonged QT interval at baseline or at increased risk for arrythmia.  A baseline electrocardiogram should be obtained to assess for QT interval prolongation and other abnormalities.  It is recommended to use appropriate diagnostic tools such as ECG to monitor patients during therapy.', '2', '"Product Information. Plaquenil (hydroxychloroquine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38773, 22238, 'Chloroquine', 'Arrhythmias, Cardiac', 'The use of 4-aminoquinolines such as hydroxychloroquine and chloroquine prolong the QT interval.  Ventricular arrhythmias and torsades de pointes have been reported in patients taking these agents.  Care should be exercised in patients with a prolonged QT interval at baseline or at increased risk for arrythmia.  A baseline electrocardiogram should be obtained to assess for QT interval prolongation and other abnormalities.  It is recommended to use appropriate diagnostic tools such as ECG to monitor patients during therapy.', '2', '"Product Information. Plaquenil (hydroxychloroquine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38774, 306, 'Chloroquine', 'Bone Marrow Failure Disorders', 'Adverse hematologic effects including neutropenia, agranulocytosis, aplastic anemia, and thrombocytopenia have been rarely associated with 4-aminoquinolines.  Therapy with 4-aminoquinolines should be administered cautiously in patients with preexisting bone marrow suppression.  A complete blood count should be performed periodically in patients on prolonged therapy.  If any severe blood disorder appears which is not attributable to the disease under treatment, discontinuance of the drug should be considered.', '2', '"Product Information. Aralen (chloroquine)." Sanofi Winthrop Pharmaceuticals  (2002):|Polano MK, Cats A, van Olden GAJ "Agranulocytosis following treatment with hydroxychloroquine sulphate." Lancet 1 (1965):  1275|Winkelman RK, Merwin CF, Brunsting LA "Antimalarial therapy of lupus erythematosus." Ann Intern Med 55 (1961):  772-6|"Product Information. Plaquenil (hydroxychloroquine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38775, 2506, 'Chloroquine', 'Bone Marrow Failure Disorders', 'Adverse hematologic effects including neutropenia, agranulocytosis, aplastic anemia, and thrombocytopenia have been rarely associated with 4-aminoquinolines.  Therapy with 4-aminoquinolines should be administered cautiously in patients with preexisting bone marrow suppression.  A complete blood count should be performed periodically in patients on prolonged therapy.  If any severe blood disorder appears which is not attributable to the disease under treatment, discontinuance of the drug should be considered.', '2', '"Product Information. Aralen (chloroquine)." Sanofi Winthrop Pharmaceuticals  (2002):|Polano MK, Cats A, van Olden GAJ "Agranulocytosis following treatment with hydroxychloroquine sulphate." Lancet 1 (1965):  1275|Winkelman RK, Merwin CF, Brunsting LA "Antimalarial therapy of lupus erythematosus." Ann Intern Med 55 (1961):  772-6|"Product Information. Plaquenil (hydroxychloroquine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38776, 16253, 'Chloroquine', 'Bone Marrow Failure Disorders', 'Adverse hematologic effects including neutropenia, agranulocytosis, aplastic anemia, and thrombocytopenia have been rarely associated with 4-aminoquinolines.  Therapy with 4-aminoquinolines should be administered cautiously in patients with preexisting bone marrow suppression.  A complete blood count should be performed periodically in patients on prolonged therapy.  If any severe blood disorder appears which is not attributable to the disease under treatment, discontinuance of the drug should be considered.', '2', '"Product Information. Aralen (chloroquine)." Sanofi Winthrop Pharmaceuticals  (2002):|Polano MK, Cats A, van Olden GAJ "Agranulocytosis following treatment with hydroxychloroquine sulphate." Lancet 1 (1965):  1275|Winkelman RK, Merwin CF, Brunsting LA "Antimalarial therapy of lupus erythematosus." Ann Intern Med 55 (1961):  772-6|"Product Information. Plaquenil (hydroxychloroquine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38777, 16254, 'Chloroquine', 'Bone Marrow Failure Disorders', 'Adverse hematologic effects including neutropenia, agranulocytosis, aplastic anemia, and thrombocytopenia have been rarely associated with 4-aminoquinolines.  Therapy with 4-aminoquinolines should be administered cautiously in patients with preexisting bone marrow suppression.  A complete blood count should be performed periodically in patients on prolonged therapy.  If any severe blood disorder appears which is not attributable to the disease under treatment, discontinuance of the drug should be considered.', '2', '"Product Information. Aralen (chloroquine)." Sanofi Winthrop Pharmaceuticals  (2002):|Polano MK, Cats A, van Olden GAJ "Agranulocytosis following treatment with hydroxychloroquine sulphate." Lancet 1 (1965):  1275|Winkelman RK, Merwin CF, Brunsting LA "Antimalarial therapy of lupus erythematosus." Ann Intern Med 55 (1961):  772-6|"Product Information. Plaquenil (hydroxychloroquine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38778, 22238, 'Chloroquine', 'Bone Marrow Failure Disorders', 'Adverse hematologic effects including neutropenia, agranulocytosis, aplastic anemia, and thrombocytopenia have been rarely associated with 4-aminoquinolines.  Therapy with 4-aminoquinolines should be administered cautiously in patients with preexisting bone marrow suppression.  A complete blood count should be performed periodically in patients on prolonged therapy.  If any severe blood disorder appears which is not attributable to the disease under treatment, discontinuance of the drug should be considered.', '2', '"Product Information. Aralen (chloroquine)." Sanofi Winthrop Pharmaceuticals  (2002):|Polano MK, Cats A, van Olden GAJ "Agranulocytosis following treatment with hydroxychloroquine sulphate." Lancet 1 (1965):  1275|Winkelman RK, Merwin CF, Brunsting LA "Antimalarial therapy of lupus erythematosus." Ann Intern Med 55 (1961):  772-6|"Product Information. Plaquenil (hydroxychloroquine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38779, 306, 'Chloroquine', 'Ototoxicity', 'The use of 4-aminoquinolines has been associated rarely with ototoxicity.  Nerve-type deafness, which is usually irreversible, has occurred during long-term, high-dose therapy.  Deafness may not be apparent until several weeks after 4-aminoquinoline therapy.  Tinnitus and reduced hearing have been reported in patients with preexisting auditory damage.  Therapy with 4-aminoquinolines should be administered cautiously in such patients.  If new auditory defects develop or if hearing loss becomes worse, therapy should be immediately discontinued and the patient closely monitored.', '2', '"Product Information. Aralen (chloroquine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Plaquenil (hydroxychloroquine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38780, 2506, 'Chloroquine', 'Ototoxicity', 'The use of 4-aminoquinolines has been associated rarely with ototoxicity.  Nerve-type deafness, which is usually irreversible, has occurred during long-term, high-dose therapy.  Deafness may not be apparent until several weeks after 4-aminoquinoline therapy.  Tinnitus and reduced hearing have been reported in patients with preexisting auditory damage.  Therapy with 4-aminoquinolines should be administered cautiously in such patients.  If new auditory defects develop or if hearing loss becomes worse, therapy should be immediately discontinued and the patient closely monitored.', '2', '"Product Information. Aralen (chloroquine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Plaquenil (hydroxychloroquine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38781, 16253, 'Chloroquine', 'Ototoxicity', 'The use of 4-aminoquinolines has been associated rarely with ototoxicity.  Nerve-type deafness, which is usually irreversible, has occurred during long-term, high-dose therapy.  Deafness may not be apparent until several weeks after 4-aminoquinoline therapy.  Tinnitus and reduced hearing have been reported in patients with preexisting auditory damage.  Therapy with 4-aminoquinolines should be administered cautiously in such patients.  If new auditory defects develop or if hearing loss becomes worse, therapy should be immediately discontinued and the patient closely monitored.', '2', '"Product Information. Aralen (chloroquine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Plaquenil (hydroxychloroquine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38782, 16254, 'Chloroquine', 'Ototoxicity', 'The use of 4-aminoquinolines has been associated rarely with ototoxicity.  Nerve-type deafness, which is usually irreversible, has occurred during long-term, high-dose therapy.  Deafness may not be apparent until several weeks after 4-aminoquinoline therapy.  Tinnitus and reduced hearing have been reported in patients with preexisting auditory damage.  Therapy with 4-aminoquinolines should be administered cautiously in such patients.  If new auditory defects develop or if hearing loss becomes worse, therapy should be immediately discontinued and the patient closely monitored.', '2', '"Product Information. Aralen (chloroquine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Plaquenil (hydroxychloroquine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38783, 22238, 'Chloroquine', 'Ototoxicity', 'The use of 4-aminoquinolines has been associated rarely with ototoxicity.  Nerve-type deafness, which is usually irreversible, has occurred during long-term, high-dose therapy.  Deafness may not be apparent until several weeks after 4-aminoquinoline therapy.  Tinnitus and reduced hearing have been reported in patients with preexisting auditory damage.  Therapy with 4-aminoquinolines should be administered cautiously in such patients.  If new auditory defects develop or if hearing loss becomes worse, therapy should be immediately discontinued and the patient closely monitored.', '2', '"Product Information. Aralen (chloroquine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Plaquenil (hydroxychloroquine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38784, 306, 'Chloroquine', 'Seizures', '4-aminoquinolines may cause epileptic seizures in susceptible individuals.  Patients with epilepsy or an otherwise low seizure threshold may be at greater risk.  Therapy with 4-aminoquinolines, particularly chloroquine, should be administered cautiously in patients with epilepsy.', '2', 'Fish DR, Espir ML "Convulsions associated with prophylactic antimalarial drugs: implications for people with epilepsy." Br Med J 297 (1988):  526-7|"Product Information. Aralen (chloroquine)." Sanofi Winthrop Pharmaceuticals  (2002):|Mulhauser P, Allemann Y "Chloroquine and nonconvulsive status epilepticus." Ann Intern Med 123 (1995):  76-7|"Product Information. Plaquenil (hydroxychloroquine)." Apothecon Inc  (2022):|Benbadis SR, Vanness PC "Chloroquine and nonconvulsive status epilepticus." Ann Intern Med 124 (1996):  614', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38785, 2506, 'Chloroquine', 'Seizures', '4-aminoquinolines may cause epileptic seizures in susceptible individuals.  Patients with epilepsy or an otherwise low seizure threshold may be at greater risk.  Therapy with 4-aminoquinolines, particularly chloroquine, should be administered cautiously in patients with epilepsy.', '2', 'Fish DR, Espir ML "Convulsions associated with prophylactic antimalarial drugs: implications for people with epilepsy." Br Med J 297 (1988):  526-7|"Product Information. Aralen (chloroquine)." Sanofi Winthrop Pharmaceuticals  (2002):|Mulhauser P, Allemann Y "Chloroquine and nonconvulsive status epilepticus." Ann Intern Med 123 (1995):  76-7|"Product Information. Plaquenil (hydroxychloroquine)." Apothecon Inc  (2022):|Benbadis SR, Vanness PC "Chloroquine and nonconvulsive status epilepticus." Ann Intern Med 124 (1996):  614', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38786, 16253, 'Chloroquine', 'Seizures', '4-aminoquinolines may cause epileptic seizures in susceptible individuals.  Patients with epilepsy or an otherwise low seizure threshold may be at greater risk.  Therapy with 4-aminoquinolines, particularly chloroquine, should be administered cautiously in patients with epilepsy.', '2', 'Fish DR, Espir ML "Convulsions associated with prophylactic antimalarial drugs: implications for people with epilepsy." Br Med J 297 (1988):  526-7|"Product Information. Aralen (chloroquine)." Sanofi Winthrop Pharmaceuticals  (2002):|Mulhauser P, Allemann Y "Chloroquine and nonconvulsive status epilepticus." Ann Intern Med 123 (1995):  76-7|"Product Information. Plaquenil (hydroxychloroquine)." Apothecon Inc  (2022):|Benbadis SR, Vanness PC "Chloroquine and nonconvulsive status epilepticus." Ann Intern Med 124 (1996):  614', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38787, 16254, 'Chloroquine', 'Seizures', '4-aminoquinolines may cause epileptic seizures in susceptible individuals.  Patients with epilepsy or an otherwise low seizure threshold may be at greater risk.  Therapy with 4-aminoquinolines, particularly chloroquine, should be administered cautiously in patients with epilepsy.', '2', 'Fish DR, Espir ML "Convulsions associated with prophylactic antimalarial drugs: implications for people with epilepsy." Br Med J 297 (1988):  526-7|"Product Information. Aralen (chloroquine)." Sanofi Winthrop Pharmaceuticals  (2002):|Mulhauser P, Allemann Y "Chloroquine and nonconvulsive status epilepticus." Ann Intern Med 123 (1995):  76-7|"Product Information. Plaquenil (hydroxychloroquine)." Apothecon Inc  (2022):|Benbadis SR, Vanness PC "Chloroquine and nonconvulsive status epilepticus." Ann Intern Med 124 (1996):  614', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38788, 22238, 'Chloroquine', 'Seizures', '4-aminoquinolines may cause epileptic seizures in susceptible individuals.  Patients with epilepsy or an otherwise low seizure threshold may be at greater risk.  Therapy with 4-aminoquinolines, particularly chloroquine, should be administered cautiously in patients with epilepsy.', '2', 'Fish DR, Espir ML "Convulsions associated with prophylactic antimalarial drugs: implications for people with epilepsy." Br Med J 297 (1988):  526-7|"Product Information. Aralen (chloroquine)." Sanofi Winthrop Pharmaceuticals  (2002):|Mulhauser P, Allemann Y "Chloroquine and nonconvulsive status epilepticus." Ann Intern Med 123 (1995):  76-7|"Product Information. Plaquenil (hydroxychloroquine)." Apothecon Inc  (2022):|Benbadis SR, Vanness PC "Chloroquine and nonconvulsive status epilepticus." Ann Intern Med 124 (1996):  614', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38789, 306, 'Chloroquine', 'Glucosephosphate Dehydrogenase Deficiency', 'Hemolysis and acute renal failure have been reported during use of aminoquinolines in patients with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.  Therapy with aminoquinolines should be administered cautiously in these patients.  Blood cell counts and hemoglobin determinations should be performed regularly.  Aminoquinoline therapy should be discontinued immediately if signs suggestive of hemolytic anemia occur, such as marked darkening of the urine or sudden decrease in hemoglobin concentration or erythrocytic count.', '2', '"Product Information. Aralen (chloroquine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Plaquenil (hydroxychloroquine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38790, 2506, 'Chloroquine', 'Glucosephosphate Dehydrogenase Deficiency', 'Hemolysis and acute renal failure have been reported during use of aminoquinolines in patients with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.  Therapy with aminoquinolines should be administered cautiously in these patients.  Blood cell counts and hemoglobin determinations should be performed regularly.  Aminoquinoline therapy should be discontinued immediately if signs suggestive of hemolytic anemia occur, such as marked darkening of the urine or sudden decrease in hemoglobin concentration or erythrocytic count.', '2', '"Product Information. Aralen (chloroquine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Plaquenil (hydroxychloroquine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38791, 16253, 'Chloroquine', 'Glucosephosphate Dehydrogenase Deficiency', 'Hemolysis and acute renal failure have been reported during use of aminoquinolines in patients with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.  Therapy with aminoquinolines should be administered cautiously in these patients.  Blood cell counts and hemoglobin determinations should be performed regularly.  Aminoquinoline therapy should be discontinued immediately if signs suggestive of hemolytic anemia occur, such as marked darkening of the urine or sudden decrease in hemoglobin concentration or erythrocytic count.', '2', '"Product Information. Aralen (chloroquine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Plaquenil (hydroxychloroquine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38792, 16254, 'Chloroquine', 'Glucosephosphate Dehydrogenase Deficiency', 'Hemolysis and acute renal failure have been reported during use of aminoquinolines in patients with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.  Therapy with aminoquinolines should be administered cautiously in these patients.  Blood cell counts and hemoglobin determinations should be performed regularly.  Aminoquinoline therapy should be discontinued immediately if signs suggestive of hemolytic anemia occur, such as marked darkening of the urine or sudden decrease in hemoglobin concentration or erythrocytic count.', '2', '"Product Information. Aralen (chloroquine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Plaquenil (hydroxychloroquine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38793, 22238, 'Chloroquine', 'Glucosephosphate Dehydrogenase Deficiency', 'Hemolysis and acute renal failure have been reported during use of aminoquinolines in patients with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.  Therapy with aminoquinolines should be administered cautiously in these patients.  Blood cell counts and hemoglobin determinations should be performed regularly.  Aminoquinoline therapy should be discontinued immediately if signs suggestive of hemolytic anemia occur, such as marked darkening of the urine or sudden decrease in hemoglobin concentration or erythrocytic count.', '2', '"Product Information. Aralen (chloroquine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Plaquenil (hydroxychloroquine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38794, 306, 'Chloroquine', 'Liver Diseases', 'Aminoquinolines may concentrate in the liver.  Isolated cases of abnormal liver function and fulminant hepatic failure have been reported.  Therapy with aminoquinolines should be administered cautiously in patients with hepatic disease or alcoholism and in patients receiving other hepatotoxic drugs.  Periodic evaluation of hepatic function should be performed during prolonged therapy.', '2', '"Product Information. Aralen (chloroquine)." Sanofi Winthrop Pharmaceuticals  (2002):|Liu AC "Hepatotoxic reaction to chloroquine phosphate in a patient with previously unrecognized porphyria cutanea tarda." West J Med 162 (1995):  548-51|"Product Information. Plaquenil (hydroxychloroquine)." Apothecon Inc  (2022):|Grossman I, Azaz-Livshits T, Fridlender Z, Muszkat M, Ben-Chetrit E "Mefloquine-induced acute hepatitis." Pharmacotherapy 20 (2000):  1517-9', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38795, 2506, 'Chloroquine', 'Liver Diseases', 'Aminoquinolines may concentrate in the liver.  Isolated cases of abnormal liver function and fulminant hepatic failure have been reported.  Therapy with aminoquinolines should be administered cautiously in patients with hepatic disease or alcoholism and in patients receiving other hepatotoxic drugs.  Periodic evaluation of hepatic function should be performed during prolonged therapy.', '2', '"Product Information. Aralen (chloroquine)." Sanofi Winthrop Pharmaceuticals  (2002):|Liu AC "Hepatotoxic reaction to chloroquine phosphate in a patient with previously unrecognized porphyria cutanea tarda." West J Med 162 (1995):  548-51|"Product Information. Plaquenil (hydroxychloroquine)." Apothecon Inc  (2022):|Grossman I, Azaz-Livshits T, Fridlender Z, Muszkat M, Ben-Chetrit E "Mefloquine-induced acute hepatitis." Pharmacotherapy 20 (2000):  1517-9', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38796, 16253, 'Chloroquine', 'Liver Diseases', 'Aminoquinolines may concentrate in the liver.  Isolated cases of abnormal liver function and fulminant hepatic failure have been reported.  Therapy with aminoquinolines should be administered cautiously in patients with hepatic disease or alcoholism and in patients receiving other hepatotoxic drugs.  Periodic evaluation of hepatic function should be performed during prolonged therapy.', '2', '"Product Information. Aralen (chloroquine)." Sanofi Winthrop Pharmaceuticals  (2002):|Liu AC "Hepatotoxic reaction to chloroquine phosphate in a patient with previously unrecognized porphyria cutanea tarda." West J Med 162 (1995):  548-51|"Product Information. Plaquenil (hydroxychloroquine)." Apothecon Inc  (2022):|Grossman I, Azaz-Livshits T, Fridlender Z, Muszkat M, Ben-Chetrit E "Mefloquine-induced acute hepatitis." Pharmacotherapy 20 (2000):  1517-9', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38797, 16254, 'Chloroquine', 'Liver Diseases', 'Aminoquinolines may concentrate in the liver.  Isolated cases of abnormal liver function and fulminant hepatic failure have been reported.  Therapy with aminoquinolines should be administered cautiously in patients with hepatic disease or alcoholism and in patients receiving other hepatotoxic drugs.  Periodic evaluation of hepatic function should be performed during prolonged therapy.', '2', '"Product Information. Aralen (chloroquine)." Sanofi Winthrop Pharmaceuticals  (2002):|Liu AC "Hepatotoxic reaction to chloroquine phosphate in a patient with previously unrecognized porphyria cutanea tarda." West J Med 162 (1995):  548-51|"Product Information. Plaquenil (hydroxychloroquine)." Apothecon Inc  (2022):|Grossman I, Azaz-Livshits T, Fridlender Z, Muszkat M, Ben-Chetrit E "Mefloquine-induced acute hepatitis." Pharmacotherapy 20 (2000):  1517-9', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38798, 22238, 'Chloroquine', 'Liver Diseases', 'Aminoquinolines may concentrate in the liver.  Isolated cases of abnormal liver function and fulminant hepatic failure have been reported.  Therapy with aminoquinolines should be administered cautiously in patients with hepatic disease or alcoholism and in patients receiving other hepatotoxic drugs.  Periodic evaluation of hepatic function should be performed during prolonged therapy.', '2', '"Product Information. Aralen (chloroquine)." Sanofi Winthrop Pharmaceuticals  (2002):|Liu AC "Hepatotoxic reaction to chloroquine phosphate in a patient with previously unrecognized porphyria cutanea tarda." West J Med 162 (1995):  548-51|"Product Information. Plaquenil (hydroxychloroquine)." Apothecon Inc  (2022):|Grossman I, Azaz-Livshits T, Fridlender Z, Muszkat M, Ben-Chetrit E "Mefloquine-induced acute hepatitis." Pharmacotherapy 20 (2000):  1517-9', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38799, 306, 'Chloroquine', 'Myasthenia Gravis', 'Certain aminoquinolines such as chloroquine, and hydroxychloroquine should be used with caution in patients with myasthenia gravis (MG).  These agents may exacerbate or trigger new onset of symptoms in patients with previously diagnosed MG.  It is recommended to advise patients with MG about this possible side effect.', '2', '"Product Information. Aralen (chloroquine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Plaquenil (hydroxychloroquine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38800, 2506, 'Chloroquine', 'Myasthenia Gravis', 'Certain aminoquinolines such as chloroquine, and hydroxychloroquine should be used with caution in patients with myasthenia gravis (MG).  These agents may exacerbate or trigger new onset of symptoms in patients with previously diagnosed MG.  It is recommended to advise patients with MG about this possible side effect.', '2', '"Product Information. Aralen (chloroquine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Plaquenil (hydroxychloroquine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38801, 16253, 'Chloroquine', 'Myasthenia Gravis', 'Certain aminoquinolines such as chloroquine, and hydroxychloroquine should be used with caution in patients with myasthenia gravis (MG).  These agents may exacerbate or trigger new onset of symptoms in patients with previously diagnosed MG.  It is recommended to advise patients with MG about this possible side effect.', '2', '"Product Information. Aralen (chloroquine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Plaquenil (hydroxychloroquine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38802, 16254, 'Chloroquine', 'Myasthenia Gravis', 'Certain aminoquinolines such as chloroquine, and hydroxychloroquine should be used with caution in patients with myasthenia gravis (MG).  These agents may exacerbate or trigger new onset of symptoms in patients with previously diagnosed MG.  It is recommended to advise patients with MG about this possible side effect.', '2', '"Product Information. Aralen (chloroquine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Plaquenil (hydroxychloroquine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38803, 22238, 'Chloroquine', 'Myasthenia Gravis', 'Certain aminoquinolines such as chloroquine, and hydroxychloroquine should be used with caution in patients with myasthenia gravis (MG).  These agents may exacerbate or trigger new onset of symptoms in patients with previously diagnosed MG.  It is recommended to advise patients with MG about this possible side effect.', '2', '"Product Information. Aralen (chloroquine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Plaquenil (hydroxychloroquine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38804, 306, 'Chloroquine', 'Psoriasis', 'The use of aminoquinolines in patients with psoriasis may precipitate a severe attack of psoriasis. Aminoquinolines should not be used in these patients unless the potential benefits are anticipated to outweigh the risks.', '2', 'Olsen TG "Chloroquine and psoriasis." Ann Intern Med 94 (1981):  546-7|Mallett R "Risks and benefits of prophylactic antimalarial drugs." Br Med J 299 (1989):  1400|Okor RS "Onset of pruritogenicity of chloroquine and the implication for the timing of suppressive therapy." J Clin Pharm Ther 16 (1991):  463-5|Kuflik EG "Effect of antimalarial drugs on psoriasis." Cutis 26 (1980):  53-5|Vestey JP, Savin JA "Psoriasis worsened by antimalarial prophylaxis." J Infect 24 (1992):  211-2|"Product Information. Aralen (chloroquine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Plaquenil (hydroxychloroquine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38805, 2506, 'Chloroquine', 'Psoriasis', 'The use of aminoquinolines in patients with psoriasis may precipitate a severe attack of psoriasis. Aminoquinolines should not be used in these patients unless the potential benefits are anticipated to outweigh the risks.', '2', 'Olsen TG "Chloroquine and psoriasis." Ann Intern Med 94 (1981):  546-7|Mallett R "Risks and benefits of prophylactic antimalarial drugs." Br Med J 299 (1989):  1400|Okor RS "Onset of pruritogenicity of chloroquine and the implication for the timing of suppressive therapy." J Clin Pharm Ther 16 (1991):  463-5|Kuflik EG "Effect of antimalarial drugs on psoriasis." Cutis 26 (1980):  53-5|Vestey JP, Savin JA "Psoriasis worsened by antimalarial prophylaxis." J Infect 24 (1992):  211-2|"Product Information. Aralen (chloroquine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Plaquenil (hydroxychloroquine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38806, 16253, 'Chloroquine', 'Psoriasis', 'The use of aminoquinolines in patients with psoriasis may precipitate a severe attack of psoriasis. Aminoquinolines should not be used in these patients unless the potential benefits are anticipated to outweigh the risks.', '2', 'Olsen TG "Chloroquine and psoriasis." Ann Intern Med 94 (1981):  546-7|Mallett R "Risks and benefits of prophylactic antimalarial drugs." Br Med J 299 (1989):  1400|Okor RS "Onset of pruritogenicity of chloroquine and the implication for the timing of suppressive therapy." J Clin Pharm Ther 16 (1991):  463-5|Kuflik EG "Effect of antimalarial drugs on psoriasis." Cutis 26 (1980):  53-5|Vestey JP, Savin JA "Psoriasis worsened by antimalarial prophylaxis." J Infect 24 (1992):  211-2|"Product Information. Aralen (chloroquine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Plaquenil (hydroxychloroquine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38807, 16254, 'Chloroquine', 'Psoriasis', 'The use of aminoquinolines in patients with psoriasis may precipitate a severe attack of psoriasis. Aminoquinolines should not be used in these patients unless the potential benefits are anticipated to outweigh the risks.', '2', 'Olsen TG "Chloroquine and psoriasis." Ann Intern Med 94 (1981):  546-7|Mallett R "Risks and benefits of prophylactic antimalarial drugs." Br Med J 299 (1989):  1400|Okor RS "Onset of pruritogenicity of chloroquine and the implication for the timing of suppressive therapy." J Clin Pharm Ther 16 (1991):  463-5|Kuflik EG "Effect of antimalarial drugs on psoriasis." Cutis 26 (1980):  53-5|Vestey JP, Savin JA "Psoriasis worsened by antimalarial prophylaxis." J Infect 24 (1992):  211-2|"Product Information. Aralen (chloroquine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Plaquenil (hydroxychloroquine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38808, 22238, 'Chloroquine', 'Psoriasis', 'The use of aminoquinolines in patients with psoriasis may precipitate a severe attack of psoriasis. Aminoquinolines should not be used in these patients unless the potential benefits are anticipated to outweigh the risks.', '2', 'Olsen TG "Chloroquine and psoriasis." Ann Intern Med 94 (1981):  546-7|Mallett R "Risks and benefits of prophylactic antimalarial drugs." Br Med J 299 (1989):  1400|Okor RS "Onset of pruritogenicity of chloroquine and the implication for the timing of suppressive therapy." J Clin Pharm Ther 16 (1991):  463-5|Kuflik EG "Effect of antimalarial drugs on psoriasis." Cutis 26 (1980):  53-5|Vestey JP, Savin JA "Psoriasis worsened by antimalarial prophylaxis." J Infect 24 (1992):  211-2|"Product Information. Aralen (chloroquine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Plaquenil (hydroxychloroquine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38809, 9771, 'Alclometasone (topical)', 'Diabetes Mellitus', 'Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.  Therapy with topical corticosteroids rarely produces these effects but should be administered cautiously nonetheless in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Systemic absorption of topical corticosteroids may occur depending on the vehicle and concentration of the preparation, the size of the application area, the integrity of the skin, and the duration of administration.  Use of occlusive dressings over the applied areas may also increase percutaneous absorption.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.', '2', 'Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38810, 9772, 'Alclometasone (topical)', 'Diabetes Mellitus', 'Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.  Therapy with topical corticosteroids rarely produces these effects but should be administered cautiously nonetheless in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Systemic absorption of topical corticosteroids may occur depending on the vehicle and concentration of the preparation, the size of the application area, the integrity of the skin, and the duration of administration.  Use of occlusive dressings over the applied areas may also increase percutaneous absorption.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.', '2', 'Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38811, 13802, 'Alclometasone (topical)', 'Diabetes Mellitus', 'Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.  Therapy with topical corticosteroids rarely produces these effects but should be administered cautiously nonetheless in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Systemic absorption of topical corticosteroids may occur depending on the vehicle and concentration of the preparation, the size of the application area, the integrity of the skin, and the duration of administration.  Use of occlusive dressings over the applied areas may also increase percutaneous absorption.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.', '2', 'Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38812, 9771, 'Alclometasone (topical)', 'Diaper Rash', 'Topical corticosteroids, especially the potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol), are generally not recommended for use in the treatment of diaper rash.  Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are usually at the greatest risk for systemic toxicity such as adrenal suppression, Cushing''s syndrome and intracranial hypertension because of their larger skin surface to body mass ratios.  If topical corticosteroids are necessary to treat diaper rash, medium- to low-potency agents should preferably be used, and parents should be advised not to put tight-fitting diapers or plastic pants over the rash, since occlusion of treated area may increase percutaneous drug absorption.', '2', 'May P, Stein EJ, Ryter RJ, Hirsh FS, Michel B, Levy RP "Cushing syndrome from percutaneous absorption of triamcinolone cream." Arch Intern Med 136 (1976):  612-3|Stoppoloni G, Prisco F, Santinelli R, Sicuranza G, Giordano C "Potential hazards of topical steroid therapy." Am J Dis Child 137 (1983):  1130-1|Ruiz-Maldonado R, Zapata G, Lourdes T, Robles C "Cushing''s syndrome after topical application of corticosteroids." Am J Dis Child 136 (1982):  274-5|Reymann F, Kehlet H "Hypothalamic-pituitary-adrenocortical function. Association with topical application of betamethasone dipropionate." Arch Dermatol 115 (1979):  362-3|Walsh P, Aeling JL, Huff L, Weston WL "Hypothalamus-pituitary-adrenal axis suppression by superpotent topical steroids." J Am Acad Dermatol 29 (1993):  501-3|Nathan AW, Rose GL "Fatal iatrogenic Cushing''s syndrome." Lancet 1 (1979):  207|Macdonald A "Topical corticosteroid preparations. Hazards and side-effects." Br J Clin Pract 25 (1971):  421-5|Salde L, Lassus A "Systemic side-effects of three topical steroids in diseased skin." Curr Med Res Opin 8 (1983):  475-80|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Ohman EM, Rogers S, Meenan FO, McKenna TJ "Adrenal suppression following low-dose topical clobetasol propionate [published erratum appears in J R Soc Med 1988 May;81(5):308]." J R Soc Med 80 (1987):  422-4|Young CA, Williams IR, MacFarlane IA "Unrecognised Cushing''s syndrome and adrenal suppression due to topical clobetasol propionate." Br J Clin Pract 45 (1991):  61-2|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|Novak E, Francom SF, Schlagel CA "Adrenal suppression with high-potency corticosteroid ointment formulations in normal subjects." Clin Ther 6 (1983):  59-71|Gomez EC, Kaminester L, Frost P "Topical halcinonide and betamethasone valerate effects on plasma cortisol: acute and subacute usage studies." Arch Dermatol 113 (1977):  1196-202|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|Patel L, Clayton PE, Addison GM, Price DA, David TJ "Adrenal function following topical steroid treatment in children with atopic dermatitis." Br J Dermatol 132 (1995):  950-5|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38813, 9772, 'Alclometasone (topical)', 'Diaper Rash', 'Topical corticosteroids, especially the potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol), are generally not recommended for use in the treatment of diaper rash.  Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are usually at the greatest risk for systemic toxicity such as adrenal suppression, Cushing''s syndrome and intracranial hypertension because of their larger skin surface to body mass ratios.  If topical corticosteroids are necessary to treat diaper rash, medium- to low-potency agents should preferably be used, and parents should be advised not to put tight-fitting diapers or plastic pants over the rash, since occlusion of treated area may increase percutaneous drug absorption.', '2', 'May P, Stein EJ, Ryter RJ, Hirsh FS, Michel B, Levy RP "Cushing syndrome from percutaneous absorption of triamcinolone cream." Arch Intern Med 136 (1976):  612-3|Stoppoloni G, Prisco F, Santinelli R, Sicuranza G, Giordano C "Potential hazards of topical steroid therapy." Am J Dis Child 137 (1983):  1130-1|Ruiz-Maldonado R, Zapata G, Lourdes T, Robles C "Cushing''s syndrome after topical application of corticosteroids." Am J Dis Child 136 (1982):  274-5|Reymann F, Kehlet H "Hypothalamic-pituitary-adrenocortical function. Association with topical application of betamethasone dipropionate." Arch Dermatol 115 (1979):  362-3|Walsh P, Aeling JL, Huff L, Weston WL "Hypothalamus-pituitary-adrenal axis suppression by superpotent topical steroids." J Am Acad Dermatol 29 (1993):  501-3|Nathan AW, Rose GL "Fatal iatrogenic Cushing''s syndrome." Lancet 1 (1979):  207|Macdonald A "Topical corticosteroid preparations. Hazards and side-effects." Br J Clin Pract 25 (1971):  421-5|Salde L, Lassus A "Systemic side-effects of three topical steroids in diseased skin." Curr Med Res Opin 8 (1983):  475-80|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Ohman EM, Rogers S, Meenan FO, McKenna TJ "Adrenal suppression following low-dose topical clobetasol propionate [published erratum appears in J R Soc Med 1988 May;81(5):308]." J R Soc Med 80 (1987):  422-4|Young CA, Williams IR, MacFarlane IA "Unrecognised Cushing''s syndrome and adrenal suppression due to topical clobetasol propionate." Br J Clin Pract 45 (1991):  61-2|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|Novak E, Francom SF, Schlagel CA "Adrenal suppression with high-potency corticosteroid ointment formulations in normal subjects." Clin Ther 6 (1983):  59-71|Gomez EC, Kaminester L, Frost P "Topical halcinonide and betamethasone valerate effects on plasma cortisol: acute and subacute usage studies." Arch Dermatol 113 (1977):  1196-202|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|Patel L, Clayton PE, Addison GM, Price DA, David TJ "Adrenal function following topical steroid treatment in children with atopic dermatitis." Br J Dermatol 132 (1995):  950-5|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38814, 13802, 'Alclometasone (topical)', 'Diaper Rash', 'Topical corticosteroids, especially the potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol), are generally not recommended for use in the treatment of diaper rash.  Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are usually at the greatest risk for systemic toxicity such as adrenal suppression, Cushing''s syndrome and intracranial hypertension because of their larger skin surface to body mass ratios.  If topical corticosteroids are necessary to treat diaper rash, medium- to low-potency agents should preferably be used, and parents should be advised not to put tight-fitting diapers or plastic pants over the rash, since occlusion of treated area may increase percutaneous drug absorption.', '2', 'May P, Stein EJ, Ryter RJ, Hirsh FS, Michel B, Levy RP "Cushing syndrome from percutaneous absorption of triamcinolone cream." Arch Intern Med 136 (1976):  612-3|Stoppoloni G, Prisco F, Santinelli R, Sicuranza G, Giordano C "Potential hazards of topical steroid therapy." Am J Dis Child 137 (1983):  1130-1|Ruiz-Maldonado R, Zapata G, Lourdes T, Robles C "Cushing''s syndrome after topical application of corticosteroids." Am J Dis Child 136 (1982):  274-5|Reymann F, Kehlet H "Hypothalamic-pituitary-adrenocortical function. Association with topical application of betamethasone dipropionate." Arch Dermatol 115 (1979):  362-3|Walsh P, Aeling JL, Huff L, Weston WL "Hypothalamus-pituitary-adrenal axis suppression by superpotent topical steroids." J Am Acad Dermatol 29 (1993):  501-3|Nathan AW, Rose GL "Fatal iatrogenic Cushing''s syndrome." Lancet 1 (1979):  207|Macdonald A "Topical corticosteroid preparations. Hazards and side-effects." Br J Clin Pract 25 (1971):  421-5|Salde L, Lassus A "Systemic side-effects of three topical steroids in diseased skin." Curr Med Res Opin 8 (1983):  475-80|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Ohman EM, Rogers S, Meenan FO, McKenna TJ "Adrenal suppression following low-dose topical clobetasol propionate [published erratum appears in J R Soc Med 1988 May;81(5):308]." J R Soc Med 80 (1987):  422-4|Young CA, Williams IR, MacFarlane IA "Unrecognised Cushing''s syndrome and adrenal suppression due to topical clobetasol propionate." Br J Clin Pract 45 (1991):  61-2|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|Novak E, Francom SF, Schlagel CA "Adrenal suppression with high-potency corticosteroid ointment formulations in normal subjects." Clin Ther 6 (1983):  59-71|Gomez EC, Kaminester L, Frost P "Topical halcinonide and betamethasone valerate effects on plasma cortisol: acute and subacute usage studies." Arch Dermatol 113 (1977):  1196-202|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|Patel L, Clayton PE, Addison GM, Price DA, David TJ "Adrenal function following topical steroid treatment in children with atopic dermatitis." Br J Dermatol 132 (1995):  950-5|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38815, 9771, 'Alclometasone (topical)', 'Adrenocortical Hyperfunction', 'The use of topical corticosteroids may precipitate or aggravate conditions of hyperadrenocorticism.  Systemic absorption of these agents can produce reversible hypothalamic-pituitary-adrenal axis suppression.  Systemic absorption, depends on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  Patients with an altered skin barrier or liver failure are also at increased risk.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.  The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during topical corticosteroid therapy may indicate excessive use.', '2', 'May P, Stein EJ, Ryter RJ, Hirsh FS, Michel B, Levy RP "Cushing syndrome from percutaneous absorption of triamcinolone cream." Arch Intern Med 136 (1976):  612-3|Stoppoloni G, Prisco F, Santinelli R, Sicuranza G, Giordano C "Potential hazards of topical steroid therapy." Am J Dis Child 137 (1983):  1130-1|Ruiz-Maldonado R, Zapata G, Lourdes T, Robles C "Cushing''s syndrome after topical application of corticosteroids." Am J Dis Child 136 (1982):  274-5|Nathan AW, Rose GL "Fatal iatrogenic Cushing''s syndrome." Lancet 1 (1979):  207|Macdonald A "Topical corticosteroid preparations. Hazards and side-effects." Br J Clin Pract 25 (1971):  421-5|Salde L, Lassus A "Systemic side-effects of three topical steroids in diseased skin." Curr Med Res Opin 8 (1983):  475-80|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Young CA, Williams IR, MacFarlane IA "Unrecognised Cushing''s syndrome and adrenal suppression due to topical clobetasol propionate." Br J Clin Pract 45 (1991):  61-2|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|Watson WA, Kalb RE, Siskin SB, Freer JP, Krochmal L "The safety of halobetasol 0.05% ointment in the treatment of psoriasis [published erratum appears in Pharmacotherapy 1991;11(3):preceding Table of Contents]." Pharmacotherapy 10 (1990):  107-11|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38816, 9772, 'Alclometasone (topical)', 'Adrenocortical Hyperfunction', 'The use of topical corticosteroids may precipitate or aggravate conditions of hyperadrenocorticism.  Systemic absorption of these agents can produce reversible hypothalamic-pituitary-adrenal axis suppression.  Systemic absorption, depends on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  Patients with an altered skin barrier or liver failure are also at increased risk.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.  The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during topical corticosteroid therapy may indicate excessive use.', '2', 'May P, Stein EJ, Ryter RJ, Hirsh FS, Michel B, Levy RP "Cushing syndrome from percutaneous absorption of triamcinolone cream." Arch Intern Med 136 (1976):  612-3|Stoppoloni G, Prisco F, Santinelli R, Sicuranza G, Giordano C "Potential hazards of topical steroid therapy." Am J Dis Child 137 (1983):  1130-1|Ruiz-Maldonado R, Zapata G, Lourdes T, Robles C "Cushing''s syndrome after topical application of corticosteroids." Am J Dis Child 136 (1982):  274-5|Nathan AW, Rose GL "Fatal iatrogenic Cushing''s syndrome." Lancet 1 (1979):  207|Macdonald A "Topical corticosteroid preparations. Hazards and side-effects." Br J Clin Pract 25 (1971):  421-5|Salde L, Lassus A "Systemic side-effects of three topical steroids in diseased skin." Curr Med Res Opin 8 (1983):  475-80|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Young CA, Williams IR, MacFarlane IA "Unrecognised Cushing''s syndrome and adrenal suppression due to topical clobetasol propionate." Br J Clin Pract 45 (1991):  61-2|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|Watson WA, Kalb RE, Siskin SB, Freer JP, Krochmal L "The safety of halobetasol 0.05% ointment in the treatment of psoriasis [published erratum appears in Pharmacotherapy 1991;11(3):preceding Table of Contents]." Pharmacotherapy 10 (1990):  107-11|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38817, 13802, 'Alclometasone (topical)', 'Adrenocortical Hyperfunction', 'The use of topical corticosteroids may precipitate or aggravate conditions of hyperadrenocorticism.  Systemic absorption of these agents can produce reversible hypothalamic-pituitary-adrenal axis suppression.  Systemic absorption, depends on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  Patients with an altered skin barrier or liver failure are also at increased risk.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.  The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during topical corticosteroid therapy may indicate excessive use.', '2', 'May P, Stein EJ, Ryter RJ, Hirsh FS, Michel B, Levy RP "Cushing syndrome from percutaneous absorption of triamcinolone cream." Arch Intern Med 136 (1976):  612-3|Stoppoloni G, Prisco F, Santinelli R, Sicuranza G, Giordano C "Potential hazards of topical steroid therapy." Am J Dis Child 137 (1983):  1130-1|Ruiz-Maldonado R, Zapata G, Lourdes T, Robles C "Cushing''s syndrome after topical application of corticosteroids." Am J Dis Child 136 (1982):  274-5|Nathan AW, Rose GL "Fatal iatrogenic Cushing''s syndrome." Lancet 1 (1979):  207|Macdonald A "Topical corticosteroid preparations. Hazards and side-effects." Br J Clin Pract 25 (1971):  421-5|Salde L, Lassus A "Systemic side-effects of three topical steroids in diseased skin." Curr Med Res Opin 8 (1983):  475-80|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Young CA, Williams IR, MacFarlane IA "Unrecognised Cushing''s syndrome and adrenal suppression due to topical clobetasol propionate." Br J Clin Pract 45 (1991):  61-2|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|Watson WA, Kalb RE, Siskin SB, Freer JP, Krochmal L "The safety of halobetasol 0.05% ointment in the treatment of psoriasis [published erratum appears in Pharmacotherapy 1991;11(3):preceding Table of Contents]." Pharmacotherapy 10 (1990):  107-11|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38818, 9771, 'Alclometasone (topical)', 'Infections', 'Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Clinically significant local as well as systemic immunosuppressant and anti-inflammatory effects may occur, which can cause or exacerbate an infection.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  Therapy with topical corticosteroids should be administered cautiously in patients with latent or active infections, particularly if a potent agent is used on a large area for prolonged periods or if occlusive dressings are used.  Effective antimicrobial therapy or other appropriate treatment should be instituted to treat the infection.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.  Occlusive dressings should not be used in patients with skin infection.', '2', 'Macdonald A "Topical corticosteroid preparations. Hazards and side-effects." Br J Clin Pract 25 (1971):  421-5|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38819, 9772, 'Alclometasone (topical)', 'Infections', 'Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Clinically significant local as well as systemic immunosuppressant and anti-inflammatory effects may occur, which can cause or exacerbate an infection.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  Therapy with topical corticosteroids should be administered cautiously in patients with latent or active infections, particularly if a potent agent is used on a large area for prolonged periods or if occlusive dressings are used.  Effective antimicrobial therapy or other appropriate treatment should be instituted to treat the infection.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.  Occlusive dressings should not be used in patients with skin infection.', '2', 'Macdonald A "Topical corticosteroid preparations. Hazards and side-effects." Br J Clin Pract 25 (1971):  421-5|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38820, 13802, 'Alclometasone (topical)', 'Infections', 'Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Clinically significant local as well as systemic immunosuppressant and anti-inflammatory effects may occur, which can cause or exacerbate an infection.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  Therapy with topical corticosteroids should be administered cautiously in patients with latent or active infections, particularly if a potent agent is used on a large area for prolonged periods or if occlusive dressings are used.  Effective antimicrobial therapy or other appropriate treatment should be instituted to treat the infection.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.  Occlusive dressings should not be used in patients with skin infection.', '2', 'Macdonald A "Topical corticosteroid preparations. Hazards and side-effects." Br J Clin Pract 25 (1971):  421-5|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38821, 9771, 'Alclometasone (topical)', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with topical corticosteroids rarely produces these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure, especially when potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) are used in the periorbital area.  Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.', '2', 'Kitazawa Y "Increased intraocular pressure induced by corticosteroids." Am J Ophthalmol 82 (1976):  492-5|Eisenlohr JE "Glaucoma following the prolonged use of topical steroid medication to the eyelids." J Am Acad Dermatol 8 (1983):  878-81|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Aggarwal RK, Potamitis T, Chong NH, Guarro M, Shah P, Kheterpal S "Extensive visual loss with topical facial steroids." Eye 7(Pt 5) (1993):  664-6|Cubey RB "Glaucoma following the application of corticosteroid to the skin of the eyelids." Br J Dermatol 95 (1976):  207-8|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38822, 9772, 'Alclometasone (topical)', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with topical corticosteroids rarely produces these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure, especially when potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) are used in the periorbital area.  Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.', '2', 'Kitazawa Y "Increased intraocular pressure induced by corticosteroids." Am J Ophthalmol 82 (1976):  492-5|Eisenlohr JE "Glaucoma following the prolonged use of topical steroid medication to the eyelids." J Am Acad Dermatol 8 (1983):  878-81|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Aggarwal RK, Potamitis T, Chong NH, Guarro M, Shah P, Kheterpal S "Extensive visual loss with topical facial steroids." Eye 7(Pt 5) (1993):  664-6|Cubey RB "Glaucoma following the application of corticosteroid to the skin of the eyelids." Br J Dermatol 95 (1976):  207-8|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38823, 13802, 'Alclometasone (topical)', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with topical corticosteroids rarely produces these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure, especially when potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) are used in the periorbital area.  Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.', '2', 'Kitazawa Y "Increased intraocular pressure induced by corticosteroids." Am J Ophthalmol 82 (1976):  492-5|Eisenlohr JE "Glaucoma following the prolonged use of topical steroid medication to the eyelids." J Am Acad Dermatol 8 (1983):  878-81|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Aggarwal RK, Potamitis T, Chong NH, Guarro M, Shah P, Kheterpal S "Extensive visual loss with topical facial steroids." Eye 7(Pt 5) (1993):  664-6|Cubey RB "Glaucoma following the application of corticosteroid to the skin of the eyelids." Br J Dermatol 95 (1976):  207-8|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38824, 66, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38825, 360, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38826, 1555, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38827, 1847, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38828, 2065, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38829, 2237, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38830, 2407, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38831, 2881, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38832, 2911, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38833, 3528, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38834, 3721, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38835, 3966, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38836, 4673, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38837, 4800, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38838, 5132, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38839, 5484, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38840, 5752, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38841, 6247, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38842, 6752, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38843, 7342, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38844, 7415, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38845, 8050, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38846, 8248, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38847, 9266, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38848, 10046, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38849, 12037, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38850, 12050, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38851, 12293, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38852, 12306, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38853, 13365, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38854, 13367, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38855, 13418, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38856, 13633, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38857, 14386, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38858, 14869, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38859, 15425, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38860, 15470, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38861, 15471, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38862, 15474, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38863, 15762, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38864, 15938, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38865, 16198, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38866, 16392, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38867, 17046, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38868, 17124, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38869, 17289, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38870, 17408, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38871, 17735, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38872, 18492, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38873, 20510, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38874, 25721, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38875, 26433, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38876, 26519, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38877, 30005, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38878, 30230, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38879, 30309, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38880, 30370, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38881, 30379, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38882, 30414, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38883, 30577, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38884, 30650, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38885, 30678, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38886, 30679, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38887, 30683, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38888, 30836, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38889, 31014, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38890, 31032, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38891, 31483, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38892, 31484, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38893, 31596, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38894, 31769, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38895, 31808, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38896, 31815, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38897, 31930, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38898, 31931, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38899, 31946, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38900, 31975, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38901, 31987, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38902, 32008, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38903, 32145, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38904, 32174, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38905, 32182, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38906, 32214, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38907, 32221, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38908, 33747, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38909, 33824, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38910, 33882, 'Cholecalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38911, 66, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38912, 360, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38913, 1555, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38914, 1847, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38915, 2065, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38916, 2237, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38917, 2407, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38918, 2881, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38919, 2911, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38920, 3528, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38921, 3721, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38922, 3966, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38923, 4673, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38924, 4800, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38925, 5132, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38926, 5484, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38927, 5752, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38928, 6247, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38929, 6752, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38930, 7342, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38931, 7415, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38932, 8050, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38933, 8248, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38934, 9266, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38935, 10046, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38936, 12037, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38937, 12050, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38938, 12293, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38939, 12306, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38940, 13365, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38941, 13367, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38942, 13418, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38943, 13633, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38944, 14386, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38945, 14869, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38946, 15425, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38947, 15470, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38948, 15471, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38949, 15474, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38950, 15762, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38951, 15938, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38952, 16198, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38953, 16392, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38954, 17046, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38955, 17124, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38956, 17289, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38957, 17408, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38958, 17735, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38959, 18492, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38960, 20510, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38961, 25721, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38962, 26433, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38963, 26519, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38964, 30005, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38965, 30230, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38966, 30309, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38967, 30370, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38968, 30379, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38969, 30414, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38970, 30577, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38971, 30650, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38972, 30678, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38973, 30679, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38974, 30683, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38975, 30836, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38976, 31014, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38977, 31032, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38978, 31483, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38979, 31484, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38980, 31596, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38981, 31769, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38982, 31808, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38983, 31815, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38984, 31930, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38985, 31931, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38986, 31946, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38987, 31975, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38988, 31987, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38989, 32008, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38990, 32145, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38991, 32174, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38992, 32182, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38993, 32214, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38994, 32221, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38995, 33747, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38996, 33824, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38997, 33882, 'Cholecalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38998, 66, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38999, 360, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39000, 1555, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
